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Diabetes Mellitus Type I and 
Health Related Quality of Life 

Diabetes mellitus type I 
Diabetes mellitus type I (DMT1 I is a chronic disease caused by the autoimmune 
destruction of the insulin-producing beta cells in the pancreas, resulting in an 
absolute inability to produce the hormone insulin which is necessary for the 
regulation of blood glucose levels. The autoimmune destruction is postulated to 
result from an interaction between genetic and environmental factors, with the 
latter triggering the onset of the disease in genetically susceptible individuals (1). 
Various theories explaining the pathogenesis have been proposed in which 
environmental agents may serve as modifiers of pathogenesis rather than as 
triggers. These environmental risk determinants may be classified into three 
groups: viral infections, early postnatal diet, and toxins. Other non-genetic disease 
modifying factors include vaccine administration, psychological stressors, and 
climatic influences (2). The incidence of DMT1 is rapidly increasing in many parts 
of the developed world, and is showing a trend toward earlier age of onset. The 
incidence of DMT1 is highly variable among different ethnic populations, 
occurring most frequently in persons of north European descent, diminishing in 
southern direction, the 'North-South gradient', with the notable exception of 
Sardinia. The incidence of DMT1 is projected to be approximately 40 percent 
higher in 2010 than it was in 1997 (1, 2). The prevalence in The Netherlands is 
0.3 percent (3). 
Diabetes mellitus type I is characterized by hyperglycemia with the eventual 
development of micro- and macrovascular complications which define the degree 
of morbidity in these patients. 
Microvascular complications which are generally accepted to be associated with 
diabetes mellitus are retinopathy, with the potential for blindness; peripheral 
neuropathy, with an increased risk of foot ulcers and amputation; autonomic 
neuropathy, with possible cardiac and gastrointestinal dysfunction; and 
nephropathy, with possible renal failure requiring renal replacement therapy. The 
most well-known macrovascular complications are angina pectoris, myocardial 
infarction, cerebrovascular accidents, and intermittent claudication. 
Hyperglycemia is recognized as the primary causal factor in the development of 
these vascular complications associated with diabetes (4, 5). Hypertension and 
dyslipidemia often make an already grim picture even more serious. 
Therapy for diabetes mellitus type I 
The primary goal of treatment is to attain acceptable metabolic control by means of 
daily insulin injections in order to avoid acute and chronic diabetic complications. 
It has been shown that intensive treatment, compared to more conventional 
treatment, delays the onset and progression of microvascular complications in 
patients with DMT1 (6-11). The Diabetes Control and Complications Trial (DCCT) 
also showed a reduction in some, but not all, cardiovascular risk factors, 
suggesting a potential beneficial effect of intensive therapy on the development of 
macrovascular complications in patients with DMT1 as well (12). 
Intensive therapy implies that patients administer a minimum of three to four 
insulin injections per day (often with an insulin pen) or make use of an external or 
internal insulin pump, striving to keep blood glucose levels as close to normal as 
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possible. To achieve this goal, patients have to monitor their blood glucose level 
regularly. The side effects of a more intensive therapy are weight gain and an 
increased frequency of hypoglycemic episodes. The initial symptoms of 
hypoglycemia are sweating, tachycardia, dizziness, irritability, and restlessness. If 
these initial symptoms are not recognized, more serious sequelae will occur, 
including cognitive dysfunction, coma, convulsions, and even death. Recurrent 
episodes of grade I hypoglycemia are apparently well tolerated by the brain, and 
no cognitive impairment has been reported (13, 14). The occurrence of a severe 
hypoglycemic episode is a potentially dangerous and unpleasant event for both the 
patient and his/her environment and should be avoided if at all possible. Recent 
reports have suggested that the number of severe hypoglycemic episodes may be 
reduced by the implementation of pump therapy (15-17). 
Furthermore, these new treatment options, such as the insulin pen and the insulin 
pump, give the patients more flexibility with respect to therapy and diet and 
greater freedom in lifestyle and in choosing a suitable job. Flexible insulin therapy 
and a liberal diet, facilitated by the use of the insulin pen/pump have been 
reported to be strongly associated with improved quality of life scores (18). 
Hanestad et al. reported that multi-injection treatment was associated with greater 
satisfaction in the domain of social life (19). The use of the insulin pump also 
helps to overcome the problems associated with preconception and pregnancy 
care (17). 
To summarize, the primary goal in treating patients with DMT1 is to normalize 
blood glucose levels in an effort to prevent or delay the onset and progression of 
diabetes related chronic complications while, at the same time, keeping the 
patient's health related quality of life as normal as possible (see next section). 
Health related quality of life 
Health related quality of life (HRQOL) refers to those aspects of quality of life 
which are related to a person's health status. It is primarily concerned with that 
aspect of quality of life which may be affected by health and disease (20). HRQOL 
is a person's subjective perception and evaluation of his/her health status. If a 
person feels that his/her health status is poor, he/she may feel that his/her overall 
quality of life is also poor, although this is not necessarily the case. The converse 
situation may also not be valid (21). 
In 1952, the World Health Organization (WHO) defined health as being not only 
the absence of disease, but also the presence of physical, mental, and social well-
being (22). HRQOL issues, related to the physical, mental, and social domains of 
a person's health, have become increasingly important in health care and clinical 
practice (23). Since the meeting of the WHO and the International Diabetes 
Federation in St. Vincent, Italy, special goals have been set for the care of patients 
with diabetes in Europe which are described in the St. Vincent Declaration (1990). 
HRQOL is specified as an important element in the modern care of patients with 
diabetes (24). 
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In the particular case of DMTl, HRQOL refers to the patient's perception of the 
way diabetes affects his/her physical, psychological, and social functioning. It 
reflects the perceived burden of living with DMTl (20). 
It is important to have a good understanding of the various influences on HRQOL 
of patients with DMTl. The potential severity, the intensive therapy and its side 
effects, and the acute and chronic complications of diabetes make it essential that 
the patient, the clinicians and the associated health care workers have a clear 
picture of the factors associated with HRQOL. 
Assessment of health related quality of life 
HRQOL may be assessed with (semi-structured) interviews and checklists. These 
assessment methods are labor intensive. Alternatively, patients may be given 
questionnaires which can be self-administered. These questionnaires have a 
multiple-choice or check-box format, allowing the patient to choose the answer 
which best describes his/ her experience. This is the most widely used monitoring 
method used in daily clinical practice (25). 
The questionnaires have to meet several practical, technical, and conceptual 
criteria (26). Practical criteria concern the feasibility: the burden for the patient 
when filling out the list, the time required to complete, the percentage correctly 
completed questionnaires, and the eventual relevance for both the clinician and 
the patient. Technical criteria concern the reliability of the measuring instruments. 
A reliable test will show a more or less similar result after repeated administration 
(test-retest reliability). The internal consistency of the instrument determines 
whether the items (of a single domain) measure the same construct (Cronbach's 
alpha). Conceptual criteria concern the validity of the measuring instrument. Does 
the instrument measure what it is supposed to be measuring? The responsiveness is 
a measure of the sensitivity in the ability to detect changes in HRQOL (26-28). 
Furthermore, a questionnaire's discriminative and evaluative features are 
important. Discriminative features refer to the ability to assess cross-sectional 
differences in HRQOL between patients at a single point in time (27, 28) and 
evaluative features refer to the questionnaire's ability to assess changes in HRQOL 
longitudinally, within patients, over a period of time (27, 28). Both aspects of 
HRQOL are important for research and for clinical practice. There are specialized 
instruments for each type of task, and even the most minute changes can be 
measured with the correct evaluative instrument. Many different instruments have 
been developed to measure HRQOL for various categories of patient problems 
(28-33). There are two basic kinds of instruments for measuring HRQOL, specific 
and generic. Specific instruments focus on the most important aspects of the 
HRQOL of a specific group of patients (disease-specific), or on a specific problem, 
such as pain or sleep (domain-specific). Generic instruments approach HRQOL 
testing broadly, and are not restricted to any specific disease or domain aspects 
(27, 28). The different health states, provided by some generic instruments, have 
been assigned values, also called utilities, by the general public (34-36). These 
utilities have been scaled in such a way that a value of zero (0) is assigned to the 
worst health state (death) and a value of one (1) is equivalent to perfect health. 
These utilities facilitate cost-effectiveness studies (34-36). 
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The main advantage of specific instruments is their responsiveness, because the 
disease-specific items predominantly concern aspects of the HRQOL which are 
important for patients with a particular disease. Consequently, these instruments 
can play an important role in the evaluation of new therapies (in clinical trials, for 
example), and are therefore closely related to clinical practice (27). 
The main advantage of the generic instruments is that they allow comparisons with 
subjects in the general population and with other patient populations. 
Furthermore, the utilities, which are derived from some generic instruments, make 
it possible to compare the impact of various treatments for different diseases. These 
are therefore important for policymakers (27, 34). 
One of the shortcomings of both types of instruments is that they are not always 
primarily focused on the patient. The number of possible answers is limited, and 
patient-respondents can not sufficiently emphasize which factors have the most 
influence on their HRQOL, when, in fact, HRQOL is by its very nature a 
subjective and individual construct (37). To address this, Gill and Feinstein have 
proposed a global rating, which gives patients the opportunity to rate the 
importance of their problems and the addition of a supplemental item in which 
patients can note additional important factors that have not been included 
elsewhere in the questionnaire (38). The Audit of Diabetes-Dependent Quality of 
Life (ADDQol) gives the individual patient the opportunity to indicate the 
importance of each domain included in the questionnaire. Each domain is then 
weighted according to the patient's rating (29, 39). 
It is evident that each type of instrument has advantages and limitations, and the 
choice of instrument will be dependent on the purpose of the assessment of 
HRQOL. 
A model 
Wilson and Cleary developed a model which conceptualises the relationship 
between traditional clinical variables and health related quality of life (HRQOL) 
(40). A part of this model will be applied here to a population of patients with 
diabetes mellitus type I (DMT1). 
First the Wilson and Cleary model, shown in figure 1, will be explained, before the 
adaptations are discussed which were necessary for it to be applied to our study 
(figure 2). 
Figure 1 shows a continuum, with at one end biological and physiological 
measures, and at the other end health status measures, such as physical 
functioning and general perceptions regarding health. Individual and 
environmental characteristics are shown to have an impact on this continuum. The 
ultimate outcome is overall quality of life (QOL), for which reason the impact of 
non-medical factors such as employment, housing, and personal relationships is 
also accounted for by this model (40). 
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A symptom is a personal perception of an abnormal physical, emotional, or 
cognitive variable or state. The relationship between Biological and Physiological 
Variables and symptoms is a complex and inconsistent one. For example, patients 
with abnormal clinical values may experience no symptoms and conversely, 
patients with symptoms may show no evidence of any clinical abnormality. The 
Symptom Status is an important determinant of a person's Functional Status. 
Finally, this functional status is associated with a person's General Health 
Perception, which is, in turn, related to the Overall Quality of Life (40). 
In the present study, the association of several patient characteristics and diabetes-
specific factors with physical, mental, and social domains of a person's health 
related quality of life (HRQOL) were investigated in a cohort of patients with 
DMT1 (figure 2). DMT1 causes symptoms of hyperglycemia (thirst, tiredness, 
weight loss, polyuria, and polydipsia), because of the patient's inability to produce 
insulin which is necessary for the regulation of levels of blood glucose. DMT1 
therapy rnay cause pain with its daily insulin injections and the associated self-
monitoring of blood glucose. Possible complications of the therapy include 
hypoglycemic events and weight gain, which also have symptoms associated with 
them. The chronic (micro- and macrovascular) complications may present with a 
variety of symptoms ranging from loss of sight to foot ulcers and angina pectoris. 
Jacobson et al. reported that, also in patients with DMT1, symptoms are a patient's 
personal perception of an abnormal physical variable. He compared patients with 
DMT1 whose blood glucose levels were well controlled with those who were 
poorly controlled. He found that those patients with chronic poor control reported 
feeling physically better at higher glucose levels than patients with good control. 
He suggested that poorly controlled patients have underlying perceptions of 
hyperglycemic symptoms and physical well-being which are different from those 
experienced by patients with well controlled diabetes (41 ). 
Although we did hypothesize that the presence of symptoms is an important 
determinant of functioning, and therefore indirectly associated with HRQOL, we 
did not investigate the presence or absence of symptoms independently, since no 
validated symptom check-list is available for patients with DMT1. 
For example, a patient undergoing intensive treatment can experience episodes of 
severe hypoglycemia with the associated symptoms (i.e. sweating, irritability, etc.), 
which causes him/ her to avoid social contact. This impairment in (social) 
functioning will have a negative influence on his/ her daily HRQOL. 
Whereas we did use Wilson and Cleary's conceptual model in our efforts to 
explain the associations between several demographic and diabetes-specific 
characteristics and HRQOL, we did not make the distinction between Functional 
Status and General Health Perceptions. 
We predominantly used the RAND-36, which assesses HRQOL 
multidimensionally, containing subscales focusing primarily on physical, social, 
and emotional functioning and general health perceptions such as the subscales 
general health and vitality (42, 43). 
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We believe that abnormal clinical findings and symptoms are associated with the 
functioning of an individual, but we do not believe they can fully explain a 
person's functioning (40). 
Personality (the patient's character) and environment (family relationships, social 
support, life events) will, to a large extent, explain a person's perception of 
symptoms and affect how they function and in this way influence their HRQOL. 
Associations of sex, age, level of education (characteristics of the patient) and 
marital status (characteristics of the environment) with the HRQOL have been 
investigated. Studies by Rose et al. and Ormel et al. support views which 
emphasize the contribution of the patient's personality and his/her environment to 
the final HRQOL outcome (44-46). 
Rose et al. developed a model which describes the different psychological 
influences on HRQOL in patients with DMT1. Their model explained 62% of the 
variance of the quality of life and 5% of the HbA 1 c values. They reported that the 
most significant determinants for the HRQOL were 'patient characteristics': 
patients with a more optimistic attitude, showing more belief in self-efficacy, and a 
generally more positive disposition had the higher HRQOL values (45, 46). 
Clinicians probably overestimate the impact of clinical variables on symptoms and 
patients' functioning, and underestimate the effect of the patient's personality and 
other characteristics (40). 
Lindenberg proposed the Social Production Function (SPF) theory in which he 
attributes the task of maintaining their HRQOL largely to the patients themselves 
(44, 47, 48). There are differences in how people achieve physical and social well-
being. There are different activity patterns or 'production functions' which can be 
used to produce well being. Different persons use different resources. Symptoms 
may also have an indirect effect on HRQOL by inhibiting functioning or 
diminishing specific activities, in accordance with Wilson et al.'s model (40). 
When symptoms negatively affect behavior, the patient may seek out alternatives 
which are similar (substitution) to prevent a decrease in their HRQOL. The 
patient's personal skills and social environment will partially determine to what 
degree substitution is possible (44). 
Both Rose's model and the Social Production Function theory of Lindenberg 
support Wilson's model, which states that clinical variables and symptoms alone 
cannot satisfactorily explain a patient's HRQOL and associated level of 
functioning. Both also emphasize the importance of the patient's personality 
characteristics and his/her social environment (40, 44, 46). 
In the present study, we primarily investigated the influence of clinical, disease-
specific variables on HRQOL, although we did briefly consider the influence of 
demographic data as well (figure 2). 
It is important to have adequate insight into the many factors which can influence 
the HRQOL of patients with DMT1. This will enable clinicians to take into account 
those factors which can negatively influence HRQOL, thereby practicing 
preventively by anticipating any decreases in HRQOL. 
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Aims of this study 
In this study we investigated the HRQOL of patients with DMT1, the changes in 
HRQOL, and the factors associated with HRQOL, in order to answer the following 
two research questions: 
I. What is the HRQOL of patients with DMT1? 
II. Can we provide recommendations for the assessment of the HRQOL in 
patients with DMT1? 
These questions lead to a number of other questions which are treated in the 
separate chapters. 
To this purpose we have followed a cohort of 281 Dutch patients with DMT1 in 
the lsala Clinics in Zwolle, The Netherlands, for six years, from 1995 to 2001. 
During this period, the patients were examined annually by a physician according 
to a standardized protocol. Various clinical data were collected. Furthermore, each 
year, patients were seen by a nurse specialized in diabetes who conducted a semi-
structured interview with the help of a standardized questionnaire which included 
questions about therapy, self-monitoring, education, employment, household, 
family, and social environment. All patients saw an ophthalmologist and podiatrist 
annually to monitor the presence or absence of retinopathy and neuropathy. 
Throughout the study period patients completed several disease-specific and 
generic HRQOL questionnaires. 
The study population and the follow-up procedure are described in Chapter Two. 
I. The HRQOl of patients with DMT1 
In Chapter Three we answer the following questions: what is the HRQOL of 
patients with DMT1 compared with persons of comparable age from the general 
population (1.1 ); and which factors are associated with their HRQOL (1.2). 
In Chapter Four we answer the following questions: what is the HRQOL of patients 
with newly diagnosed DMT1 during the first year post-diagnosis, and what is their 
HRQOL one year post-diagnosis, compared with subjects of comparable age from 
the general population, and compared with subjects with DMT1 with a longer 
(longer than one year) disease duration (1.3). 
In Chapter Five we answer the following questions: how does the HRQOL of a 
patient with DMT1 develop and change over time, and how does this compare 
with subjects of similar age from the general population (1.4). 
In Chapter Six we describe to what extent we can identify factors which are 
predictive for the degree of change in HRQOL (1.5). 
II. The use of HRQOl questionnaires in patients with DMT1 
In Chapter Seven we answer the following question: can we use the utilities from 
generic instruments for patients with DMT1 to make cost-effectiveness studies 
possible (11.1). 
In Chapter Eight we answer the following questions: do generic instruments 
accurately measure changes in HRQOL over time in patients with DMT1 (11.2); do 
generic instruments provide information about diabetes-specific influences on 
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HRQOL in patients with DMT1 (11.3); and do diabetes-specific and generic 
instruments identify the same patients with a lower HRQOL (11.4). 
Chapter Nine will contain the general discussion, conclusions and 
recommendations. Chapter Ten will summarize the thesis. 
22 
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A cohort of patients with 
Diabetes Me II it us Type I 
-Long term clinical follow-up-
Abstract 
Objective 
The purpose of this study was to investigate long-term clinical follow-up, 
therapeutic trends in the late 1990s, and the development of chronic 
complications in a cohort of patients with diabetes mellitus type I (DMT 1 ). 
Methods 
234 Dutch patients with DMT 1 were followed from 1995 to 2001. Annually, 
patients underwent a physical examination, and data concerning therapy, 
therapeutic side effects, and complications were recorded. Data, at different 
moments, were compared with McNemar and T-tests using paired samples. 
Results 
In the six-year study period, therapy was intensified. The percentage of pump-
users increased from 26.9% in 1995 to 32.6% in 1998 (p~0.016) to 43.6% in 
2001 (p<0.001), which corresponded to a decrease in pen-users. The HbA1c 
level decreases, from 8.1% in 1995 to 7.9% in 1998 (p~0.016) to 7.6% in 2001 
(p<0.001), were significant. The bodymass-index showed significant increases 
from 24.8 in 1995 to 25.6 in 1998 (p<0.001) to 26.1 kg/m 2 in 2001 (p<0.001). 
The percentage of patients reporting hypoglycaemic events tended to increase 
from 80.8% in 1995 to 87.4% in 2001. The percentage of patients with 
microvascular complications increased from 45.8% in 1995 to 58.1% in 1998 
(p~0.005) to 65.7% in 2001 (p~0.248). The prevalence of macrovascular 
complications increased from 4.3% in 1995 to 9.8% in 2001 (p<0.001). 
Conclusion 
In the cohort of patients studied, therapy was intensified during the six year study 
period, and this was accompanied by an increase in the incidence of side effects. 
The percentage of patients with microvascular and macrovascular complications 
increased over time. 
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Introduction 
A study was initiated at the lsala Clinics, Department of Internal Medicine, in 
Zwolle, the Netherlands, to investigate several disease factors in patients with 
diabetes mellitus type I (DMT I) including oxidative stress and health related 
quality of life (HRQOL) (1 ). From january 1995 through january 1996, 293 patients 
seen consecutively in the outpatient department were invited to participate in the 
study, of whom 281 agreed. After the initial investigations in 1995, the patients 
were followed for a period of six years (1995-2001). DMT 1 was defined in 
patients when insulin therapy was started within six months of onset of the first 
signs of diabetes and prior to age 30 or in the absence of C-peptide secretion. 
Approval for the study was granted by the Hospital Scientific and Ethics 
Committee. All patients provided informed consent. 
This chapter concerns the clinical follow-up of the cohort with a focus on the 
therapy and on the development of chronic complications of diabetes. 
Methods 
Clinical data 
All patients were examined according to a standardized protocol. Demographic 
data (age, sex, married I having a partner, level of education) and data concerning 
therapy (HbA 1 c, frequency of insulin injection, frequency of self monitoring of 
blood glucose, presence of hypoglycaemic events and hyperglycaemic complaints) 
were recorded annually. Patients recorded all hypoglycaemic events ('did you 
have a hypo in the past three rnonths?') during the three months preceding the 
outpatient visit. Patients were asked to report whether they had one or more of six 
different hyperglycaemic complaints during the last three months (yes I no): 
tiredness, weight loss, pruritus, thirst, polyuria, and polydipsia. Metabolic control 
was assessed by measuring glycosylated haemoglobin A 1 c (HbA 1 c). 
Comorbidity (presence of one or more diseases in addition to the diabetes) was 
assessed using a list of 26 chronic diseases (2). 
Macrovascular complications 
Patients were classified as having macrovascular complications when one or more 
of the following diagnoses were present: angina pectoris, myocardial infarction, 
intermittent claudication, transient ischaemic attack (TIA), or cerebrovascular 
accident (CVA). These diagnoses were, in 1995 and in 2001, recorded in the 
patient's dossier. 
Microvascular complications 
Patients with retinopathy, neuropathy, or nephropathy were classified as having 
microvascular complications. 
Retinopathy 
All patients received an annual ophthalmological examination. The degree of 
diabetic retinopathy was assessed by fundoscopy in mydriasis. Diabetic 
retinopathy was classified according to de jong (3): no retinopathy (~0), 
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background retinopathy (~I) preproliferative (~II), proliferative diabetic 
retinopathy (~Ill). 
The patient was scored positive for retinopathy when any type of retinopathy was 
present in either eye. When the degree was different in each eye, the highest 
degree was scored. 
Neuropathy 
The Semmes-Weinstein pressure aesthesiometer was used to test sensitivity (4). Six 
different monofilaments were used to test (left and right) foot sensitivity at five 
dorsal and plantar sites. The patient was diagnosed as having a neuropathy when 
the monofilament 5.07 was not felt at one of the ten test sites. In 2001, 
monofilament 5.07 was used as the test filament, and sensitivity was tested at four 
sites on the (left and right) feet. 
Nephropathy 
The 24-hour urinary excretion of albumin (UAER) was measured annually. UAER 
was considered abnormal when it was " 30mg/ 24 hours. Micro-albuminuria was 
defined as 30-300 mg/24 hours, and macro-albuminuria as "300 mg/24 hours. All 
patients with abnormal UAER values were defined as having nephropathy (5-7). In 
1995 patients with a micro-albuminuria > 100 mg/24 hours were prescribed an 
angiotensin converting enzyme inhibitor (ACE-inhibitor) at the lsala Clinics. 
Patients using ACE-inhibitors were therefore classified as having nephropathy 
unless ACE-inhibition was initiated specifically for hypertension. 
Results 
Study population 
The characteristics of the study population are presented in Table 1. 54.4% of the 
study population was male. The mean patient age was 38.2 years. Mean diabetes 
duration was 17.2 years. At entry, almost one-third of the patient population 
smoked (29.9%) and 62.4% used alcohol. 
Study drop-outs 
The drop-out rate of the study was 16.7% (n ~47). The reasons for withdrawal are 
presented in Table 2. In most cases, the reason for withdrawal was unknown 
(n~28). Five patients died: one in a motor vehicle accident, one due to a 
cerebrovascular accident, two because of cardiac problems, and in one case the 
cause was unknown. 
Patients who withdrew from the study shared the following characteristics: there 
were more females than males (59.6% versus 42.7%, p~0.04), longer disease 
duration (20.6 versus 16.5 years, p~0.05), more often single (24.0% versus 9.2%, 
p~O.Ol), and a higher HbA1c (9.0% versus 8.1%, p~0.007). The drop-out group 
showed no other statistically significant differences in personal and disease related 
characteristics (Table 3). 
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Table 1 
Personal and disease-specific characteristics of the study population; n=281 (1995) 
Gender (men) 153 
Age (years/ SD) 38.2 
Duration of diabetes (years/50) 17.2 
Married/ cohabiting 242 
High level of education 90 
Smoking 70 
Alcohol consumption 146 
SO- Standard deviation 
Table 2 
Withdrawal from study/ reasons for withdrawal (n = 47) 
Reason unknown 
Moved out of region Zwolle 
Deceased 
Pancreas transplantation 
Car accident, comatose 
Psychiatric admission 
Passant 1 
28 
10 
5 
(50) % 
54.4 
(12.4) 
(1 0.7) 
88.3 
32 
29.9 
62.4 
1Patient came temporarily to Zwolle for a pump, but dropped out of the study when this did not 
take place 
In the drop-outs the health related quality of life (HRQOLI, assessed by the generic 
RAND-36 and EuroQol (EQI instruments, was partially lower. The RAND-36 
subscales physical functioning, bodily pain, general health, social functioning, role 
emotional, and mental health were lower than those of the patients continuing the 
study. Their mental component summary score (MCS) was significantly lower than 
those of the continuing patients as were their EuroQol scores (Table 4). 
Therapy and self-management over time (Table 5) 
Table 5 shows that the percentage of pump-users increased from 26.9% in 1995 to 
32.6% in 1998 (p=0.016) to 43.6% in 2001 (p<0.001). There was a 
corresponding decrease in pen-users. The mean HbA 1 c decreased from 8.1% in 
1995 to 7.9% in 1998 (p=0.016) to 7.6% in 2001 (p<0.001). The body mass 
index showed a statistically significant increase over both three-year periods. 
The percentage of patients reporting hypoglycaemic events during the three 
months immediately preceding the visit to the outpatient clinic tended to increase 
from 80.8% in 1995 to 84.9% in 1998 (p =0.11 0) to 87.4% in 2001 (p=0.736). 
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Table 3 
Personal and disease-specific characteristics of the study population 
- Patients in the cohort versus patients withdrawn from the study -
n-234 n=47 
SD % SD % 
Gender (men) 134 57.3 19 40.4 0.038 
Age (years) 38.2 11.5 38.2 16.5 0.997 
Diabetes duration (yrs} 16.5 10.1 20.6 13.1 0.050 
Married/ cohabiting 207 90.8 35 76.0 0.010 
High level of education 76 33.6 14 31.1 0.863 
Smoking 70 29.9 21 44.7 0.060 
Alcohol consumption 146 62.4 26 55.3 0.413 
SBP (mm Hg) 138.9 17.8 140.0 21.6 0.709 
DBP (mm Hgl 83.0 8.4 82.5 7.8 0.676 
Pulse pressure 55.9 15.2 57.5 20.7 0.523 
Cholesterol/ HDL ratio 3.8 1.2 3.8 1.2 0.889 
Body mass index (kg/m2) 24.8 3.2 24.2 3.1 0.197 
Hba1c (%) 8.1 1.9 9.0 1.9 0.007 
Insulin pump 63 26.9 9 19.1 0.360 
Self monitoring blood 12.0 11.3 11.4 12.7 0.775 
glucose per week 
Number of patients with: 
hypoglycaemic events 185 80.8 39 84.8 0.678 
hyperglycaemic 122 53.2 28 60.9 0.418 
complaints 
Prevalence of diabetic 
complications 
Microvascular 104 45.8 25 53.2 0.423 
Retinopathy 79 34.6 18 44.9 0.492 
Nephropathy 43 18.4 10 21.3 0.683 
Neuropathy 24 10.7 8 17.0 0.211 
Macrovascular 10 4.3 3 6.4 0.462 
Comorbidity 133 58.1 28 60.9 0.746 
SD - standard deviation 
SBP -systolic blood pressure 
DBP -diastolic blood pressure 
For the continuous variables p values are result of independent sample T-tests 
For the binary and categorical variables p values are from Fisher's Exact Test 
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Table 4 
Health Related Quality of life (HRQOL) of patients in the cohort compared with the 
HRQOl of patients who left the study (1995) 
Cohort 
n=234 
RAN0-36 
Physical functioning 91.7 (12.9) 
Role physical 84.4 (30.9) 
Bodily pain 89.9 (16.8) 
General health 69.3 (19.8) 
Vitality 68.4 (19.4) 
Social functioning 88.6 (19.2) 
Role emotional 86.6 (29.7) 
Mental health 78.3 (16.2) 
PCS 52.6 ( 7.0) 
MCS 51.6 ( 9.7) 
EuroQol 
Utility index 0.90 0.15 
Visual analogue scale 82.1 14.1 
Values are means with standard deviation in parentheses 
P values are result of independent sample T-test 
PCS - Physical Component Summary score 
MCS -Mental Component Summary score 
Patients 
withdrawn 
n=47 
84.1 (20.6) 
75.0 (38.7) 
82.8 (21.5) 
61.4 (20.4) 
62.8 (22.4) 
78.5 (22.2) 
71.0 (38.2) 
68.0 (19.6) 
50.4 ( 8.5) 
46.4 (1 0.9) 
0.79 0.23 
74.8 19.0 
p value 
0.021 
0.127 
0.040 
0.015 
0.122 
0.006 
0.012 
<0.001 
0.066 
0.001 
0.003 
0.017 
Over the six year period, the percentage of patients reporting hyperglycaemic 
complaints tended to increase from 53.3% to 58.3%. 
The frequency of self monitoring blood glucose increased from 12.0 in 1995 to 
18.2 in 1998 (p < 0.001) to 20.0 in 2001 (p = 0.038) per week. 
Chronic diabetic complications and comorbidity (table 6) 
The percentage of patients with microvascular complications increased from 
45.8% in 1995 to 58.1% in 1998 (p=0.005), and increased again from 1998 to 
2001 (from 58.1% to 65.7%), but this increase was not statistically significant 
(p=0.248). 
The percentage of patients with retinopathy increased significantly during the first 
three-year period (34.6% to 44.9%, p=0.007), but showed only a modest, non-
significant increase during the second, three-year period (44.9% to 48.5%, 
p=0.442). The percentage of patients with an increased urinary albumin excretion 
rate (used as a measure of nephropathy) decreased during the initial three years 
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(from 18.4% to 16.7%, p~0.210), but increased during the second three-year 
period (16.7% to 23.0%, p~0.023). 
The percentage of patients with neuropathy increased between 1995 and 1998 
(p~0.004), but declined during the second three-year period (p~0.039). 
The number of patients with macrovascular complications increased from 10 
(4.3%) in 1995 to 23 (9.8%) in 2001 (p<0.001). The most common diagnoses in 
1995 were angina pectoris (n~6) and intermittent claudication (n~4). By the end 
of the study period (2001), myocardial infarction (n~2) and CVA (n~4) were also 
recorded. 
The patients with comorbidity did not show statistically significant changes during 
the study period (Table 6). 
Cardiovascular risk factors (Table 7) 
During the first three-year period both systolic and diastolic blood pressure 
showed a significant decrease (p<0.001), whereas only diastolic blood pressure 
showed a further significant decrease during the second three year period 
(p~0.029). Pulse pressure decreased significantly during the first three years of the 
study (p<0.001), but tended to increase during the latter three-year period 
(p~0.057). 
The cholesterol/ HDL ratio showed a decrease over both three-year periods 
(p~0.031, p<0.001). 
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Table 6 
D
iabetic co
m
plications and co
m
o
rbidity of the study population (n 
=
 234); change o
v
e
r tim
e 
1995 
Patients w
ith diabetic c
o
m
plications 
M
icrovascular 
104 
(45.8%
) 
R
etinopathy 
79 
(34.6%
) 
N
ephropathy 
43 
(18.4%
) 
N
europathy 
24 
(10.4%
) 
M
acrovascular 
10 
( 4.3%
) 
C
om
orbidity 
133 
(58.1%
) 
Values are n
u
m
ber of patients (with valid percentages in parentheses) 
P v
alues a
re
 result of M
e N
em
ar test 
1998 
111 
(58.1%
) 
88 
(44.9%
) 
33 
(16.7%
) 
32 
(15.2%
) 
130 
(62.5%
) 
pwvalue 
pwvalue 
1995 v
s. 
2001 
1998 v
s. 
1998 
2001 
0.005 
119 
(65.7%
) 
0.248 
0.007 
99 
(48.5%
) 
0.442 
0.210 
45 
(23.0%
) 
0.023 
0.004 
23 
(12.2%
) 
0.039 
<0.001 
23 
( 9.8%
) 
0.212 
107 
(52.7%
) 
0.130 
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Discussion and conclusion 
In this Dutch cohort of 234 patients with DMT1, treatment was intensified over the 
six year study period. The percentage of pump-users increased and HbA 1 c 
decreased at the cost of an increase in body mass index and an increased 
percentage of patients that reported hypoglycaemic events. Contrary to 
expectation, with the more intensive treatment the percentage of patients that 
reported hyperglycaemic complaints tended to increase during both three-year 
periods studied. The increased frequency of self-monitoring of blood glucose is 
inherent to the intensified therapy. 
The decrease from 8.1 to 7.6% in the HbA 1 c levels is satisfactory, particularly 
considering the observational nature of the study. Comparatively, in the Diabetes 
Control and Complications Trial (DCCT), the patients in the intensive treatment 
group reached a median HbA1c level of 7.3% under very special study 
circumstances, whereas this level increased to 8.2% in the succeeding seven years, 
during the observational follow-up of the DCCT, the Epidemiology of Diabetes 
Interventions and Complications (EDIC) study (8, 9). 
Despite the intensified treatment in the six-year study period, the percentage of 
patients with micro- and macrovascular complications increased. 
An increased incidence of nephropathy among diabetic patients may be expected. 
The decrease in urinary albumin secretion rate during the first three-year period 
may possibly be explained, however, by the reversibility, spontaneous remission, 
of the early stages of urinary albumin excretion (1 0). Improved metabolic control 
may also play a role. 
The apparent decrease in the number of patients with neuropathy from 1998 to 
2001 may be explained by the reduced number of test sites for the monofilament 
in 2001. An additional factor is the relatively large number of patients who did not 
visit the podiatrist in 2001 (19.2%). 
The decreased prevalence of comorbidity during the second three-year period may 
be explained by the large percentage of missing records for 2001 (13.2%). The 
presence of complications related to the diabetes may have had a greater impact 
than the presence of non-diabetes related co-morbidities, causing the patients not 
to record the latter. 
Although cardiovascular risk factors decreased during the study period, the 
percentage of patients with macrovascular complications increased. Comparing the 
percentages of micro- and macrovascular complications found in this study with 
other studies is complicated by variation in population characteristics and 
differences in assessment techniques (3, 5, 6, 8, 9, 11-13). The patient population 
of this study can be considered too small for definitive conclusions to be drawn. 
Nevertheless, the complication frequencies seen in the present cohort appear 
comparable to, or somewhat lower than those mentioned in the literature (14, 15). 
Although many studies have shown the profound negative influence of smoking 
on the progression of nephropathy and retinopathy (14-18), we made no specific 
interventions aiming to diminish the number of smokers. 
The Steno-2 study showed that intensified multifactorial intervention, including 
behavior modification and pharmacologic therapy targeting hyperglycemia, 
hypertension, dyslipidemia, and microalbuminuria, as well as secondary 
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prevention of cardiovascular disease with aspirin reduced the risk of 
cardiovascular and microvascular events by approximately 50 percent in patients 
with type 2 diabetes (19). Exercise has been shown to improve the vascular 
endothelial function in patients with DMT1. However, the beneficial effect on 
vascular function was not maintained when the exercise was discontinued (20). 
Moreover, several studies showed that light to moderate alcohol consumption is 
associated with a decreased incidence of coronary heart disease in persons with 
diabetes (21). 
In this observational study, too little attention has been paid to several potentially 
modifiable risk factors for the development of both types of com pi ications. 
Lifestyle factors, such as smoking and exercise, can be influenced by lifestyle 
interventions, and offer new possibilities for slowing the onset and the progression 
of complications related to diabetes. Successful intervention in these areas is 
labour intensive and requires trained specialists. This type of intervention was not 
one of the aims of the present study. 
Conclusion 
In this Dutch cohort of patients with DMT 1, insulin therapy was intensified during 
the six-year study period, at the cost of the well-known side effects of this 
intensified therapy. The HbA 1c level thus reached (7.6%) was satisfactory. Despite 
this reasonable HbA 1 c, the percentage of patients with micro- and macrovascular 
complications increased during the study period. More attention for other 
modifiable lifestyle factors, such as smoking, diet, and exercise, may offer more 
and better opportunities for lowering the incidence of chronic complications 
related to diabetes. 
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Abstract 
Objective 
The objective of this study was to assess health related quality of life (HRQOL) in 
patients with type I diabetes mellitus (DMT1) and to compare their HRQOL with 
the HRQOL of persons of comparable age in the general population. Furthermore 
we wanted to investigate which factors mostly influence HRQOL. 
Research design and methods 
In a Dutch cohort of 281 patients with DMT1 HRQOL was assessed using two 
generic instruments: the EuroQol and the RAND-36. We performed regression 
analyses to investigate relationships between several demographic (e.g. sex, age, 
marital status) and diabetes-specific variables (e.g. HbA1c, frequency of insulin 
injection, presence of acute and chronic complications) and HRQOL. The 
Spearman rank correlations between RAND-36 subscales and EuroQol were 
analysed. 
Results 
RAND-36 results showed, for almost all subscales, a HRQOL comparable with 
persons of comparable age in the general population. In contrast the HRQOL 
measured with the EuroQol was lower for subjects with DMT1. Hyperglycaemic 
complaints and macrovascular complications had a profound negative influence 
on HRQOL. Most correlations between the RAND-36 results and the EuroQol 
results corresponded with our expectations. 
Conclusion 
HRQOL in patients with DMT1 is comparable with that of a general population 
sample. The presence of hyperglycaemic complaints and macrovascular 
complications had the most pronounced negative association with HQOL. 
Longitudinal data and comparison with results of several diabetes-specific 
questionnaires should help to establish which instrument might be most 
appropriate to measure HRQOL in patients with DMT1. 
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Introduction 
Diabetes mellitus type I (DMT1) is a chronic disease caused by auto-immune 
destruction of the insulin-producing pancreatic beta cells resulting in an absolute 
inability to produce insulin, necessary for the regulation of blood glucose [1]. 
The primary goal of treatment is to reach adequate metabolic control by daily 
insulin injections to avoid diabetic complications. The more intensive the 
treatment, the better the chance to delay the onset and the progression of 
complications [2]. Side effects of more intensive therapy are body weight gain and 
an increased frequency of hypoglycaemic episodes. In particular, the frequency of 
hypoglycaemia can influence a patient's life [3]. 
It can be difficult to find a balance between food intake, exercise and insulin dose 
to reach a satisfactory metabolic control. This may affect health related quality of 
life (HRQOL) in many different ways [4]. 
In recent years, HRQOL consisting of physical, psychological and social aspects 
has become more important in health care. Different instruments have been 
developed to measure HRQOL in various patient categories: generic instruments 
to allow comparisons with other patient populations or samples of the general 
population and disease-specific instruments to assess the influence of different 
aspects of a specific disease and its treatment [5-9]. 
The attention paid to the HRQOL of patients with DMT1 is very important [4, 10-
13]. The patients with DMT1 have a lifelong, chronic and serious disease and will 
develop several micro- and macrovascular complications, which will have a daily 
impact on their physical and psychological functioning. In addition to the fact that 
DMT1 is a serious chronic disease, it is a frequently occurring disease. 
It is not clear, which factors influence HRQOL the most, how the individuals 
appraise the different aspects of the regimen, or which patients have the lowest 
HRQOL, or whether clinicians can influence those factors negatively influencing 
HRQOL. For these reasons it is of great importance to have good insight in the 
factors influencing the well being of this group of patients. 
In this study we addressed the following questions: 
How do subjects with DMT1 assess their HRQOL compared to persons of 
comparable age from the general population? Which factors influence the HRQOL 
of patients with DMT1? 
Methods 
Patients 
From january 1995 to January 1996, 293 consecutive DMT1 patients, treated at 
the outpatient internal clinic of the lsala Clinics in Zwolle, the Netherlands, were 
invited to participate in the study. A group of 281 patients agreed to participate 
and was investigated in 1995. DMT1 was defined as starting insulin therapy within 
six months after the first signs of diabetes mellitus and before the age of 30 years, 
or the absence of (-peptide secretion. Approval was obtained from the Hospital 
Scientific and Ethical Committee. All patients gave informed consent. 
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Health Related Quality of life 
HRQOL was assessed using two generic instruments, the RAND-36-item Health 
Survey (RAND-36) and the EuroQol. Questionnaires were sent by mail to the 
patient's home address. Patients were asked to fill in the questionnaires at home. 
Upon the visit to the outpatient clinic, the patients returned the completed 
questionnaires to the diabetes specialist nurse. Patients who did not return the 
completed questionnaires when visiting the clinic were asked to send their 
completed questionnaires afterwards. 
The RAND-36 is a self-administered questionnaire containing 36 items involving 
eight different subscales: physical functioning, role limitations due to physical 
problems, bodily pain, general health perception, vitality, social functioning, role 
limitations due to emotional problems, and mental health. For each subscale, 
scores were coded, summed up and transformed to a scale from 0 (worst health) to 
100 (best health) [14, 15]. In addition, physical and mental component summary 
scores were determined (PCS/ MCS) [16]. The questionnaire takes about ten 
minutes to complete. The instrument has been translated in Dutch [17] and 
validated for the Dutch population [18]. 
The EuroQol is a simple generic measure, consisting of two parts (EQ-5D and EQ-
VAS), developed by a multidisciplinary group of researchers from five European 
countries [19]. For the EQ-5D part, there are five questions covering the areas 
Mobility, Self Care, Usual Activities, Pain/ discomfort and Anxiety/ depression. 
Each dimension is divided into three levels: no problem, some/ moderate 
problems and extreme problems/ unable to perform. A respondent's health state is 
defined by combining one level from each of the five dimensions (EQ-5D). A total 
of 243 possible health states can be defined in this way. Valuations of these health 
states have been made by the U.K. general public, using a valuation technique 
called time trade-off. The values, or utilities, are scaled on a scale on which 0 is 
the value of dead and 1 is the value of perfect health [20]. Furthermore a single 
overall score can be elicited using the EuroQol thermometer, a self rated health 
status using a graduated (0-1 00) visual analogue scale, similar to a thermometer 
(EQ-VAS). The EuroQol takes about two minutes to complete and has been 
validated for the Dutch situation [21]. 
Clinical data 
One trained physician U.H.A.) examined all patients according to a standardised 
protocol. Demographic data (age, sex, married/ having a partner, level of 
education) and data concerning therapy (HbA 1 c, frequency of insulin injection, 
frequency of self monitoring of blood glucose and presence of hyperglycaemic 
complaints) were recorded. Patients recorded all hypoglycaemic events ('did you 
have a hypo in the past three months?') during the three months preceding the 
outpatient visit. Patients were asked to report whether they had one of six different 
hyperglycaemic complaints during the last three months (yes/ no): tiredness, 
weight loss, pruritus, thirst, polyuria and polydipsia (Cronbach's alpha 6-iterns 
0.74). Metabolic control was assessed by measuring glycosylated haemoglobin 
A 1 c (HbA 1 c). The presence of comorbidity (one or more diseases besides diabetes) 
was assessed using a list of 26 chronic diseases [22]. 
46 
Macrovascular complications 
Patients were classified as having macrovascular complications when one or more 
of the following diagnoses was present: angina pectoris, myocardial infarction, 
intermittent claudication, transient ischaemic attack (TIA), or a cerebrovascular 
accident (CVA). The physician recorded these diagnoses in the clinical status of all 
patients. 
Microvascular complications 
Patients with retinopathy, neuropathy or nephropathy were diagnosed as having 
microvascular complications. 
Retinopathy 
The ophthalmologist examined all patients annually. The degree of diabetic 
retinopathy was assessed by fundoscopy in mydriasis. The classification of diabetic 
retinopathy used was based on de jong [23]: no retinopathy (~0), background 
retinopathy (~I) preproliferative (~II) and proliferative diabetic retinopathy (~Ill). 
Retinopathy was scored positive, when any type of retinopathy was present in 
either eye. When the degree of retinopathy was different in two eyes, the highest 
degree was scored. 
Neuropathy 
Sensitivity was tested by the Semmes-Weinstein pressure aesthesiometer [24]. At 
five dorsal and plantar sites on the feet sensitivity was tested using six different 
monofilaments. When the monofilament 5.07 was not felt at one of the ten test 
sites, patients were diagnosed as having neuropathy. 
Nephropathy 
The 24-hour urinary excretion of albumin (UAER) was measured yearly. UAER was 
considered abnormal when it was ?: 30mg/ 24 hours. Micro-albuminuria was 
defined as 30-300 mg/ 24 hours and macro-albuminuria as <:300 mg/ 24 hours. All 
patients with micro-albuminuria or macro-albuminuria were defined as having 
nephropathy [25-27]. 
At the time of the study (1995) patients with a micro-albuminuria > 100 mg/ 24 
hour received an angiotensin converting enzyme inhibitor (ACE-inhibitor) in the 
lsala Clinics. We classified ACE-inhibitor users as having nephropathy, unless ACE-
inhibition was started specifically for hypertension. 
Analysis 
HRQOL of patients was compared with the HRQOL of the general population 
using the T-test for independent samples. Univariate and multivariate stepwise 
regression analyses (with the PCS, MCS, the EuroQol 5-D, and the EuroQoi-VAS 
being the dependent variables) were performed to investigate the relationships 
between HRQOL scores (RAND-36 and EuroQol) and demographic data (sex, age, 
marital status, level of education) and data concerning the disease and its therapy 
(e.g. frequency of insulin injection, HbA 1 c, acute and chronic complications). 
Furthermore we calculated the Spearman rank order correlations between the 
subscales of the RAND-36 and the dimensions of the EuroQol. We expected 
correlations between 'Mobility' and the subscales 'physical functioning' and 'role 
physical', between 'Self-care' and 'physical functioning and 'role physical', 
between 'Usual activities' and most subscales of the RAND-36, between 'Pain/ 
discomfort' and 'bodily pain' and between 'Anxiety I depression' and the more 
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mental subscales of the RAND-36. We considered correlations <0.39 as weak, 
0.40-0.59 as moderate and > 0.60 as strong. 
Relationships were considered statistically significant when p-values :o; 0.05 were 
reached. Data were analysed using SPSS for Windows version 1 0.0.7. 
Results 
A total of 281 adult patients with DMT1 entered the study. Baseline characteristics 
of the study population are shown in table 1. 
Mean age in the study population was 38.2 years and 54.4% were men. Most 
patients (87.9%) received intensive therapy (i.e. insulin pump or minimal 4 times 
daily pen injection) and self-monitored their blood glucose values. Almost half of 
the patients had microvascular com pi ications (47.1 %) (Table1 ). Most patients with 
retinopathy had grade I diabetic retinopathy, almost always in both eyes. Of the 
patients with nephropathy (n ~53), 21% had macro-albuminuria (n ~ 11), the others 
micro-albuminuria. About 10% of the patients had macrovascular complications, 
the most frequently reported diagnoses being angina pectoris and intermittent 
claudication. Most patients with comorbidity had one or two other chronic 
medical conditions besides their diabetes. 
The HRQOL questionnaires were completed by 274 patients (97.5%) (Table 2). 
The RAND-36 subscale scores were comparable with those of persons of 
comparable age in the Dutch general population [14], except for the General 
Health subscale that was lower than in the general population (p~0.022) and the 
Bodily Pain subscale that was higher than in the general population (p~O.OlO). 
The EQ-SD and the EQ-VAS-score were lower in our study group compared to 
persons of comparable age from the U.K. general population [28]. 
Univariate analysis showed that females reported a lower HRQOL (MCS and EQ-
SD) than males. Older patients had lower scores for the PCS, the EQ-SD and the 
EQ-VAS. Patients having a partner and patients using alcohol reported a higher 
MCS and EQ-VAS. A higher HbAlc was associated with a lower EQ-VAS. Patients 
with continuous insulin therapy had a lower MCS and a lower EQ-SD than patients 
with 2-3 injections daily. Whereas patients with 4-times daily insulin injection 
reported a higher PCS, than patients with 2-3 injections daily. Patients with a high 
frequency of self-monitoring had lower scores for the PCS, the EQ-SD and the EQ-
VAS. Patients having hyperglycaemic complaints, macrovascular complications 
and comorbidity reported a lower HRQOL (PCS, MCS, EQ-SD, EQ-VAS). Patients 
having microvascular complications also reported a lower HRQOL (MCS, EQ-SD 
and EQ-VAS). 
Multivariate analysis for the RAND-36 and the EuroQol showed that the presence 
of a macrovascular complication had the most pronounced negative influence on 
HRQOL (Table 3). 
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Table 1 
Personal and disease-specific characteristics of the study population (n-281) 
Gender (men) 
Age (years) 
Duration of diabetes (years) 
Married/ cohabiting 
High level of education 
Smoking 
Alcohol consumption 
Systolic blood pressure (mm Hg) 
Diastolic blood pressure (mm Hg) 
153 
38.2 
17.2 
242 
90 
91 
172 
139.1 
82.9 
(54.4%) 
(12.4) 
(1 0.7) 
(88.3%) 
(32%) 
(32.4%) 
(61.2%) 
(18.4) 
(8.3) 
Ratio of total cholesterol (mmol/1)/ HDL-cholesterol 3.8 (1.2) 
(mmol/1) 
Body mass index (kg!m') 
Hba1c (%) 
Frequency of insulin injection (per day): 
2-3 
4 
Pump 
Self monitoring of blood glucose 
Number of control measurements per week 
Number of patients with: 
hypoglycaemic events last 3 months 
hyperglycaemic complaints last 3 months 
Prevalence of diabetic complications 
Microvascular 
Retinopathy 
Nephropathy 
Neuropathy 
Macrovascular 
Comorbidity 
(one or more chronic medical condition) 
24.7 
8.3 
34 
175 
72 
275 
11 . 9 
224 
150 
129 
97 
53 
32 
27 
161 
(3.2) 
(1.9) 
(12.1 %) 
(62.3%) 
(25.6%) 
(100%) 
(11.6) 
(81.5%) 
(54.5%) 
(47.1 %) 
(35.7%) 
(18.9%) 
(11.5%) 
(9.6%) 
(58.5%) 
Values are number of patients or means with valid percentage or standard deviation 
between parentheses 
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Table 2 
Comparison of health related quality of life scores seen in the study population with 
scores seen in the general population 
Age in years 
Percentage men 
RAND-36 
Physical functioning 
Role physical 
Bodily pain' 
General health 
Vitality 
Social functioning 
Role emotional 
Mental health 
EuroQol 
Age in years 
Percentage men 
EQ-SD 
EQ-VAS 
Diabetes mellitus type I 
EuroQol utility 
This study 
(DMT1) 
n~274 
38.2 
54.4% 
90.4 (14.7) 
82.8 (32.4) 
88.7 (17.8) 
68.0 (20.1 I 
67.5 (20.0) 
86.9 (20.0) 
84.0 (31.8) 
76.6 (17.3) 
This study 
(DMT1) 
n~274 
38.3 
54.4% 
0.88 (0.17) 
80.8 (15.2) 
DMT1 
EQ-SD 
EQ-VAS- EuroQol Visual Analogue Scale 
General 
population [14] 
n ~ 195 
35-44 
31% 
90.0 (14.4) 
82.9 (32.0) 
83.8 (21.7) 
74.0 (20.7) 
67.1 (18.9) 
88.0 (17.6) 
82.2 (33.5) 
76.9 (18.0) 
General 
population [28] 
n ~561 
35-44 
45.6% 
0.91 (0.16) 
86.6 (13.8) 
Values are means with standard deviations between parentheses 
p-values concern T-test for independent samples 
1Higher Bodily pain score indicates less pain 
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p·values 
0.769 
0.974 
0.010 
0.002 
0.826 
0.529 
0.558 
0.857 
0.052 
< 0.001 
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Physical functioning 
-0.490 (p<0.0011 
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Older age, higher frequency of self-monitoring a week, macrovascular 
complications and comorbidity were associated with lower PCS scores (Table 3). 
The assessment of the impact of age and frequency of self-monitoring is based on a 
combination of the beta coefficient with the observed range in values. For 
example, a decrease in PCS score of 0.91 per 10 years increase in age was seen. In 
contrast, younger age, unmarried status, hyperglycaemic complaints and 
macrovascular complications were associated with lower MCS scores (Table 3). 
The presence of hyperglycaemic complaints, macrovascular complications and 
comorbidity were associated with lower EQ-50 scores (table 3). High level of 
education, higher Hba1 c, higher frequency of self-monitoring, hyperglycaemic 
complaints and macrovascular complications were associated with lower EQ-VAS 
scores (table 3). 
The Spearman rank correlations between the subscales of the RAND-36 and the 
EuroQol dimensions are shown in Table 4. The correlations between Mobility and 
'physical functioning' and 'role physical' were moderate. The dimension Self-care 
did not show any significant correlation with one of the RAND-36 subscales, while 
the Usual activities dimension was moderately/ strongly correlated with all 
subscales of the RAND-36. Pain/ discomfort was strongly correlated with the 
subscale 'bodily pain'. Anxiety/ depression was particularly correlated with the 
subscale 'mental health'. 
Discussion and conclusion 
HRQOL measured in our study population was comparable with the HRQOL of 
persons of comparable age in the Dutch general population (using the RAND-36), 
except for the subscales of 'bodily pain' and 'general health', which were 
respectively higher and lower than in the general population. We cannot explain 
why patients with DMT1 reported less pain (i.e. higher RAND-36 Bodily pain 
scores) than patients in the general population. A possible explanation is the fact 
that the percentage of females in the general population sample was higher than in 
our cohort (69% versus 46%) and that females tend to report more symptoms such 
as bodily pain [14, 29]. The EuroQol gave lower HRQOL levels for subjects with 
DMT1 than patients in a U.K. sample of the general population. Wikblad et al 
reported a HRQOL equal to persons in the general population just as in our study 
(mean age 43.5 years) [30]. In the study of Wandell et al, diabetic patients reported 
a HRQOL lower than persons in a population sample [31]. However their cohort 
was older (mean 51.5 year) than our cohort (mean 38.2 years). Recently Hahl et al 
reported a lower HRQOL for patients with DMT1 (in the age groups 35-44 and 45-
54) compared to the general population, measured with the 15-D, a generic 
measure [32]. 
The frequency of macrovascular complications was relatively low (9.6%) in our 
cohort, whereas microvascular complications were more prevalent (47.1 %), as 
could be expected with this duration of diabetes (mean 17.2 years). Almost by 
definition, the early stages of microvascular complications will not have an impact 
on daily life. Most complications were in the early stages in our patient group. 
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When considering our results of the uni- and multivariate regression analyses it is 
important to remember that statistically significant associations are not the same as 
clinically important relationships. The problem is the interpretation of one's 
statistical exercises [33]. Although the developers of the instruments do not 
promote the use of the smallest change which is still considered clinically 
significant, score changes of > 1 point for the summary scores [34], 0.05 points for 
the EQ-50 and 5 points for the EQ-VAS [EuroQol group] can be used as a guide. If 
we apply these arbitrary cut-off points, the components found in the regression 
models have a clinically important negative impact on the HRQOL of patients with 
DMT1. We can conclude that the presence of macrovascular complications 
definitely has a large negative impact on the HRQOL of patients with DMT1. 
Other studies also reported a worse HRQOL, measured with generic as well as 
diabetes-specific instruments, when late complications were present, but these 
studies did not differentiate between microvascular and macrovascular 
complications [30, 35-37]. 
Hahl et al, also reported a significant negative influence on HRQOL by the 
symptoms of long-term micro- and macrovascular complications [32]. In this study 
however, they used self-reported symptoms of the complications instead of the 
objective scoring of complications in our cohort. The presence of microvascular 
complications seemed to be of minor influence on the HRQOL in our study. In the 
multivariate regression analyses these complications did not have a statistically 
significant influence on HRQOL. Perhaps this finding can be explained by the fact 
that a light to moderate degree of neuropathy, retinopathy and/ or nephropathy 
will not even cause minor symptoms or complaints and thus will not interrupt 
daily life in subjects with DMT1. In contrast, macrovascular complications will 
virtually always cause manifest symptoms or complaints. However, two studies 
described an influence of microvascular complications on HRQOL [38, 39]. 
Hanestad et al reported that the presence of nephropathy had a negative effect on 
HRQOL, whereas neuropathy was associated with a better HRQOL in her study. 
The severity of complications was not properly clarified. Wu et al observed a 
higher HRQOL (measured with the SF-36) for patients with retinopathy and 
concluded that further study was needed to explore the underlying reasons for this 
surprising finding. The U.K. Prospective Diabetes Study (UKPDS) reported for 
patients with diabetes mellitus type 2 (DMT2) the same negative impact on 
HRQOL by the presence of long-term complications [40]. Patients with 
macrovascular complications reported a lower EQ-50, while patients with 
microvascular complications reported more tension and a total mood disturbance 
(Profile of Mood State). In this study, too, the generic measure (EQ-50) did not 
measure a lowered HRQOL by microvascular complications. Perhaps the generic 
instruments, such as the EQ-50, are not sensitive enough to measure the 
sometimes mild symptoms associated with the microvascular complications. 
Redekop et al however did find an association between microvascular 
complications and reduced HRQOL [41]. 
Another negative influence on HRQOL is the presence of hyperglycaemic 
complaints. These had a negative association with the RAND-36 and the EuroQol 
scores, whereas - remarkably- the presence of hypoglycaemic events was of less 
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importance. Only the univariate analysis for the EQ-VAS showed a significant 
negative influence of the presence of hypoglycaemic events. However, in the 
intensive treatment group of the Diabetes Control and Complications Trial the 
presence of hypoglycaemia was the only factor which tended to cause a decreased 
HRQOL, by more symptomatic distress [3]. 
In our study, patients receiving continuous insulin pump therapy reported a lower 
MCS and EQ-5D. Such an intensive therapy obliges the patients to monitor their 
blood glucose levels more frequently. However, and especially, it was the 
frequency of self-monitoring, which remained of significant negative influence in 
the multivariate analysis of both the PCS and the EQ-VAS. The correlation between 
the frequency of self-monitoring and continuous insulin therapy was moderate 
(0.503, p~ 0.010). Therefore, the obligatory high frequency of self-monitoring 
associated with continuous insulin therapy could explain the perceived lower 
HRQOL of patients using continuous therapy. 
The finding that women, older patients and patients without a partner reported a 
lower HRQOL confirms the results of other studies [30, 35, 36, 38, 42]. The 
positive influence of age on the MCS has not been described before (Table 3). 
Perhaps the fact that these patients have learned to cope with a chronic disease 
like DMT1, positively influences mental state. The finding that patients with a 
higher education reported a lower EQ-VAS score is new. The reason for this 
finding is unclear. 
What is the relevance of knowing these relationships between patient 
characteristics and HRQOL? Many personal characteristics such as sex and age 
cannot be influenced. Nevertheless it is of great importance for clinicians to be 
aware of patients likely to have a lower HRQOL. Concerning other factors, for 
example the frequency of self-monitoring, it might be possible to try to reduce the 
frequency to what is absolutely necessary. 
Most correlations between the dimensions of the EQ and the subscales of the 
RAND-36 were as expected. Oddly enough the dimension 'self care' did not show 
any statistically significant correlation with any RAND-36 subscale. It is possible 
that this item, concerning washing and dressing oneself, is too specific to be 
reflected in the total score for a RAND subscale. Usual activities are shown to be 
influenced by both physical and mental factors. The highest correlation of the 
dimension Anxiety/ depression was with the mental health subscale, the RAND 
subscale with the highest correlation with the MCS [34]. 
The response rates for both instruments were equal, so the length of the RAND-36 
did not seem to be a problem for this group of patients, but this is likely due to 
their incorporation into one questionnaire. Most relationships between patient 
characteristics and HRQOL were assessed by both instruments, except for age and 
having a partner by the RAND-36 and the level of education and Hba1c by the 
EuroQol. The shortness and simplicity of the EuroQol as well as its capacity to 
make economic evaluations possible are major advantages of this instrument. Still, 
the more detailed information (eight different subscales) and the distinction 
between a 'physical score' and a 'mental score' are clear advantages of the RAND-
36. 
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Conclusion 
HRQOL in patients with DMTl is comparable with that of a general population 
sample. The presence of hyperglycaemic complaints and macrovascular 
complications had the most pronounced negative association with HQOL. 
Longitudinal data and comparison with results of several diabetes-specific HRQOL 
questionnaires should help to establish which instrument might be most 
appropriate to measure HRQOL in patients with DMTl. 
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Abstract 
Objective 
The aim of this study was to investigate the health related quality of life (HRQOL) 
of patients with newly diagnosed diabetes mellitus type I (DMT1) during the first 
year after diagnosis and to compare their HRQOL, one year after diagnosis, with 
people of comparable age from the general population and with other patients 
who were diagnosed with DMT1 longer than one year prior to the start of the 
study period. 
Research design and methods 
We used the RAND-36 and the EuroQol to assess the HRQOL of fifteen patients 
who had been newly diagnosed with DMT1. To compare HRQOL scores, we 
converted the individual raw scores into percentiles based on the average scores of 
the comparison population. 
Results 
The improvements in the subscales role physical, vitality, and mental health as 
well those seen in the physical summary score and in the EQ-VAS were statistically 
significant within the first six months of diagnosis. The next half-year did not show 
any further significant changes in HRQOL After one year, the HRQOL of the 
newly diagnosed patients was comparable with that of persons in the general 
population and with patients with a longer disease duration. 
Conclusion 
The HRQOL improved in newly diagnosed patients during the first six months 
following diagnosis. One year after diagnosis the HRQOL is comparable with 
persons from the general population and with patients with DMT1 with a longer 
disease duration. 
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Introduction 
The diagnosis of diabetes mellitus type I (DMTl) permanently changes a person's 
life. The transition from being a healthy person to a person with a chronic illness 
can have a considerable impact (1). Newly diagnosed patients have to consider 
their diet, insulin therapy, exercise and daily self-monitoring of their blood glucose 
which will likely affect their health related quality of life (HRQOL) (2). The aim of 
the present study was to investigate the HRQOL in patients newly diagnosed with 
DMT1 (1), to follow their progress during the year following the diagnosis to 
monitor the effect on their HRQOL (2), and to determine which factors are 
important in influencing the HRQOL during those first twelve months after the 
diagnosis has been made (3). We also compared the patients' one year HRQOL 
reports with those obtained from age matched controls from the general 
population (4.1) and from patients with DMT1 with a longer duration of disease 
(4.2). 
Methods 
Patients 
During 1995 and 1996, 15 patients who were diagnosed with diabetes mellitus 
type I (DMTl) at the outpatient clinic of the lsala Clinics in Zwolle, The 
Netherlands were included in this study. They were followed for a period of 
twelve months from the time of diagnosis. The diagnosis of DMT1 was based on 
the initiation of insulin therapy within six months of the manifestation of the 
diabetes mellitus, with the diagnosis occurring before the age of thirty, or on the 
absence of (-peptide secretion. Approval for the study was obtained from the 
Hospital Scientific and Ethics Committee. All patients gave informed consent. 
Clinical data 
Demographic data such as gender, age, and level of education were recorded at 
baseline. 
Patients underwent a physical examination at the time of diagnosis (baseline), and 
at six and twelve months. Metabolic control was assessed by measuring levels of 
glycosylated hemoglobin Ale (HbA1c) at baseline, monthly during the first six 
months, at nine months, and then again after twelve months. The lipid profile and 
micro-albuminuria were measured at the same time intervals. 
Comorbidity was assessed using a list of 26 chronic diseases, on which patients 
were asked to indicate any which applied to them (3). When they indicated one 
or more chronic diseases apart from their diagnosis of DMT1, they were scored 
positive for comorbidity. 
During each of the three outpatient visits, one at baseline, one at six months, and 
one at twelve months, patients were asked to report whether they had experienced 
one of a list of six hyperglycaemic complaints, including fatigue, weight loss, 
pruritus, thirst, polyuria, and polydipsia. They were also asked, at baseline and at 
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twelve months, whether they experienced any problems with the activities of daily 
living such as shopping, work, school, and household chores. 
Any acute complications arising from the therapy were recorded: the patients 
recorded all hypoglycaemic events during the three months preceding the 
outpatients visits at six and twelve months. 
Health Related Quality of life: 
Health related quality of life (HRQOL) was assessed at baseline, at six months, and 
at twelve months, using two generic instruments. Generic instruments were 
chosen to facilitate comparisons with persons from the general population. The 
questionnaires were mailed to the patient's home address shortly before a 
scheduled outpatient visit. Patients were directed to complete the questionnaires at 
home before coming in for their appointment and to return the completed 
questionnaire to the nurse when they came in. 
The RAND-36-item Health Survey (RAND-36) 
The RAND-36 is a self-administered, generic, multi-dimensional questionnaire 
consisting of 36 items, which measures HRQOL, and takes approximately ten 
minutes to complete (4, 5). The response alternatives vary from 2 ('yes' and 'no') 
to 6 (Likert scale). The reference period is four weeks. The 36 items are divided 
into eight subscales: physical functioning, role limitations due to physical 
problems, bodily pain, general health perception, vitality, social functioning, role 
limitations due to emotional problems, and mental health. For each subscale 
scores were coded, summed, and converted to a scale from zero (worst health) to 
one hundred (best health) (6). Physical and mental component summary scores 
were also determined (Physical Component Summary [PCS]/ Mental Component 
Summary [MCS]) (7). The instrument has been translated into the Dutch language 
(8), and has been validated for the Dutch population (9). 
The EuroQol (EQ) 
The EuroQol was developed by a multidisciplinary group of researchers from five 
European countries to describe and evaluate state of health (1 0). It is a simple, 
generic, multidimensional measure, consisting of two parts, which takes the 
patient about two minutes to complete. The reference period is the day of the 
measurement. Part one consists of five questions covering the areas Mobility, Self-
Care, Usual Activities, Pain/ Discomfort, and Anxiety/ Depression. The patient is 
asked to choose from three levels of functioning: 'no problem', 'some/ moderate 
problems', and 'extreme/ unable to'. The respondent's state of health is described 
by combining the levels indicated for each of the dimensions (EQ-5D). A total of 
243 possible states of health can be defined using this method. The UK general 
public has used a valuation technique called a time trade-off to make valuations of 
these health states (utility indices). The set of possible values has a range of -0.549 
to 1, where 1 indicates perfect health, 0 indicates death, and -0.549 indicates the 
worst possible health state, which is viewed as considerably worse than death by 
the UK general public (11). The EuroQol utility index facilitates economic 
evaluation. Furthermore, part two, a single overall score, can also be obtained 
from the EuroQol thermometer: a self-rated health-status using a graduated (0-1 00) 
visual analogue scale, similar to a thermometer (EQ-VAS). With the thermometer, 0 
64 
indicates the worst HRQOL and 100 indicates the best possible HRQOL. The 
EuroQol has been validated for the Dutch population (12). 
Analysis 
We performed Wilcoxon signed ranks tests to compare clinical data (i.e. HbA 1c, 
body mass index) and HRQOL at different points in time. We also carried out 
univariate and multivariate stepwise regression analyses, with HRQOL as the 
dependent variable, to investigate the relationship between HRQOL and 
demographic data (sex, age, marital status, and level of education) and diabetes 
related data (HbA 1 c, hyperglycaemic complaints, hypoglycaemic events). 
To compare the HRQOL of the study patients with age matched controls from the 
general population we converted individual scores into percentiles based on the 
general population average and standard deviation. A similar procedure was used 
when comparing the HRQOL of newly diagnosed patients with the HRQOL of 
patients with a longer disease duration, with the exception that no adjustment was 
made for age differences. AT-test for independent samples was used to compare 
the HRQOL of patients newly diagnosed with DMT1 with the HRQOL in the 
general population. The Mann Whitney U test was used to compare the HRQOL 
between newly diagnosed patients and patients with DMT1 of longer duration. 
We considered relationships to be statistically significant when p-values were 
,;; 0.05. Data were analyzed using SPSS for Windows, version 1 0.0.7. 
Results 
Fifteen patients were included in this study, one third of which was men. The 
mean age was 29.2 with a standard deviation of 12.0, and a range of fourteen to 
54 years (table 1). In the first six months following diagnosis, HbA 1 c levels 
declined significantly, from 14.3% to 5.9% (p<0.001; table 2). The percentage of 
patients that reported hyperglycaemic events showed a similar trend, decreasing 
from 93% to 53% (p~0.014). Body mass index increased significantly during the 
first six months of the study, from 22.2 to 23.9 kg/m' (p ~ 0.001 ). During the latter 
half of the year, there was no further significant change in either HbA 1 c levels or 
reported hyperglycaemic complaints (table 2). 
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Table 1 
Characteristics of patients with newly diagnosed diabetes mellitus type I (n= 15) 
Gender (men) 
Age (years) 
Married/ cohabiting 
High level of education 
Comorbidity (one or more chronic medical condition)* 
5 
29.2 
12 
2 
9 
(33.3%) 
(12.0) 
(80.0%) 
(13.3%) 
(69.0%) 
Values are number of patients or means with percentage or standard deviation between 
parentheses. 
*!n addHion to diabetes mellitus type I 
Table 2 
Clinical data during the first year following diagnosis (n= 15) 
Baseline 6 months 12 
months 
HbA1c(%) 14.3 (3.7) 5.9 (0.8) 6.9 (1.5) 
Cholesterol/ HDL ratio 4.5 (1.8) 3.3 (1.0) 3.5 (1.4) 
Body mass index (kg/m 2) 22.2 (3.7) 23.9 (3.7) 23.3 (3.0) 
Micro-albuminuria (mg/24 9.3 (6.7) 10.7 (12.4) 12.3 (14.8) 
hr) 
Number of patients with: 
hyperglycaemic complaints 14 (93 %) 8 (53%) 9 (60 %) 
hypoglycaemic events 12 (80 %) 10 (67 °/o) 
problems with ADL * 4 (27 %) 3 (20 %) 
Values are means with standard deviations (SD) in parentheses 
P values are result of Wilcoxon signed ranks tests. 
' Not applicable 
2 Not measured 
*Activif1es of Daily Living 
p value p value 
0-6 6-12 
0.001 0.075 
0.001 0.068 
0.001 0.441 
0.955 0.454 
0.014 0.564 
0.317 
The same was true for the body mass index. Hypoglycaemic events were reported 
by twelve patients (80%) at the six month point and ten patients (66.7%) at the 
twelve month point in the study. Table 3 gives a detailed overview of the follow-
up of the HbA 1 c levels for the first six months following diagnosis. The first three 
months showed significant declines, which tapered off entirely during months four, 
five, and six. 
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Table 3 
Follow up of HbA1c during the first six months following diagnosis 
Mean SD Range p-value 
Baseline 14.3 3.7 8.2 21.9 
Month 1 9.6 2.0 6.9 13. 1 0.001 
Month 2 7.0 0.8 5.6 8.7 0.001 
Month 3 5.9 1.0 4.4 8.0 0.006 
Month 4 5.8 0.6 4.9 6.9 0.533 
Month 5 6.0 0.8 4.7 7.2 0.211 
Month 6 5.9 0.8 4.8 7.3 0.972 
Mean -meanHbA1c 
SD -standard deviation 
Range - range of the H bA 1 c values 
P values are the result of Wilcoxon signed ranks test 
HRQOL- from baseline to six months after diagnosis 
RAN0-36 All subscales and both summary scores showed an increase during the 
first six months after diagnosis. The increases of the subscales 'role physical', 
'vitality', and 'mental health', and the PCS were statistically significant (table 4). 
EuroQol Both the EQ-50 and the EQ-VAS showed an increase during the first six 
months. The increase of the EQ-VAS was statistically significant. 
HRQOL- from six to twelve months after diagnosis 
There were no statistically significant changes in the HRQOL (i.e. all RAND-36 
and EuroQol outcomes) during the last six months of the twelve month study 
period. 
HRQOL- from baseline to twelve months after diagnosis 
RAN0-36 The subscales 'physical functioning' and 'role physical' and the PCS 
showed an increase immediately following diagnosis and continued to increase 
significantly during the entire twelve month period. The subscale 'vitality' tended 
to decrease during the last six months of the twelve months study period, but 
reached a value (70.0 with a standard deviation 21.6) that was significant higher 
than at baseline. The other RAND subscales and the MCS did not change (table 4). 
EuroQol The EQ-50 did not show statistically significant changes during the 
overall study period. The EQ-VAS increased significantly from its baseline value. 
Associations with HRQOL at the moment of diagnosis 
The univariate analysis showed that patients who were either married or 
cohabiting reported a higher EQ-50 and a lower EQ-VAS than other respondents. 
Patients who were positive for comorbidity reported a lower MCS (table 5). These 
associations were still present following multivariate regression analysis (table 5). 
67 
Table 4 
H
ealth related quality of life during the first year after the diagnosis of diabetes m
ellitus type I (n ~ 15) 
Baseline 
6 m
o
nths 
12 m
o
nths 
P v
alue 
P v
alue 
P v
alue 
0-6 m
o
nths 
6-12 m
o
nths 
0-12 m
o
nths 
R
A
N
D
-
36 
Physical functioning 
82.3 (22.0) 
89.0 (18.2) 
93.7 (9.7) 
0.081 
0.168 
0.018 
R
ole physical 
56.7 (44.8) 
83.3 (34.9) 
88.3 (18.6) 
0.034 
0.518 
0.001 
B
odily pain 
86.8 (14.8) 
90.8 (16.6) 
87.8 (21.5) 
0.360 
0.416 
0.506 
G
eneral health 
68.0 (20.2) 
80.7 (14.5) 
78.3 (16.9) 
0.063 
0.428 
0.214 
V
itality 
50.3 (23.9) 
71.7 (19.3) 
70.0 (21.6) 
0.005 
0.860 
0.004 
Social functioning 
80.0 (25.8) 
90.0 (17.8) 
85.0 (27.6) 
0.200 
0.290 
0.389 
Role e
m
otional 
80.0 (35.2) 
84.4 (30.5) 
86.7 (30.3) 
0.607 
0.783 
0.276 
M
ental health 
68.3 (26.1) 
80.8 (16.3) 
77.1 (23.5) 
0.037 
0.404 
0.082 
Physical Com
ponent Sum
m
ary 
48.8 (7.3) 
53.4 (6.1) 
54.4 (3.4) 
0.009 
0.730 
0.004 
M
ental C
om
ponent Sum
m
ary 
47.1 112.5) 
52.8 (7.8) 
50.8 (11.5) 
0.088 
0.331 
0.173 
EuroQol 
U
tility index 
0.79 (0.19) 
0.88 (0.19) 
0.88 (0.19) 
0.154 
0.917 
0.061 
Visual Analogue Scale 
74.0 (19.8) 
87.6 (11.5) 
84.9 (12.4) 
0.005 
0.331 
0.036 
Values are m
eans w
ith standard deviation in parentheses 
P-values a
re
 re
sult of W
ilcoxon signed ranks tests 
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Table 6 
Com
parison of H
RQOL of patients n
ew
ly diagnosed w
ith DM
T1 
w
ith that of persons from
 the general population a
nd that of patients 
w
ith DM
T1 
w
ith a longer disease duration 
Patients w
ith 
Patients 
a longer 
G
eneral 
w
ith D
M
T1 
disease 
This study at 
population 
I 
w
ith a 
II 
duration: 
Ill 
12 m
o
nths 
sa
m
ple
1 
longer 
<
 40 yrs. old 
disease 
a
nd w
ithout 
duration
2 
m
a
c
ro
v
a
sc
ular 
c
o
m
plications 
RA
N
D
-36 
Physical functioning 
93.7 I 9.71 
89.4 14.01 
0.60 10.201 
90.4114.71 
0.59 10.231 
94.7 I 8.01 
0.53 10.291 
R
ole physical 
88.3 118.61 
83.7 12.51 
0.56 10.201 
82.8 132.41 
0.5710.211 
88.6 126.51 
0.52 10.231 
B
odily pain 
87.8 121.51 
85.3 12.71 
0.57 10.251 
88.7 117.81 
0.55 10.271 
91.6 115.61 
0.50 10.281 
G
eneral health 
78.3 116.91 
75.8 12.1 I 
0.54 (0.261 
68.0 120.1) 
0.65 10.261 
71.6 118.31 
0.61 10.291 
V
itality 
70.0 121.61 
68.5 10.91 
0.56 10.321 
67.5 120.01 
0.56 10.31 I 
68.5118.11 
0.56 10.331 
Social functioning 
85.0 127.61 
87.1 12.1) 
0.55 10.281 
86.9 120.01 
0.55 10.281 
89.6 117.61 
0.52 10.281 
R
ole e
m
otional 
86.7 130.31 
82.8 12.31 
0.58 10.251 
84.0 131.81 
0.58 10.251 
88.2 128.1 I 
0.55 10.251 
M
ental health 
77.1 123.51 
75.6 12.31 
0.5610.311 
76.6 117.31 
0.56 10.331 
77.2 116.11 
0.55 10.341 
PCS 
54.4 I 3.41 
52.2 I 7.31 
0.6110.171 
54.1 I 5.91 
0.52 10.201 
M
CS 
50.8111.51 
50.8110.11 
0.54 10.31 I 
51.119.91 
0.54 10.31) 
EuroQol 
EQ-5D 
0.88 10.191 
0.92 10.031 
0.47 10.291 
0.88 10.171 
0.55 10.271 
0.9210.131 
0.49 10.31) 
EQ-VAS 
84.9112.41 
86.0 11.61 
0.49 10.281 
80.8 115.31 
0.59 10.271 
82.9 113.31 
0.55 10.301 
I 
Percentiles in co
m
parison w
ith general population sa
m
ple 
II 
Percentiles in co
m
parison w
ith patients w
ith a
 longer disease duration 
Ill 
Percentiles in co
m
parison w
ith patients a
 longer disease duration, but <
40 years a
nd w
ithout m
a
cro
va
scular co
m
plications 
Values are m
eans w
ith standard deviations in parentheses 
' A
ge adjusted w
ith D
utch general population IRA
N
D
-361 a
nd w
ith age a
nd sex
 adjusted UK G
eneral population IEQI 16, 131 
'M
ean duration of diabetes 17.2 years 110.71, m
e
a
n
 age 38.2 years 112.411141 
Associations with HRQOL six months after diagnosis 
Older patients reported a lower MCS. Patients with a higher body mass index 
(which increased during the first six months) reported a lower MCS. No significant 
associations were found following multivariate analysis, however (table 5). 
Associations with HRQOL twelve months after diagnosis 
Older patients and patients having problems with the activities of daily living 
reported a lower PCS. The age-related difference remained apparent following 
multivariate regression analysis (table 5). Patients with a higher HbA 1c reported a 
lower MCS and EQ-50. The same result was found with the multivariate analysis 
(table 5). Patients with hyperglycaemic complaints reported a lower EQ-VAS (table 
5). 
Comparison in HRQOL with the general population 
One year post-diagnosis, we compared the RAN D-36 scores of the patient 
population with scores obtained from age matched controls from the general 
population (6). The mean percentiles for the RAND-36 ranged from 0.54 to 0.60 
for the eight subscales. This meant that patients newly diagnosed with DMT1 were 
reporting a HRQOL that tended to be somewhat higher than that being reported by 
persons from the general population. These differences were not statistically 
significant, however. 
We also compared the one year post-diagnosis EuroQol scores of the study 
population patients with those obtained from age matched controls from the 
general population (13). The mean percentiles were 0.47 (EQ-50) and 0.49 (EQ-
VAS). This meant that the patients were reporting their HRQOLs to be marginally 
lower than persons in the general population. Here again, however, the differences 
were not statistically significant. 
Comparison in HRQOL with diabetes patients with a longer disease duration 
One year after diagnosis, we compared the HRQOL of the study population 
patients with the HRQOL of patients who had been diagnosed with DMT1 an 
average of 17.2 years earlier (14). The mean percentiles for the RAND-36 and the 
EuroQol were 0.54-0.65. This meant that the patients who were newly diagnosed 
were reporting a HRQOL which was somewhat higher than that reported by the 
patients who had had the disease for a longer time duration. These differences 
were not statistically significant. 
We expected the HRQOL of the newly diagnosed patients to be similar to the 
scores of patients with a longer disease duration who were younger ( <40 years), 
and who were without complications (macrovascular) from their diabetes (2, 15). 
In fact, when we compared the HRQOL of the study population with that of a 
subgroup of patients without macrovascular complications and who were younger 
than 40 years, the differences largely disappeared, except in the subscale of 
'general health', where the newly diagnosed group tended to score higher. 
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Discussion 
After the diagnosis DMT1 is made, all HRQOL scores improved during the first 
half year of the study period. One year post-diagnosis all HRQOL scores are higher 
than at baseline. Whether this result is due to the use of a generic instrument 
instead of a disease-specific instrument remains to be investigated. 
All the cumbersome aspects of the disease, such as diet, insulin injections, and 
daily blood glucose monitoring, appear to be accepted fairly quickly, and 
incorporated in daily lifestile, within twelve months of the diagnosis. 
It should be noted that the presence of comorbidity and hyperglycaemic 
complaints had a measurable negative influence on HRQOL, however. We 
concluded that the presence of DMT1 does not decrease HRQOL, unless there are 
symptoms present. 
Although the sample size included of the present study is limited, we think that the 
results obtained are representative. 
After one year, when in a stable situation, the patients in the study population 
reported a HRQOL which tended to be somewhat higher (RAND-36) and 
marginally lower (EuroQol) than that of the age matched controls. These 
differences were not significant, however. Unfortunately, only the EuroQol 
allowed for comparisons on the basis of gender. 
When comparing on the basis of disease duration, the newly diagnosed patients 
tended to report a somewhat better HRQOL, though these results, too, were not 
significant. The patients in our study were generally somewhat younger, and did 
not yet have any of the macrovascular complications, which affect HRQOL (15). 
The HRQOL improves during the first six months after a patient is diagnosed with 
diabetes mellitus type I. One year after the diagnosis the HRQOL of the patient is 
comparable to that of persons in the general population and patients with DMT1 of 
longer duration. 
Acknowledgements: We thank the Northern Centre for Healthcare Research of the 
University of Croningen for providing data to compare our data with those of a sample of 
the general Dutch population. 
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Abstract 
Objective 
The objective of this study was to investigate the health related quality of life 
(HRQOL) of patients with type I diabetes mellitus (DMT1) over time and to 
compare change in perceived HRQOL with that of a sample of the general 
population. 
Methods 
In a Dutch cohort of 234 patients with DMT1 we assessed, over a period of six 
years, the HRQOL with two generic instruments: RAND-36 and EuroQol. We 
applied multilevel modelling to estimate the change in HRQOL over the years 
1995-2001. We compared change in HRQOL with the change estimated from a 
comparably aged sample from the general population using a one sample T-test. 
Results 
Patients reported a statistically significant decrease in HRQOL for most RAND-36 
subscales and the PCS. Mean changes in RAND-36 scores ranged from -0.09 per 
year (mental health) to -1.18 per year (bodily pain). EQ scores decreased 
significantly as well. Patients in the cohort had a faster decrease over time in five 
RAND-36 subscales, the PCS and MCS, and the EQ-VAS than the estimated 
decrease in the general population. 
Conclusion 
This study showed that patients with DMT1 have a faster decrease in HRQOL over 
time than comparably aged persons from the general population. The generic 
instruments used in our study were sensitive enough to measure changes in 
HRQOL over time in an adult diabetes population. 
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Introduction 
Type I diabetes mellitus (DMT1) is a chronic disease with an onset in childhood or 
adolescence. The total inability to produce insulin obliges patients to administer 
(multiple) daily insulin injections to regulate their blood glucose properly (1, 2). 
Despite such efforts, many patients will develop chronic diabetic complications, 
both microvascular and macrovascular. 
The Diabetes Control and Complications Trial (DCCT) has shown that the more 
intense the treatment, the better the chances to delay the onset and the progression 
of microvascular complications (3). For this reason, patients have to administer 
insulin injections at least four times daily or use an insulin pump, besides regularly 
monitoring blood glucose levels. 
Throughout their entire lives, patients will need to find a balance between food 
intake, exercise and insulin dose in order to reach and maintain a good glucose 
control. Thus, DMT1 and its therapy may have a considerable impact on health 
related quality of life (HRQOL). 
For afflictions like DMT1, with its onset in youth and a lifelong therapy and self-
management regime, it is important to be able to assess and interpret factors 
influencing HRQOL properly (4). Indeed, many studies have investigated 
influences on HRQOL. Most HRQOL measurements were at one moment (cross-
sectional), showing that patients with DMT1 have slightly poorer scores than 
persons in the general population, especially women, the older and the less 
educated patients, and patients without a partner (5-20). Furthermore, patients with 
complications have a lower HRQOL (9, 16, 19, 21-24). 
Very little has been published regarding the long-term changes in HRQOL 
amongst type 1 diabetes patients. Only two studies, the study of Wandell et al 
(n~20) and the DCCT study (n~1441) have examined HRQOL over time in adult 
patients with DMT1 (18, 25). Both reported no change in HRQOL over time, over 
three and six years respectively. While Wandell et al used a generic instrument, 
the DCCT study used a diabetes-specific instrument. 
The aim of this study was (1) to measure the HRQOL of patients with DMT1 over 
time and (2) to compare changes in HRQOL over time, with changes expected in 
the general population. 
Methods 
Patients 
From january to july 1995 293 consecutive DMT1 patients, treated at the 
outpatient department of the lsala Clinics in Zwolle, the Netherlands, were invited 
to participate in this study. Of these patients 95.6% (n~281) agreed to participate 
and was included in the study. DMT1 was defined as starting insulin therapy 
within six months after the first signs of diabetes mellitus and before the age of 30 
years, or the absence of C-peptide secretion. Approval was obtained from the 
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Hospital Scientific and Ethics Committee. All patients gave informed consent. This 
cohort has been followed for six years (1995-2001 ). 
Health Related Quality of life 
HRQOL was assessed using two generic instruments, the RAND-36-item Health 
Survey (RAND-361 and the EuroQol. 
The RAND-36 is a self-administered questionnaire containing 36 items involving 
eight different subscales: physical functioning, role limitations due to physical 
problems, bodily pain, general health perception, vitality, social functioning, role 
limitations due to emotional problems, and mental health. For each subscale, 
scores were coded, summed up and transformed to a scale from 0 (worst health) to 
100 (best health) (26, 27). In addition, physical and mental component summary 
scores were determined (PCS/ MCS) (28). Both summary scales are based on all 
eight calculated subscales. These subscales are factor analysed, using Principal 
Component Analysis, followed by an orthogonal rotation. Each of the summary 
scales were standardized and transformed, so that both PCS and MCS had a mean 
of 50 and a standard deviation of 10 (28). The subscales physical functioning, role 
physical and bodily pain contribute most to the scoring of the PCS. Mental health, 
role emotional and social functioning subscales contribute most to the scoring of 
the MCS (29). The questionnaire takes about ten minutes to complete. The 
instrument has been translated into Dutch and validated for the Dutch population 
(30, 31). The RAND-36 was completed annually. 
The EuroQol is a simple generic measure, consisting of two parts (EQ-5D and EQ-
VAS), and was developed by a multidisciplinary group of researchers from five 
European countries (32). For the EQ-SD part, there are five questions covering the 
areas Mobility, Self Care, Usual Activities, Pain/ discomfort and Anxiety/ 
depression. Each dimension is divided into three levels: no problem, some/ 
moderate problems and extreme problems/ unable to perform. A respondent's 
health state is defined by combining the status regarding each of the five 
dimensions (EQ-SD). A total of 243 possible health states can be defined in this 
way. Valuations of these health states have been made by the U.K. general public, 
using a valuation technique called time trade-off. The values, or utilities, are scaled 
on a scale on which 0 is the value of dead and 1 is the value of perfect health (33). 
Furthermore a single overall score can be elicited using the EuroQol thermometer, 
a self rated health status using a graduated (0-1 00) visual analogue scale, similar to 
a thermometer (EQ-VAS). The EuroQol takes about two minutes to complete and 
has been validated for the Dutch situation (34). The EuroQol was completed in the 
years 1995 to 1998 and in the year 2001. 
Questionnaires were sent by mail to the patient's home address. Patients were 
asked to fill in the questionnaires at home. At the time of the visit to the outpatient 
clinic, the patients returned the completed questionnaires to the diabetes specialist 
nurse. Patients who did not return the completed questionnaires when visiting the 
clinic were asked to send their completed questionnaires afterwards. 
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Clinical data 
One trained physician examined all patients according to a standardised protocol 
at the entry of the study. Demographic data (marital status, level of education) and 
data concerning therapy (frequency of insulin injection, frequency of self 
monitoring of blood glucose) were recorded annually. Patients recorded all 
hypoglycaemic events ('did you have a hypo in the past three months?') during the 
three months preceding the outpatient visit and were asked to report whether they 
had one or more of six different hyperglycaemic complaints during the last three 
months (yes/ no): tiredness, weight loss, pruritus, thirst, polyuria and polydipsia. 
Metabolic control was assessed by measuring glycosylated haemoglobin A 1 c 
(HbA1c). 
The presence of comorbidity (one or more diseases besides diabetes or diabetic 
complications) was assessed using a list of 26 chronic diseases in the years 1995, 
1998 and 2001 (35). 
Macrovascular complications 
Macrovascular complications comprised angina pectoris, myocardial infarction, 
intermittent claudication, transient ischaemic attack (TIA), and cerebrovascular 
accident (CVA). The physician recorded these diagnoses in the clinical status of all 
patients in 1995 and 2001. 
Microvascular complications 
Patients with retinopathy, neuropathy or nephropathy were diagnosed as having 
microvascular complications. 
Retinopathy 
The ophthalmologist examined all patients annually. The degree of diabetic 
retinopathy was assessed by fundoscopy in mydriasis. The classification of diabetic 
retinopathy used was based on de Jong (36): no retinopathy (~0), background 
retinopathy (~I) preproliferative (~II) and proliferative diabetic retinopathy (~Ill). 
Retinopathy was scored positive when any type of retinopathy was present in 
either eye. When the degree of retinopathy was different in two eyes, the highest 
degree was scored. 
Neuropathy 
Sensitivity was tested by the Semmes-Weinstein pressure aesthesiometer (37). At 
five dorsal and plantar sites on the feet sensitivity was tested using six different 
monofilaments. When the monofilament 5.07 was not felt at one of the ten test 
sites, patients were diagnosed as having neuropathy. Patients were examined by 
the podotherapist in the years 1995, 1998 and 2001. 
Nephropathy 
The 24-hour urinary excretion of albumin (UAER) was measured annually. UAER 
was considered abnormal when it was eo 30mg/ 24 hours. Micro-albuminuria was 
defined as 30-300 mg/ 24 hours and macro-albuminuria as 2:300 mg/ 24 hours. All 
patients with micro-albuminuria or macro-albuminuria were defined as having 
nephropathy (38-40). At the start of the study (1995) patients with micro-
albuminuria > 100 mg/ 24 hour received an angiotensin converting enzyme 
inhibitor (ACE-inhibitor). We classified ACE-inhibitor users as having nephropathy, 
unless ACE-inhibition was started specifically for hypertension. 
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Analysis 
To compare the dropouts with the patients who continued in the study we used an 
independent sample T-test for the continuous variables and the Fishers Exact Test 
for the categorical variables. 
We applied multilevel modelling to investigate the change in HRQOL over the 
years 1995 - 2001 (41). This method, also known as growth curve analysis, 
enables the use of all HRQOL values for an individual patient, unlike repeated 
measures analysis where only patients with complete data can be included in the 
analysis (42). In simple terms, the approach can be likened to a linear regression 
approach. If the HRQOL scores for a single patient are drawn on a graph where 
the x-axis represents time and y-axis represents HRQOL and if a line is drawn 
through these scores, the slope of this line can be seen to represent the rate of 
change in HRQOL over time for that individual patient. If this process is repeated 
for all patients, the average rate of change in HRQOL over time in the study 
population can be estimated. One general assumption in the analysis is that 
missing values are missing at random. As well, we assumed that change in 
HRQOL was linear in form since there was no reason to assume a more complex 
form. 
We tested the null hypothesis that there was no change in HRQOL over time. The 
developers of both the RAND-36 and the EuroQol do not provide cut-off points for 
clinically important changes in HRQOL scores. However, changes of> 2-5 points 
for the RAND-subscales and > 1 point for the RAND summary scores are 
sometimes considered as the smallest clinically significant changes (44-46). For the 
EQ-5D and the EQ-VAS, 0.05 points and five points can be used as a rough guide 
although formally the EuroQol Group has not published any minimally significant 
values. 
HRQOL of patients was compared with the HRQOL of a sample from the general 
population by comparing the annual change in HRQOL in the cohort with the 
expected annual change in the general population using a one-sample t-test (27, 
47). Since no longitudinal HRQOL data were available for the general population, 
we compared data from persons in two consecutive age categories (age groups 35-
44 and 45-54 years). We divided the difference in HRQOL of these two age 
categories by ten to estimate the expected change per year. 
Additionally we performed univariate regression analyses, HRQOL scores in 2001 
being the dependent variable, to investigate associations of the presence of 
comorbidity, microvascular and macrovascular complications in 2001 with 
HRQOL scores in 2001. 
Changes were considered statistically significant when p-values less than 0.05 
were observed. Data were analysed using SAS version 8.2. 
Results 
A total of 281 adult patients with DMT1 entered the study in 1995. 
The dropout rate over these six years was low (16.7%, n~47). Dropouts from the 
study were more frequently female (59.6% vs. 42.7%, p~0.04), were patients with 
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a longer disease duration (20.6 vs. 16.5 years, p~0.05), were more often single 
(24.0% vs. 9.2%, p~0.01) and had a higher HbA1c (9.0% vs. 8.1 %, p~0.007) 
than the patients who remained in the study period for six years. 
Dropouts reported a lower baseline HRQOL for the following RAND-36 subscales: 
physical functioning, bodily pain, general health, social functioning, role 
emotional, mental health and the MCS. The PCS was not statistically significant 
lower. EuroQol scores were also significantly lower. 
With regarding to the parameters shown in Table 1, dropouts showed no other 
statistically significant differences from the patients who completed the total study 
period. Of the dropouts, five patients died for the following reasons: motor vehicle 
accident (n ~ 1), cerebrovascular accident (n ~ 1), cardiac problems (n ~2), reason 
unknown (n ~ 1 ). 
Personal and disease-specific characteristics of the 234 patients followed for the 
total study period of six years are shown in Table 1. 
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Table 1 
Personal and disease-specific characteristics of the study population (n = 234) 
1995 2001 
Gender (men) 134 (57.3%) 134 (57.3%) 
Age (years) 38.2 (11 .5) 44.2 (11.5) 
Duration of diabetes (years) 16.5 110.1 I 22.5 110.1 I 
Married/ cohabiting 207 (90.8%) 189 (87.9%) 
High level of education 76 (33.6%) 76 (35.5%) 
Systolic blood pressure (mm Hg) 138.9 (17.8) 131.5 (19.2) 
Diastolic blood pressure (mm Hg) 83.0 ( 8.4) 77.8 (1 0.4) 
Pulse pressure 55.9 (15.2) 53.7 (16.9) 
Ratio cholesterol/ HDL(mmol/1) 3.8 ( 1.2) 3.3 ( 1.1) 
Body mass index (kg/m2) 24.8 (3.2) 26.1 (4.0) 
Hba1c (%) 8.1 (1.9) 7.6 11.1 I 
Insulin pump 63 (26.9%) 102 (43.6%) 
Number of control measurements 
per week 12.0 (11.3) 20.0 (15.2) 
Number of patients with: 
hypoglycaem ic events 185 (80.8%) 173 (87.4%) 
hyperglycaemic complaints 122 (53.2%) 116 (58.3%) 
Prevalence of diabetic complications 
Microvascular 104 (45.8%) 119 (65.7%) 
Retinopathy 79 (34.6%) 99 (48.5%) 
Nephropathy 43 (18.4%) 45 (23.0%) 
Neuropathy 24 (10.4%) 23 (12.2%) 
Macrovascular 10 I 4.3%1 23 (9.8%) 
Comorbidity 133 (58.1 %) 107 (52.7%) 
Values are number of patients or means with valid percentage or standard deviation 
between parentheses 
Mean age in the study population at the start of the study was 38.2 years and 
57.3% were men. A quarter of the patients used a pump (26.9%). 
Almost half of the patients had microvascular complications (45.8%, up to 65.7% 
in 2001), whereas only 4.3 % had macrovascular complications (mainly angina 
pectoris and intermittent claudication), up to 9.8% in 2001. Those patients with 
comorbidity (58.1 %) mostly had one or two other chronic medical conditions 
besides their diabetes. This percentage did not show statistically significant 
changes during the study period (McNemar test, p~0.526). 
Table 2 shows the changes in RAND-36 and EuroQol scores over time. The 
response rate, the percentage of patients from the study population (n ~234) that 
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completed the questionnaires, was high, ranging from 97.4 % in 1995 to 91.0 % 
in 2001. 
RAN0-36 
Change per year: patients reported a statistically significant decrease per year, for 
six of the eight RAND subscales and the PCS (table 3). The subscales role 
emotional and mental health and the MCS did not show statistically significant 
changes over time. 
Change per year compared with Dutch general population: for five RAND 
subscales and the PCS, patients with DMT1 reported a decrease in HRQOL, which 
was faster than that seen in the general population. The expected changes per year 
of the subscales vitality and role emotional and the MCS were positive in the 
general population, whereas these were slightly negative in the cohort. The 
differences were statistically significant (p < 0.001 and p ~ 0.05) for the subscale 
vitality and the MCS. Changes in the subscales physical functioning, role 
emotional and mental health were not statistically significant between the study 
population and the general population sample (table 3) (27). 
EuroQol 
Change per year: the EQ-50 and the EQ-VAS showed a statistically significant 
decrease per year (table 3). The five dimensions of the EQ-50 all changed 
statistically significantly over time. A large percentage (46.6 - 59.0%) of the 
patients reported the highest possible EQ-50 score of one. 
Change per year compared with U.K. general population: patients with DMT1 
reported a faster decrease in EQ-VAS over time than the estimated change in the 
general population (table 3) (47). 
HRQOL in 2001 
We checked the association of comorbidity and microvascular or macrovascular 
complications in 2001 with HRQOL scores in 2001. The presence of 
macrovascular complications in 2001 was associated with lower EQ-50 (-0.205, 
p<0.001), EQ-VAS 1-14.681, p<0.001), PCS 1-10.796, p<0.001) and MCS 
(-4.876, p~0.026) scores. The presence of microvascular complications was only 
associated with lower EQ-VAS scores (-4.361, p~0.049). While the presence of 
comorbidity was associated with lower EQ-50 l-0.083, p<0.001), EQ-VAS 
(-4.300, p ~ 0.021) and PCS scores (-4.636, p < 0.001). 
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Table 2 
H
ealth related quality of life o
v
e
r tim
e of patients w
ith diabetes m
ellitus type I (n 
=
 234) 
1995 
1996 
1997 
1998 
1999 
2000 
2001 
R
esponse rate 
97.4%
 
98.3%
 
94.0%
 
92.7%
 
91.5%
 
92.7%
 
91.0%
 
R
AN
D
-36 
M
ean 
SD 
M
ean 
SD 
M
ean 
SD 
M
ean 
SD 
M
ean 
SD 
M
ean 
SD 
M
ean 
SD 
Physical functioning 
91.7 
12.9 
91.2 
14.7 
90.6 
15.1 
91.0 
15.8 
88.7 
19.0 
87.4 
19.0 
87.3 
19.0 
R
ole physical 
84.4 
30.9 
85.3 
29.3 
80.3 
34.0 
81.2 
33.3 
78.4 
36.6 
81.1 
34.1 
76.2 
37.8 
B
odily pain 
89.9 
16.8 
88.3 
17.7 
87.9 
18.1 
87.5 
19.9 
83.3 
24.6 
83.7 
22.9 
83.6 
20.2 
G
eneral health 
69.3 
19.8 
69.3 
18.5 
67.8 
17.6 
66.8 
18.9 
65.6 
20.6 
65.5 
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64.4 
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68.4 
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66.3 
17.5 
68.3 
19.8 
65.8 
21.6 
65.0 
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61.6 
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88.6 
19.2 
88.3 
18.5 
88.5 
17.4 
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18.6 
88.2 
18.8 
86.3 
19.6 
84.2 
20.3 
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m
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86.6 
29.7 
88.3 
28.3 
87.7 
29.4 
83.0 
35.5 
83.2 
33.9 
85.5 
31.1 
83.5 
32.6 
M
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78.3 
16.2 
79.0 
15.2 
78.5 
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79.9 
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16.0 
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77.1 
16.1 
PCS 
52.6 
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8.6 
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9.5 
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50.9 
9.3 
EuroQol 
EQ-5D 
0.90 
0.15 
0.88 
0.16 
0.87 
0.17 
0.87 
0.18 
0.85 
0.19 
EQ-VAS 
82.1 
14.1 
78.6 
15.1 
76.8 
14.1 
77.1 
14.4 
76.0 
13.5 
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Discussion and conclusion 
In this longitudinal study, a cohort of 234 adult patients with DMT1 was followed 
for six years. These patients showed a statistically significant decrease per year for 
the majority of HRQOL scales. The question remains of course, whether these 
statistically significant changes are of clinical relevance. When applying the 
arbitrary cut-off points described in the methods paragraph, changes over time in 
RAND subscale scores can be seen as clinically relevant too, after two to four 
years time, except for the subscales role emotional and mental health. The EQ-5D 
did not show a clinically relevant decline in HRQOL over these six years, whereas 
the EQ-VAS showed this only after six years. However, the EuroQol group has 
never officially reported the minimally important change in EQ-5D or EQ-VAS we 
used, since there is no need to establish such thresholds. The main function of the 
EQ-5D is for use in cost-effectiveness analyses, which result in an estimate of the 
additional costs needed in order to gain one quality-adjusted life-year (QALY), 
where health related quality of life can be based on the EQ-5D. Since no Dutch 
EQ-SD scores were available to compare with scores in our cohort, we compared 
our data with the available UK data. However, preliminary evidence suggests that 
there are few prominent differences between western countries in the ranking of 
health states that are representative of HRQOL dimensions (48). 
The finding that patients with DMT1 had a partially steeper decline in HRQOL 
over time than the general population, can possibly be explained by the growing 
percentage of patients with microvascular and macrovascular complications. 
Indeed, we know that in 2001 in our cohort almost 66% (up from 45.8%) of the 
patients had microvascular complications, whereas almost 10% (up from 4.3%) 
had macrovascular complications and that these complications were negatively 
associated with HRQOL scores. These chronic complications may elicit symptoms, 
which will influence patients functioning negatively and result in a decrease in 
HRQOL scores (49). The symptoms due to comorbidity (non-diabetes morbidity) 
will be present in both the study population and the general population sample 
and their influence will be measured in both populations by the generic 
instruments we used. For this reason, Woodcock et al have argued for the 
complementary use of generic and diabetes-specific instruments to distinguish 
between the impact of diabetes-specific morbidity and non-diabetes-specific 
morbidity on HRQOL (50). 
The dropout patients had statistically significant lower baseline scores than other 
patients. This might have caused an underestimate of the decrease in scores over 
time if all subjects had been studied. Moreover, the mean MCS score of the 
dropouts was lower than patients who continued in the study. This fact might 
partly explain the fact that the subscales role emotional and mental health did not 
decrease statistically significantly in the study population. 
In our study particularly the physical subscales and the PCS decreased statistically 
significantly over time and not the more mental subscales and the MCS. The more 
mental subscales remained more or less stable over time. This lack of change in 
MCS over time may be related to other observations regarding the relationship 
between age and mental health. In a previous cross-sectional study we reported 
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that older patients reported higher MCS scores (24). In a cross-sectional study, 
Lloyd et al. reported that older patients reported lower Short Form-36 scores on 
average, except for the subscales role emotional and mental health (21). Parkerson 
et al. described a mixed effect of age on HRQOL as well, where older patients 
tended to show less social worry but also reported lower physical and current 
health (16). Perhaps the fact that these patients with DMT1 have learned to cope 
with a chronic disease like DMT1, positively influences their mental health. The 
ability of older patients to be able to attribute their health problems to ageing 
might also explain this phenomenon (51). 
The changes in questionnaire scores that we found were often not only statistically 
significant but could be viewed as clinically relevant. However, Wandell et al and 
the DCCT did not find such changes (18, 25). The follow-up of the study of 
Wandell et al might have been too short (3 years) to measure a significant change 
over time. Moreover, their sample of patients with DMT1 was too small (n~20), 
resulting in a reduced ability to detect changes in HRQOL (i.e., low statistical 
power). In contrast, the DCCT study had a mean follow-up duration of 6.5 years 
and a large study population (n ~ 1.441). Nevertheless, they too did not find a 
change in HRQOL using the Diabetes Quality of Life Measure (DQOL), a diabetes-
specific instrument. 
In our study we used two generic HRQOL instruments to allow comparisons with 
samples from the general population. Despite the fact we did not use a diabetes-
specific instrument (considered to be more sensitive to changes in diabetes 
populations) we still found a significant change in HRQOL in our study. Moreover, 
the RAND-36 gave, by its further differentiation into eight subscales and its use of 
36 items, more detailed insight into which aspects of HRQOL changed and which 
did not. Since the individual dimensions of the EQ-5D all changed over time, the 
EQ-5D instrument did not show the kind of change over time seen with the 
RAND-36. Furthermore the EQ-5D utility index showed a large ceiling effect, with 
half of the patients reporting the highest possible score. 
Conclusion 
This longitudinal, observational study in a large cohort of 234 patients with DMT1 
showed that patients with DMT1 have a clinically relevant loss of predominantly 
physical aspects of HRQOL over time and have a faster decrease over time, for 
most subscales, than comparably aged persons from the general population. This 
faster decline in HRQOL is probably due to the development of chronic diabetic 
complications. Further studies should investigate which factors are mostly 
associated with these changes in HRQOL over time to give a more detailed insight 
in this decline in HRQOL. 
The generic instruments used in our study were responsive to change in HRQOL 
over time in an adult DMT1 population. Future studies should investigate the 
possibilities and limitations of generic and diabetes-specific instruments in patients 
with DMT1. Studies including both type of instruments could help to distinguish 
between the impact of diabetes-specific factors and the impact of more general 
factors on HRQOL. 
Acknowledgements: We thank the Northern Centre for Healthcare Research of the 
University of Groningen for providing data of a sample of the general Dutch population. 
We also thank the diabetes specialist nurses of the /sa/a Clinics for their help. 
87 
References 
1. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes 
mellitus. N Eng I J Med 1994;331 121 ):1428-36. 
2. Atkinson MA, Eisenbarth GS. Type I diabetes: new perspectives on disease 
pathogenesis and treatment. The Lancet 2001;358(92771:221-229. 
3. DCCT. The effect of intensive treatment of diabetes on the development and 
progression of long-term complications in insulin-dependent diabetes mellitus. The 
Diabetes Control and Complications Trial Research Group. N Engl J Med 
1993;329(14):977-86. 
4. Bradley C. Importance of differentiating health status from quality of life. The 
Lancet 2001 ;357Uanuary 6):7-8. 
5. Klein R, Klein BE. Relation of glycemic control to diabetic complications and 
health outcomes. Diabetes Care 1998;21 Suppl 3:C39-43. 
6. Aalto AM, Uutela A, Aro AR. Health related quality of life among insulin-
dependent diabetics: disease-related and psychosocial correlates. Patient Educ 
Couns 1997;30(3):215-25. 
7. Aalto AM, Uutela A, Kangas T. Health behaviour, social integration, perceived 
health and dysfunction. A comparison between patients with type I and II diabetes 
and controls. Scand J Soc Med 1996;24(4):272-81. 
8. Bardsley MJ, Astell S, McCallum A, Home PD. The performance of three measures 
of health status in an outpatient diabetes population. Diabet Med 1993;1 0(7):619-
26. 
9. Batt U, Muhlhauser I, Overmann H, Berger M. Validation of a diabetes-specific 
quality-of-life scale for patients with type 1 diabetes. Diabetes Care 
1998;21 (5):757-69. 
10. Glasgow RE, Ruggiero L, Eakin EG, Dryfoos J, Chobanian L. Quality of life and 
associated characteristics in a large national sample of adults with diabetes. 
Diabetes Care 1997;20(4):562-7. 
11. Hanestad BR. Self-reported quality of life and the effect of different clinical and 
demographic characteristics in people with type 1 diabetes. Diabetes Res Clin 
Pract 1993;19(2):139-49. 
12. Jacobson AM, de Groot M, Samson JA. The evaluation of two measures of quality 
of life in patients with type I and type II diabetes. Diabetes Care 1994;17(4):267-
74. 
13. jacobson AM, de Groot M, Samson JA. The effects of psychiatric disorders and 
symptoms on quality of life in patients with type I and type II diabetes mellitus. 
Qual Life Res 1997;6(1):11-20. 
14. Kent LA, Gill GV, Williams G. Mortality and outcome of patients with brittle 
diabetes and recurrent ketoacidosis. Lancet 1994;344(8925):778-81. 
15. Muhlhauser I, Overmann H, Bender R, Batt U, jorgens V, Trautner C, et al. Social 
status and the quality of care for adult people with type I (insulin-dependent) 
diabetes mellitus-a population-based study. Diabetologia 1998;41(1 0):1139-50. 
16. Parkerson GR, Jr., Connis RT, Broadhead WE, Patrick DL, Taylor TR, Tse CK. 
Disease-specific versus generic measurement of health-related quality of life in 
insulin-dependent diabetic patients. Med Care 1993;31 (7):629-39. 
17. Reviriego J. Millan MD, Millan M. Evaluation of the diabetes quality-of-life 
questionnaire in a Spanish population. An experience of translation and reliability. 
Pharmacoeconomics 1996;1 0(6):614-22. 
88 
18. Wandell PE, Brorsson B, Aberg H. Quality of life among diabetic patients in 
Swedish primary health care and in the general population: comparison between 
1992 and 1995. Qual Life Res 1998;718):751-60. 
19. Wikblad K, Leksell J. Wibell L. Health-related quality of life in relation to 
metabolic control and late complications in patients with insulin dependent 
diabetes mellitus. Qual Life Res 1996;5(1 ):123-30. 
20. Wu SY, Sainfort F, Tomar RH, Tollios JL, Fryback DG, Klein R, et al. Development 
and application of a model to estimate the impact of type 1 diabetes on health-
related quality of life. Diabetes Care 1998;21 (5):725-31. 
21. Lloyd CE, Orchard Tj. Physical and psychological well-being in adults with Type 1 
diabetes. Diabetes Res Clin Pract 1999;44(1 ):9-19. 
22. Pouwer F, van der Ploeg HM, Ader HJ. Heine RJ. Snoek F). The 12-item well-being 
questionnaire. An evaluation of its validity and reliability in Dutch people with 
diabetes. Diabetes Care 1999;22(12):2004-1 0. 
23. Hahl J. Hamalainen H, Sintonen H, Simell T, Arinen S, Simell 0. Health related 
quality of life in type I diabetes without or with symptoms of long-term 
complications. Qual Life Res 2002;11 :427-436. 
24. Hart HE, Bilo HJG, Redekop WK, Stalk RP, Assink JH, Meyboom-de jong B. 
Quality of life of patients with type I diabetes mellitus. Qual Life Res 
2003;12(8):1 089-1097. 
25. DCCT. Influence of intensive diabetes treatment on quality-of-life outcomes in the 
diabetes control and complications trial. Diabetes Care 1996;19(3):195-203. 
26. Hays RD, Sherbourne CD, Maze! RM. The RAND 36-item Health Survey 1.0. 
Health Econ 1993;2:217-227. 
27. Zee vdKl, Sanderman R. Het meten van de algemene gezondheidstoestand met de 
RAND-36. Een handleiding [Measuring general state of health with the RAND-36. 
A guide]. Groningen: University of Groningen; 1993. 
28. Ware JE, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. 
Comparison of methods for the scoring and statistical analysis of SF-36 health 
profile and summary measures: summary of results from the Medical Outcomes 
Study. Med Care 1995;33(4 Suppi):AS264-79. 
29. Ware j. SF-36 Health Survey Update. Spine 2000;25(24):3130-3139. 
30. Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, et al. 
Translation, validation, and norming of the Dutch language version of the SF-36 
Health Survey in community and chronic disease populations. J Clin Epidemiol 
1998;51 (11 ):1 055-68. 
31. Zee vdKI, Sanderman R, Heyink J. Haes dH. The psychometric qualities of the 
RAND 36-item Health Survey 1.0: a multidimensional measure of general health 
status. lnt j Behav Med 1996;3:1 04-122. 
32. EuroQol Group. EuroQol - a new facility for the measurement of health related 
quality of life. The EuroQol Group. Health Policy 1990;16(3):199-208. 
33. Dolan P. Modelling valuations for health states: the effect of duration. Health 
Policy 1996;38(3):189-203. 
34. Essink-Bot ML, Stouthard ME, Bonsel Gj. Generalizability of valuations on health 
states collected with the EuroQol-questionnaire. Health Econ 1993;2(3):237-46. 
35. Dutch Advisory on Health Research. Advice on chronic diseases: priorities for 
research. 's Gravenhage, the Netherlands; 1991. 
36. de jong PTVM. Screening op diabetische retinopathie [Screening for diabetic 
retinopathy]. Ned Tijdschr Geneeskd 1993;137(34):1701-1705. 
89 
37. Holewski JJ, Stess RM, Graf PM, Grunfeld C. Aesthesiometry: quantification of 
cutaneous pressure sensation in diabetic peripheral neuropathy. J Rehabil Res Dev 
1988;25(2): 1-1 0. 
38. Centraal Begeleidingsorgaan voor de lntercollegiale Toetsing, Nederlandse 
Diabetes Federatie. Diabetische retinopathie, diabetische nefropathie, diabetische 
voet, hart- en vaatziekten bij diabetes mellitus [Diabetic retinopathy, diabetic 
nephropathy, diabetic foot, cardiac and vascular pathology in diabetes mellitus]. 
Utrecht: Centraal Begeleidingsorgaan voor de lntercollegiale Toetsing; 1998. 
39. EURODIAB. Microvascular and acute complications in lOOM patients: the 
EURODIAB IDDM Complications Study. Diabetologia 1994;37(3):278-85. 
40. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin 
treatment on the development of microvascular complications of diabetes mellitus. 
N Eng! j Med 1993;329(5):304-9. 
41. Singer j. Using SAS PROC MIXED to fit multilevel models, hierarchical models, 
and individual growth models. j. Educ Behav Stat 1998;24(4):323-355. 
42. Crosby R, Kolotkin R, Williams G. Defining clinically meaningful change in 
health-related quality of life. J. Clin Epidemiol 2003;56:395-407. 
43. Rubin D. Inference and missing data. Biometrika 1976:581-592. 
44. Brook RH, Ware JE, Rogers WH, Keeler EB, Davies AR, Donald CA, et al. Does 
free care improve adults' health? Results from a Randomized Controlled Trial. N 
Eng! j Med 1983;309(23): 1426-1434. 
45. Hays RD, Morales LS. The RAND-36 measure of health related quality of life. Ann 
Med 2001 ;33:350-357. 
46. Ware JE, Kosinki M. Interpreting SF-36 summary health measures: A response. 
Qual Life Res 2001 ;1 0:405-413. 
47. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D. York, United 
Kingdom; 1999. 
48. Anderson RT, Aaronson NK, Bullinger M, McBee WL. A review of the progress 
towards developing health related quality of life instruments for international 
clinical studies and outcomes research. Pharmacoeconomics 1996;1 0(4):336-355. 
49. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. 
A conceptual model of patient outcomes. JAMA 1995;273(1):59-65. 
50. Woodcock A, Julious SA, Kinmouth AL, Campbell MJ. Problems with the 
performance of the SF-36 among people with type 2 diabetes in genera! practice. 
Qual Life Res 2001 ;1 0:661-670. 
51. Leventhal E, Prohaska T-. Age, symptom interpretation, and health behavior. J Am 
Geriatr Soc 1986;34(3):185-91. 
90 
Factors predicting rate of change 
in Health Related Quality of Life 
in patients with 
Diabetes Mellitus Type I 
Hart HE, Redekop WK, Berg M, Bilo H)G, Meyboom-de )ong B: Factors predicting the rate 
of change in health related quality of life in patients with diabetes mellitus type I. 
2004;submitted 
Abstract 
Objective 
The aim of this study was to investigate whether sociodemographic and diabetes-
specific characteristics in 1995 can predict the rate of change in health related 
quality of life (HRQOL) over time in patients with diabetes mellitus type I IDMT1). 
Methods 
A Dutch cohort of 234 patients with DMT1 was followed for six years (1995-
2001). HRQOL (RAND-36 and EuroQol) and several patient characteristics 
(demographic and clinical) were recorded annually during the study period. 
Baseline characteristics associated with rate of change in HRQOL were identified 
using multilevel modelling. 
Results 
Patients showed a statistically significant decrease over time in most HRQOL 
scales. Higher baseline diastolic blood pressure was predictive of a faster decrease 
in RAND-36 PCS score (-0.025, p~0.02), whereas higher baseline systolic blood 
pressure was predictive of a slower decrease in RAND-36 MCS score (0.015, 
p~0.0034). Patients with macrovascular complications at baseline showed a faster 
decrease in EQ-VAS score -1.678 (p ~ 0.016). 
Conclusion 
In this cohort of patients with DMT1, it was possible to identify factors predicting 
change in HRQOL. Late diabetic complications and a higher diastolic blood 
pressure are predictive of a lower HRQOL in the coming years. 
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Introduction 
Many associations with the health related quality of life (HRQOL) of patients with 
diabetes mellitus have been described (1-3). All these associations were reported 
cross-sectionally. 
In a previous study we reported that adult patients with diabetes mellitus type I 
(DMT1) reported a statistically significant and clinically relevant decrease in 
HRQOL, and we found that these patients had a faster decrease in HRQOL over 
time than persons from the general population (4). 
Although we know that the HRQOL of patients with DMT1 decreases faster over 
time than in people without DMT1, we do not know in which patients HRQOL 
decreases faster over time and which factors are associated with it. To date, no 
studies have investigated the associations between patient characteristics and 
changes in HRQOL. 
More knowledge about patient and/ or disease-specific characteristics predictive of 
change in HRQOL for the individual patient with DMT1 provides possibilities to 
identify which patients are likely to experience a faster decrease in HRQOL than 
other patients. 
When it is possible to more accurately predict such changes for the individual 
patient, it is worth trying to prevent a future decrease in HRQOL or act quickly and 
effectively on changes in HRQOL. This might benefit patients with DMT1. 
We hypothesized that patients with microvascular and macrovascular 
complications already at study entry, will lose HRQOL faster due to the 
development of symptoms of these long-term complications (5, 6). 
To test this hypothesis we followed a cohort of patients with DMT1 over six years, 
measured HRQOL yearly and investigated which baseline characteristics could 
predict for the degree of change in HRQOL over time. 
Methods 
Patients 
In early 1995, 293 consecutive DMT1 patients, treated at the outpatient clinic of 
the lsala Clinics in Zwolle, the Netherlands, were invited to participate in this 
study. In total 281 patients agreed to participate and were included in the study. 
DMT1 was defined as starting insulin therapy within six months after the first signs 
of diabetes mellitus and before the age of 30 years, or the absence of C-peptide 
secretion. Approval was obtained from the Hospital Scientific and Ethics 
Committee. All patients gave informed consent. This cohort has been followed for 
six years (1995-2001). 
Health Related Quality of Life 
HRQOL was assessed using two generic instruments, the RAND-36-item Health 
Survey (RAND-36) and the EuroQol. Questionnaires were sent by mail to the 
patient's home address. Patients were asked to fill in the questionnaires at home. 
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Upon the visit to the outpatient clinic, the patients returned the completed 
questionnaires to the diabetes specialist nurse. Patients who did not return the 
completed questionnaires when visiting the clinic were asked to send their 
completed questionnaires afterwards. 
The RAND-36 is a self-administered questionnaire containing 36 items involving 
eight different subscales: physical functioning, role limitations due to physical 
problems, bodily pain, general health perception, vitality, social functioning, role 
limitations due to emotional problems, and mental health. For each subscale, 
scores were coded, summed up and transformed to a scale from 0 (worst health) to 
100 (best health) (7, 8). In addition, physical and mental component summary 
scores were determined (PCS/ MCS) (9). The questionnaire takes about ten minutes 
to complete. The instrument has been translated in Dutch (1 0) and validated for 
the Dutch population (11). The RAND-36 was completed yearly. 
The EuroQol is a simple generic measure, consisting of two parts (EQ-5D and EQ-
VAS) , developed by a multidisciplinary group of researchers from five European 
countries (12). For the EQ-5D part, there are five questions covering the areas 
Mobility, Self Care, Usual Activities, Pain/ discomfort and Anxiety/ depression. 
Each dimension is divided into three levels: no problem, some/ moderate 
problems and extreme problems/ unable to perform. A respondent's health state is 
defined by combining one level from each of the five dimensions (EQ-5D). A total 
of 243 possible health states can be defined in this way. Valuations of these health 
states have been made by the U.K. general public, using a valuation technique 
called time trade-off. The values, or utilities, are scaled on a scale on which 0 is 
the value of dead and 1 is the value of perfect health (13). Furthermore a single 
overall score can be elicited using the EuroQol thermometer, a self rated health 
status using a graduated (0-100) visual analogue scale, similar to a thermometer 
(EQ-VAS). The EuroQol takes about two minutes to complete and has been 
validated for the Dutch situation (14). The EuroQOI was completed in the years 
1995 ti II 1998 and in the year 2001. 
Clinical data 
One trained physician examined all patients according to a standardised protocol 
at the entry of the study. Demographic data (age, sex, married/ having a partner, 
level of education) and data concerning therapy (frequency of insulin injection, 
frequency of self monitoring of blood glucose) were recorded yearly. Patients 
recorded all hypoglycaemic events ('did you have a hypo in the past three 
months?') during the three months preceding the outpatient visit and were asked to 
report whether they had one or more of six different hyperglycaemic complaints 
during the last three months (yes/ no): tiredness, weight loss, pruritus, thirst, 
polyuria and polydipsia. 
Metabolic control was assessed by measuring glycosylated haemoglobin A 1 c 
(HbA 1 c). 
The presence of comorbidity (one or more diseases besides diabetes) was assessed 
using a list of 26 chronic diseases (15). 
Macrovascular complications: 
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In 1995 and 2001 the physician recorded the presence, or absence, of 
macrovascular complications of all patients. Macrovascular complications 
comprised angina pectoris, myocardial infarction, intermittent claudication, 
transient ischaemic attack (TIA), and cerebrovascular accident (CVA). 
Microvascular complications: 
Presence, or absence, of microvascular complications was recorded annually. 
Patients with retinopathy, neuropathy or nephropathy were diagnosed as having 
microvascular complications. 
Retinopathy 
The ophthalmologist examined all patients annually. The degree of diabetic 
retinopathy was assessed by fundoscopy in mydriasis. The classification of diabetic 
retinopathy used was based on the method described by de jong (16): no 
retinopathy ( ~0), background retinopathy (~I) preproliferative (~II) and 
proliferative diabetic retinopathy (~Ill). Retinopathy was scored positive when any 
type of retinopathy was present in either eye. When the degree of retinopathy was 
different in two eyes, the highest degree was scored. 
Neuropathy 
Sensitivity was tested by the Semmes-Weinstein pressure aesthesiometer (17). At 
five dorsal and plantar sites on the feet sensitivity was tested using six different 
monofilaments. When the monofilament 5.07 was not felt at one of the ten test 
sites, patients were diagnosed as having neuropathy. 
Nephropathy 
The 24-hour urinary excretion of albumin (UAER) was measured yearly. UAER was 
considered abnormal when it was <: 30mg/ 24 hours. Micro-albuminuria was 
defined as 30-300 mg/ 24 hours and macro-albuminuria as <:300 mg/ 24 hours. All 
patients with micro-albuminuria or macro-albuminuria were defined as having 
nephropathy (18-20). At the time of start of the study (1995) patients with a micro-
albuminuria > 100 mg/ 24 hour received an angiotensin converting enzyme 
inhibitor (ACE-inhibitor) in the lsala Clinics. We classified ACE-inhibitor users as 
having nephropathy, unless ACE-inhibition was started specifically for 
hypertension. 
Analysis 
We applied multilevel modelling to investigate the change in HRQOL over the 
years 1995 - 2001 (21). This method, also known as growth curve analysis, 
enables the use of all HRQOL values for an individual patient, unlike repeated 
measures analysis where only patients with complete data can be included in the 
analysis (22). In simple terms, the approach can be likened to a linear regression 
approach. If the HRQOL scores for a single patient are drawn on a graph where 
the x-axis represents time and y-axis represents HRQOL and if a line is drawn 
through these scores, the slope of this line can be seen to represent the rate of 
change in HRQOL over time for that individual patient. If this process is repeated 
for all patients, the average rate of change in HRQOL over time in the study 
population can be estimated. One general assumption in the analysis is that 
missing values are missing at random. As well, we assumed that change in 
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HRQOL was linear in form since there was no reason to assume a more complex 
form. 
Factors associated with the change in HRQOL were identified using this 
technique. This type of analysis has previously been used in diabetes research (23). 
In a backward stepwise fashion we excluded variables (with a p-value>O.OS) from 
the model, where a p-value ,; 0.05 provided a guideline for a variable to remain 
in the model. 
Data were analysed using the statistical computer package SAS for Windows 
version 6.12. Changes were considered statistically significant when p-values less 
than or equal to 0.05 were reached. 
Results 
A total of 281 adult patients with diabetes mellitus type I entered the study in 
1995. 
The dropout rate over the six-year study period was 16.7% (n~47). Patients who 
withdrew from the study were more frequently female (59.6% vs. 42.7%, p~0.04), 
had a longer disease duration (20.6 vs 16.5 years, p~0.05), were more often single 
(24.0% vs 9.2%, p~0.01), had a higher HbA1c (9.0 vs 8.1, p~0.007) and 
reported a lower baseline HRQOL. 
Personal and disease-specific characteristics of the 234 patients who fulfilled the 
study period of six years are shown in table 1. Mean age at entry in the study 
population was 38.2 years and 57.3% were men. A quarter of the patients used a 
pump (26.9%). Almost half of the patients had microvascular complications 
(45.8%), whereas only 4.3 % had macrovascular complications. The most 
frequently recorded macrovascular diagnoses were angina pectoris and 
intermittent claudication. Most patients with comorbidity had one or two other 
chronic medical conditions besides their diabetes. 
Table 2 shows the change in HRQOL over time, assessed by the RAND-36 and the 
EuroQol. Patients reported a statistically significant decrease per year, over the six 
year study period, for six of the eight RAN D-subscales and the Physical 
Component Summary (PCS). The decreases in the subscales role emotional and 
mental health and the Mental Component Summary were not statistically 
significant (table 2). The EQ-5D and the EQ-VAS showed a statistically significant 
decrease per year (table 2). 
Table 3 shows the socio-demographic and diabetes-specific factors associated 
cross-sectionally with HRQOL at baseline. For all four outcomes (PCS, MCS, EQ-
5D, EQ-VAS) hyperglycaemic symptoms were associated with a lower HRQOL. 
Comorbidity was associated with a reduced PCS, MCS and EQ-5D. Other factors 
were mainly associated with a lower baseline PCS score: having a partner, a longer 
duration of disease since diagnosis, a higher frequency of self monitoring blood 
glucose per week and the presence of microvascular and macrovascular 
complications, particularly neuropathy and intermittent claudication. The presence 
of retinopathy was associated with a lower EQ-5D (table 3). 
The baseline HRQOL value (alpha) in 1995 is estimated on the basis of the 
constant combined with the factors associated with HRQOL. For example, a 
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patient without hyperglycaemic symptoms, retinopathy or comorbidity, has an 
estimated EQ-5D of 0.982 (constant). A patient with retinopathy will have an EQ-
5D of 0.982-0.048 ~ 0.934. 
Table 1 
Personal and disease-specific characteristics of the study population (1995, 
n~234) 
Gender (men) 134 
Age (years) 38.2 
Duration of diabetes (years) 16.5 
Married/ cohabiting 207 
High level of education 76 
Smoking 70 
Alcohol use 146 
Systolic blood pressure (mm Hg) 138.9 
Diastolic blood pressure (mm Hg) 83.0 
Pulse pressure 55.9 
Ratio cholesterol/ HDL(mmol/1) 3.8 
Body mass index (kg/m 2) 24.8 
Hba1c(%) 8.1 
Use of insulin pump 63 
Frequency of self-monitoring blood glucose per week 12.0 
Number of patients with: 
hypoglycaemic events 185 
hyperglycaemic complaints 122 
Prevalence of diabetic complications 
Microvascular 104 
Retinopathy 79 
Nephropathy 43 
Neuropathy 24 
Macrovascular 10 
Comorbidity 133 
Values are number of patients or means with valid percentage or standard 
deviation between parentheses 
(57.3%) 
(11.5) 
(1 0.1) 
(90.8%) 
(33.6%) 
(29.9%) 
(62.4%) 
(17.8) 
( 8.4) 
(15.2) 
( 1.2) 
(3.2) 
(1.9) 
(26.9%) 
(11.3) 
(80.8%) 
(53.2%) 
(45.8%) 
(34.6%) 
(18.4%) 
(1 0.4%) 
( 4.3%) 
(58.1%) 
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Table 2 
Health related quality of life over time in a cohort of patients with diabetes 
mellitus type I 
RAND-36 
Physical functioning 
Role physical 
Bodily pain 
General health 
Vitality 
Social functioning 
Role emotional 
Mental health 
PCS 
MCS 
EuroQol 
Utility index 
Visual analogue scale 
Mean change 
per year in 
cohort' 
- 0.791 
-1.118 
- 1.180 
-0.904 
- 0.916 
- 0.598 
- 0.298 
- 0.093 
-0.504 
- 0.088 
- 0.007 
- 0.934 
Confidence 
interval (95%) 
(-1.184, -0.397) 
(-1.81 0, -0.425) 
(-1.616,-0.744) 
(-1.253, -0.555) 
(-1.279, -0.554) 
(-1.009, -0.187) 
(-1.594, 0.999) 
(-0.465, 0.162) 
(-0.688,-0.320) 
(-0.305, 0.128) 
(-0.011, -0.003) 
(-1.230, -0.638) 
Values are means with standard deviations between parentheses 
1 Change per year estimated by using multilevel modeling 
p value is result from multilevel modeling 
PCS 
MCS 
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Physical Component Summary 
Mental Component Summery 
p value' 
< 0.001 
0.002 
< 0.001 
< 0.001 
< 0.001 
0.004 
0.653 
0.344 
< 0.001 
0.425 
< 0.001 
< 0.001 
Table 3 
Determination of baseline health related quality of life values for the individual 
patients 
RAND-36 RAND-36 EuroQOL EuroQol 
PCS MCS EQ-50 EQ-VAS 
Constant 61.48 55.81 0.982 85.23 (p<0.0001) (p<0.0001) (p<0.0001) (p<0.0001) 
Married/ cohabiting - 2.880 (p~0.034) 
Duration of disease 
(in years/ diagnosis to - 0.111 
baseline) (p~0.007) 
Frequency of self - 0.129 
monitoring per week (p<0.001) 
Hyperglycaemia - 2.492 - 4.960 - 0.072 - 9.223 (p~0.003) (p<0.0001) (p<0.0001) (p<O.OOOl) 
Neuropathy - 2.869 (p~0.028) 
Retinopathy - 0.048 (p~0.004) 
Intermittent claudication - 10.030 (p~0.002) 
Comorbidity - 1.919 - 2.150 - 0.061 (p~0.022) (p~0.018) (p<0.0002) 
PCS - Physical Component Summary 
MCS - Mental Component Summary 
EQ-50 - EuroQol Utility Index 
EQ-VAS - EuroQol Visual Analogue Scale 
Table 4 shows the socio-demographic and diabetes-specific factors associated with 
changes in HRQOL over time. A higher baseline diastolic blood pressure in 1995 
was associated with a faster decrease in PCS over time. The presence of 
nephropathy (in 1995) was also associated with a faster decrease in PCS over time. 
99 
Table 4 
Factors predicting change in health related quality of life 
Tim
e since baseline in years (T) 
Predictors 
T* diastolic blood pressure 
T* n
ephropathy 
T* systolic blood pressure 
T* interm
ittent 
claudication 
T* m
a
rried/ cohabiting 
T* m
a
cro
va
scular co
m
plications 
R
AN
D
-36 
PCS 
2.01 
(p~0.0345) 
-0.025 (p ~ 0.020) 
-0.711 (p~0.002) 
PCS 
-physical co
m
ponent su
m
m
a
ry 
M
CS 
EQ-5D 
EQ-VAS 
T T*covariate 
-m
e
ntal c
o
m
ponent s
u
m
m
a
ry 
-EuroQol U
tility Index 
-EuroQol Visual Analogue Scale 
-tim
e since baseline in years 
-m
ultiplication of tim
e by co
va
riate 
R
AN
D
-36 
M
CS 
-2.14 (p~0.003) 
0.015 (p~0.0034) 
E
uroQol 
EQ-50 
-0.007 (p ~ 0.0007) 
-0.051 (p ~ 0.004) 
E
uroQol 
EQ-VAS 
-1.817 (p<0.0001) 
1.021 (p ~ 0.036) 
-1.678 (p ~ 0.016) 
Figure 1 shows the predicted change in PCS over time for patients, divided into 
four subgroups on the basis of diastolic blood pressure and nephropathy in 1995. 
Patients with a higher diastolic blood pressure and with nephropathy showed the 
fastest decrease in PCS. 
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A higher systolic blood pressure (in 1995) was associated with a slower decrease 
in MCS over time. Figure 2 shows that patients within the three highest systolic 
blood pressure quartiles seem to maintain their MCS level over time, in 
comparison with the faster decrease in MCS of the patients within the lowest 
quartile. 
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Patients with intermittent claudication in 1995 experienced a faster decrease in 
EQ-5D than patients without intermittent claudication. Patients with macrovascular 
complications showed a faster decrease in EQ-VAS than patients without 
macrovascular complications. Married patients showed a slower decrease in EQ-
VAS over time than unmarried patients. 
Since we expected that patients with a baseline diastolic blood pressure greater 
than the mean value in 1995 had, and will develop, more diabetic complications, 
we investigated the complication status of these patients. In 1995 these patients 
already had a somewhat higher prevalence of microvascular complications (51.5 
vs. 41.1%, p~0.08). In 2001 the same was true (76.2 vs. 56.7%, p~0.004) and in 
that year they also tended to have more macrovascular complications (12.4 vs. 
7.8%, p~0.173). 
Patients with a baseline systolic blood pressure higher than the mean value (138.9 
mm Hg) reported hyperglycaemic complaints more frequently at baseline (57.3 vs. 
49.6%, p~0.151) and already had an increased prevalence of microvascular 
complications (59.1 vs. 33.3%, p < 0.001) and somewhat higher prevalence of 
macrovascular complications (5.3 vs. 3.3%, p~0.343) and comorbidity (62.7 vs. 
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53.8%, p~0.108). They reported lower baseline PCS scores (51.3 vs. 53.8, 
p~0.007) and baseline EQ-50 scores (0.86 vs. 0.92, p~0.006). 
Discussion and conclusion 
In this longitudinal study, a cohort of 234 adult patients with DMT1 was followed 
for six years. These patients showed a statistically significant decrease per year for 
almost all of the HRQOL outcomes we studied. Moreover, patients who left the 
study had a lower HRQOL at baseline, which might have caused an 
underestimation of the annual decrease in HRQOL, since these patients might 
have lost HRQOL even faster. 
Cross-sectionally the presence of hyperglycaemic complaints, a higher frequency 
of self-monitoring blood glucose (SMBG), diabetic complications and comorbidity 
had the most profound negative association with HRQOL. 
Remarkably, the frequency of self-monitoring blood glucose and presence of 
hyperglycaemic complaints were not associated with changes in HRQOL over 
time. This might possibly be explained by the use of generic instruments in this 
study. 
Longitudinally, higher diastolic blood pressure and macrovascular complications 
showed the most negative influence on changes in HRQOL. 
Patients with a higher baseline diastolic blood pressure had in 2001 a PCS score 
lower than the PCS scores seen in other patients. We might explain this by the fact 
that high blood pressures are a risk factor for the development of cardiovascular 
disease. Patients with, in this case, a higher diastolic blood pressure in 1995 are 
more at risk to develop macro- and microvascular complications in the future, 
which are known to be associated with a lower HRQOL (6, 24-26). 
Indeed, the United Kingdom Prospective Diabetes Study Group (UKPDS) showed 
that in patients with diabetes mellitus type II (DMT2), tight blood pressure control 
achieved a clinically important reduction of diabetic complications (27). Moreover, 
in patients with DMT2, complications affected HRQOL, whereas therapeutic 
policies shown to reduce the risk of complications, i.e. improving blood glucose or 
blood pressure, had no direct effect on HRQOL (28). 
In our study, patients with a higher baseline diastolic blood pressure, had indeed a 
higher prevalence of chronic complications in 2001, which can explain their loss 
in HRQOL compared with patients with a lower diastolic blood pressure. 
However, a higher systolic blood pressure was associated with a slower decrease 
in MCS. We cannot explain this finding. It might be possible that, where others 
experience a faster decrease over time, this specific category of patients might 
recover from an earlier loss of MCS by their higher prevalence of hyperglycaemic 
complaints and comorbidity in 1995. 
Moreover, these patients reported a significant lower PCS in 1995 too. This lower 
baseline physical health will also inevitably reduce their mental health and be 
responsible for a lower baseline MCS. We cannot confirm this hypothesis. This is 
inherent to the choice of the use of orthogonally rotated summary scores, resulting 
in uncorrelated summary scores (9, 29). 
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Whereas we formulated possible explanations for the predictive value of higher 
systolic blood pressures, we still cannot explain this finding and further 
investigations concerning this item are necessary. A change association is one 
possible explanation. 
The lower PCS in 2001 for patients with nephropathy in 1995 can be explained by 
the fact that these patients have a higher risk to develop cardiovascular disease in 
the future, which will negatively influence their PCS in 2001 (30-34). 
The fact that patients with complications in 1995, i.e. nephropathy [PCS], 
claudication [EQ-50] and macrovascular complications [EQ-VAS] show a faster 
decrease in HRQOL than patients without these complications confirms our 
hypothesis that patients with late complications at study entry will lose HRQOL 
faster than other patients. The late complications, already present in 1995, will be 
increased in severity several years later. Further progression of these complications 
will likely become symptomatic in 2001 and will impair their daily functioning 
and thereby reduce their HRQOL (5). 
Married patients reported a lower PCS in 1995, but showed a slower decrease in 
EQ-VAS than unmarried patients. Many studies have reported the positive 
influence of having a partner on HRQOL (25, 26, 35-38). It is possible that patients 
with poorer physical health, i.e. lower PCS scores in 1995, needed and searched 
for more social and marital support, and were therefore more often married than 
other patients. The presence of a partner probably will support patients with the 
handling of their chronic disease. Trief et al. even showed that the quality of 
marriage prospectively predicted the diabetes related HRQOL in patients with 
DMT1; less diabetes-related distress was predicted by better marital adjustment at 
baseline (39). 
Conclusion 
This study shows that patients with DMT1 report a statistically significant decrease 
in HRQOL over time. Cross-sectionally, the symptoms of the disease 
(hyperglycaemic complaints) and its therapy (e.g. self-monitoring blood glucose) 
were negatively associated with HRQOL. Longitudinally, higher diastolic blood 
pressure and late diabetic complications were negatively associated with HRQOL. 
This study identified patients who were at risk for a faster decrease in HRQOL. 
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The use of uti I ities in a cohort 
of patients with 
Diabetes Mellitus Type I 
Hart HE, Redekop WK, Dikkeschei LD, Berg M, Meyboom-de )ong B, Bilo HJG. The use 
of utilities in a cohort of patients with diabetes mellitus type I. 2004; submitted. 
Abstract 
Objective 
The objective of this study was to investigate the suitability of two generic utilities 
and their Quality Adjusted Life Years (QALYs) in patients with diabetes mellitus 
type I (DMTl). We wanted to investigate whether these utilities are sensitive to 
changes over time and can provide information about associations of diabetes-
specific factors with health related quality of life (HRQOLJ, expressed in utilities 
and QALYs, in patients with DMT1. 
Research design and methods 
The HRQOL in a Dutch cohort of 234 patients with DMT1 was assessed annually 
for 6 years using the utilities of the Short Form- 36 (SF-60) and the EuroQol (EQ-
50). QALYs were calculated for two three-year periods. We performed stepwise 
multivariate regression analysis to investigate associations between QALYs and 
several socio-demographic (sex, age, marital status, level of education) and 
diabetes-specific variables (e.g. HbA 1 c, therapy, hyper-/ hypoglycaemic 
complaints, diabetic complications). 
Results 
Both utilities assessed changes over time; the declines in SF-6D and EQ-5D were 
statistically significant (p ~ 0.001 and p ~ 0.004). The utilities assessed associations 
of diabetes-specifc factors with HRQOL. Hyperglycaemic complaints, 
macrovascular complications and comorbidity had the most negative association 
with the QALYs. 
Conclusion 
The generic utilities SF-6D and EQ-SD were responsive to changes in HRQOL 
over time and measured associations between QALYs and diabetes-specific 
variables, already known to be associated with HRQOL. Both generic utilities offer 
possibilities for survival analyses and health economic studies in patients with 
DMT1. 
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Introduction 
In past decades, many studies have been performed concerning health related 
quality of life (HRQOL) in patients with diabetes mellitus. In these studies, generic 
as well as diabetes specific questionnaires have been used (1, 2). Both types of 
instruments have their possibilities and limitations and each measure may be 
valuable for certain purposes (3). Diabetes specific instruments are said to be more 
sensitive to changes over time in patients with diabetes, while generic instruments 
allow comparisons with patients with other diseases and persons form the general 
population (4, 5). Different health states, provided by some generic questionnaires, 
have been given a value by the general public (6-8). These values, or utilities, are 
put on a scale on which 0 expresses worst health/ death and 1 expresses perfect 
health (7-9). These utilities, based on generic instruments, offer possiblities for 
health economic studies. 
Quality-adjusted life-years (QAL Ys) are the multiplication of the utility score by the 
number of years (e.g. until death) and describes the amount of years lived adjusted 
for HRQOL. 
For patients with diabetes mellitus type I (DMT1) few studies have used 
empirically derived utilities (10, 11). These studies examined indirectly assessed 
utilities based on generic instruments. Wu et al. calculated Quality of Well-Being 
Index (QWB) scores, derived from SF-36 scores, from which they calculated a 
utility score (10). Coffey et al. used the Self-Administered Quality of Well Being 
index (QWB-SA) to calculate a utility score (11). For patients with diabetes mellitus 
type II, the EuroQol has been applied to calculate a utility score (12, 13). 
In the present study, we applied the QALY method to describe the HRQOL over 
time in a Dutch cohort of patients with DMT1. We calculated QAL Ys using two 
different utility scales, derived from the generic Short Form-36 and from the 
EuroQol, to compare the results between them, and to investigate the usefulness of 
these utilities in DMT1 studies. 
Furthermore we examined associations of patient characteristics with QALYs, and 
investigated whether these associations with QALYs persisted over time and 
whether the use of different utility scales led to the same or different associations. 
The possible use of QALYs can facilitate cost-effectiveness studies to determine 
best diabetes treatment strategies. 
Methods 
Patients 
From january 1995 to january 1996, 293 consecutive DMT1 patients, treated at 
the outpatient clinic of the lsala Clinics in Zwolle, the Netherlands, were invited to 
participate in this study. A group of 281 patients agreed to participate and were 
included in the study. DMT1 was defined as starting insulin therapy within six 
months after the first signs of diabetes mellitus and before the age of 30 years, or 
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the absence of C-peptide secretion. Approval was obtained from the Hospital 
Scientific and Ethics Committee. All patients gave informed consent. This cohort 
was followed for six years (1995-2001 ). 
Health Related Quality of life 
HRQOL was assessed using two generic instruments: the Short Form-36 and the 
EuroQol. Questionnaires were sent by mail to the patient's home address. Patients 
were asked to fill in the questionnaires at home. When attending the next 
outpatient appointment, the patients returned the completed questionnaires to the 
diabetes specialist nurse. Patients who did not return the completed questionnaires 
when visiting the clinic were asked to send their completed questionnaires 
afterwards. 
A six-dimensional health state classification (SF-6D) has been derived by using a 
subset of 11 items of the SF-36 questionnaire: physical functioning, role 
limitations, social functioning, pain, mental health and vitality (14). A sample of 
states, defined by these six dimensions, has been valued by a representative 
sample of the UK general population, using the standard gamble method. The 
values, or utilities, are put on a scale on which 0 is the value of death and 1 is the 
value of perfect health (14). The instrument has been translated into Dutch and 
validated for the Dutch population (15). The SF-36 is seen as an appropriate 
measure of HRQOL in patients with DMTI (3, 10, 16). Since the SF-36 
questionnaire was completed yearly from 1995-2001, SF-6D scores could be 
calculated for all years. 
The EuroQol, a simple generic measure, consists of two parts (EQ-50 and EQ-VAS) 
(7). For the EQ-5D part, there are five questions covering the areas of Mobility, Self 
Care, Usual Activities, Pain/ discomfort and Anxiety/ depression. Each dimension 
is divided into three levels: no problem, some/ moderate problems and extreme 
problems/ unable to perform. A respondent's health state is defined by combining 
one level from each of the five dimensions (EQ-50). A total of 243 possible health 
states can be defined in this way. Valuations of these health states have been made 
by the U.K. general public, using time trade-off. The values, or utilities, are scaled 
on a scale on which -0.594 is even worse than death, 0 is the value of death and 1 
is the value of perfect health (17).The EuroQol has been validated for the Dutch 
situation (18) and was completed yearly between 1995 and 1998 and in 2001. 
Clinical data 
One trained physician examined all patients according to a standardised protocol 
at the entry of the study. Demographic data (age, sex, married/ having a partner, 
level of education) and data concerning therapy (frequency of insulin injection, 
frequency of self monitoring of blood glucose) were recorded yearly. Patients 
recorded all hypoglycaemic events ('did you have a hypo in the past three 
months?') during the three months preceding the outpatient visit and were asked to 
report whether they had one or more of six different hyperglycaemic complaints 
during the last three months (yes/ no): tiredness, weight loss, pruritus, thirst, 
polyuria and polydipsia. 
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Metabolic control was assessed by measuring glycosylated haemoglobin A 1 c 
(HbA 1 c). 
The presence of comorbidity (one or more diseases besides diabetes) was assessed 
using a list of 26 chronic diseases (19). 
Macrovascular complications 
The physician recorded the presence, or absence, of macrovascular complications 
in 1995 and 2001. Macrovascular complications were not recorded in 1998. 
Macrovascular complications comprised angina pectoris, myocardial infarction, 
intermittent claudication, transient ischaemic attack (TIA), and cerebrovascular 
accident (CVA). 
Microvascular complications 
The presence of the different microvascular complications was recorded yearly. 
Patients with retinopathy, neuropathy or nephropathy were diagnosed as having 
microvascular complications. 
Retinopathy 
The ophthalmologist examined all patients annually. The degree of diabetic 
retinopathy was assessed by fundoscopy in mydriasis. The classification of diabetic 
retinopathy used was based on de Jong (20): no retinopathy (~0), background 
retinopathy (~I) preproliferative (~II) and proliferative diabetic retinopathy (~Ill). 
Retinopathy was scored positive, when any type of retinopathy was present in 
either eye. When the degree of retinopathy was different in two eyes, the highest 
degree was scored. 
Neuropathy 
Sensitivity was tested by the Semmes-Weinstein pressure aesthesiometer (21). At 
five dorsal and plantar sites on the feet sensitivity was tested using six different 
monofilaments. When the monofilament 5.07 was not felt at one of the ten test 
sites, patients were diagnosed as having neuropathy. 
Nephropathy 
The 24-hour urinary excretion of albumin (UAER) was measured yearly. UAER was 
considered abnormal when it was " 30mg/ 24 hours. Micro-albuminuria was 
defined as 30-300 mg/ 24 hours and macro-albuminuria as "300 mg/ 24 hours. All 
patients with micro-albuminuria or macro-albuminuria were defined as having 
nephropathy (22-24). At the time of start of the study (1995) patients with a micro-
albuminuria > 100 mg/ 24 hour received an angiotensin converting enzyme 
inhibitor (ACE-inhibitor) in the lsala Clinics. We classified ACE-inhibitor users as 
having nephropathy, unless ACE-inhibition was started specifically for 
hypertension. 
Analysis 
We calculated Quality Adjusted Life Years (QALYs) from the SF-60 and EQ-50. 
We performed repeated measures analyses to measure change in HRQOL over 
time. 
We defined two three-year periods: 1995-1998 and 1998-2001. 
Since the EuroQol was not assessed in 1999 and 2000, we calculated three QALY 
values for each patient: SF-60 (1995-1998), SF-60 (1998-2001) and EQ-50 (1995-
1998). The QALYs were essentially a weighted average of HRQOL scores over a 
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given time period. For example, the SF-6D QALY (1995-1998) was calculated 
using the following formula: 
y, * SF-6D (1995) + SF-6D (1996) + SF-6D (1997) + Y2 * SF-6D (1998). 
To investigate whether these utitilies can provide information about associations of 
diabetes-specific factors we performed a multivariate stepwise regression analysis, 
once for each of the three QALY scores as a dependent variable. For the first three-
year period (1995-1998) the patient and diabetes-specific characteristics in 1995 
were the independent variables, for the second three-year period (1998-2001) the 
characteristics in 1998 were the independent variables, with the exception of the 
macrovascular complications. For the second three-year period we added the 
factor 'macrovascular complications in 1995' in the regression analysis since the 
macrovascular complications were not recorded in 1998. 
We compared the adjusted R2 of the models to compare the percentage explained 
variance in HRQOL. 
Furthermore we determined Spearman rank order correlations between the QALYs 
derived from the SF-6D and the EQ-50. 
Data were analysed using the statistical computer package SPSS for Windows 
version 1 0.0. We considered changes statistically significant when p-values less 
than or equal to 0.05 were observed. 
Results 
A total of 281 adult patients with diabetes mellitus type I entered the study in 
1995. The dropout rate over these six years was 16.7% (n~47); 234 patients 
completed the study period of six years. Patients who withdrew from the study 
were more frequently female (59.6% vs. 42.7%, p~0.04), were patients with a 
longer disease duration (20.6 vs.16.5 years, p~0.05), were more often single (24.0 
vs. 9.2%, p~0.01), had a higher HbA1c (9.0 vs. 8.1%, p~0.007), and had a 
statistically lower baseline HRQOL than the patients continuing the study. 
Personal and disease-specific characteristics of the patients who completed the 
entire study period of six years are shown in table 1. At the start of the study mean 
age was 38.2 years and 57.3% were men. At that time, one quarter of the patients 
used a pump (26.9%). Almost half of the patients had microvascular complications 
(45.8%), whereas only 4.3 % had macrovascular complications (mainly angina 
pectoris and intermittent claudication). A majority of those patients with 
comorbidity had one or two other chronic medical conditions besides their 
diabetes (mean 1.2, range 0-7). 
In 1998, after three years of follow-up, the percentage of patients using a 
subcutaneous pump (26.9% to 32.6%, p~0.016), the body mass index (24.8 to 
25.6 kg/m2 , p < 0.001) and the percentage of patients with microvascular 
complications (45.8% to 58.1%, p~O.OOS) increased. The HbA1c declined 
significantly (8.1% to 7.9 %, p~0.016). 
Both utility indices declined over six years: the SF-6D declined from 0.83 (0.12) to 
0.80 (0.13) (p~0.001) and the EQ-SD declined from 0.90 (0.15) to 0.85 (0.19) 
(p ~ 0.004) (table 2). 
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The percentage of patients reporting the best possible EQ-50 health state (value 1) 
varied from 51.5- 59.0% across the follow-up period, whereas this was only 5.0-
15.3% for the SF-60. 
The SF QALYs for the first three-year period were 2.50 (S0~0.31), for the second 
three-year period 2.46 (S0~0.36). EQ-QALYs for the first three-year period were 
2.64 (SD~0.40) (table 2). The difference between the SF QALYs and EQ QALYs 
was 0.137 (95% Cl: 0.100-0.174, p< 0.001 ). 
Multivariate regression analysis, with patient characteristics in 1995, showed that 
in the first three-year period a longer disease duration, a higher frequency of self-
monitoring blood glucose and the presence of hyperglycaemic complaints, 
macrovascular complications and comorbidity (in 1995) were associated with 
lower SF QALYs (table 3). 
The negative influence of a higher frequency of self-monitoring blood glucose and 
the presence of hyperglycaemic complaints and comorbidity (in 1998) remained 
statistically significant in the second period. The presence of microvascular 
complications was associated with lower SF QALYs. 
The presence of hyperglycaemic complaints, retinopathy and comorbidity was 
associated with lower EQ QALYs (table 3). 
Patient characteristics (sex, age, marital status, level of education), HbA 1 c, body 
mass index, diastolic and systolic blood pressure, frequency of insulin injection 
and the presence of hypoglycaemic complaints were not associated with either of 
the QALYs. 
The SF QALY (1995-1998) scores correlated strongly with SF QALY (1998-2001) 
scores (Spearman rank correlation coefficient 0.807, p<0.001), as well with the 
EQ (1995-1998) QALY scores (Spearman rank correlation coefficient 0.759, 
p<0.001). 
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Table1 
Personal and disease-specific characteristics of the study population (n = 234) 
1995 1998 
Gender (men} 134 (57.3%} 134 157.3%) 
Age (years) 38.2 (11.5) 41.2 111.5) 
Duration of diabetes {years) 16.5 (10.1) 19.5 110.1 I 
Married/ cohabiting 207 190.8%) 194 (89.4%) 
High level of education 76 133.6%) 72 (34.0%) 
Systolic blood pressure (mm Hg) 138.9 117.8) 131.1 (19.4) < 0.001 1 
Diastolic blood pressure (mm Hg) 83.0 I 8.41 79.4 (10.2) < 0.001 1 
Pulse pressure 55.9 115.2) 51.6 (15.9) < 0.001 1 
Ratio cholestero!/H DL 3.8 I 1.21 3.6 (1.3) 0.031' 
Body mass index (kgfm 2) 24.8 (3.2) 25.6 (3.6) < 0.001' 
Hba1c 1%1 8.1 11.9) 7.9 (1.3) 0.016' 
Insulin pump 63 (26.9%) 76 (32.6%) 0.016' 
N r. of control measurements/week 12.0 111.3) 18.2 (14.4) < 0.001 1 
Number of patients with: 
hypoglycaemic events 185 (80.8%) 180 (84.9%) 0.1102 
hyperglycaemic complaints 122 (53.2%) 105 (50.5%) 1.000' 
Prevalence of diabetic 
complications 
Microvascular 104 (45.8%) 111 158.1 %) 0.005 2 
Retinopathy 79 134.6%) 88 (44.9%) 0.0072 
Nephropathy 43 (18.4%) 33 {16.7"/o) 0.210' 
Neuropathy 24 (10.7%) 32 115.2%) 0.0042 
Macrovascular 10 ( 4.3%) 
Comorbidity 133 (58.1%) 130 162.5%) 0.212 2 
Values are number of patients or means with valid percentage or standard deviation 
between parentheses 
1 P values are result of paired samples T-test 
2 P values are result of Me Nemar test 
3 Not recorded 
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Table 2 
Health Related Quality of life over time in patients with diabetes mellitus type I 
(n=234) 
SF-60 
Mean so 
1995 0.83 0.12 
1996 0.84 0.12 
1997 0.83 0.12 
1998 0.83 0.13 
1999 0.82 0.14 
2000 0.82 0.14 
2001 0.80 0.13 
p value 2 0.001 
QALYs 
1995-1998 
1998-2001 
Mean 
2.50 
2.46 
so 
0.31 
0.37 
SF-60 -Short Form utility index 
EQ-50 - EuroQol utility index 
QALYs -Quality Adjusted Life Years 
SO -standard deviation 
Range 
0.45-1.00 
0.50-1.00 
0.50-1.00 
0.33-1.00 
0.40-1.00 
0.40-1.00 
0.40-1.00 
1 EuroQol was not assessed in 1999 and 2000. 
2 P values are result of repeated measure analysis 
EQ-50 
Mean so Range 
0.90 0.15 0.17-1.00 
0.88 0.16 0.10-1.00 
0.87 0.17 -0.07-1.00 
0.87 0.18 -0.23-1.00 
0.85 0.19 -0.17-1.00 
0.004 
QALYs 
Mean so 
2.64 0.40 
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Table 3 
Results of the multivariate regression analysis of the Quality Adjusted life Years 
Intercept 
Diabetes duration 
Selfmonitoring a week 
Hyperglycaemic 
complaints 
Microvascular 
campi ications 
(and specifically retino-l 
neu ro-/neph ropathy) 
Macrovascular 
complications 
Comorbidity 
Sf- QAlYs 
1995-1998 
R' = 0.290 
(n= 174) 
Characteristics 
1995 
2.821 
-0.006 (p=0.008) 
(-0.01, -0.002) 
-0.005 (p = 0.008) 
(-0.009, -0.001) 
-0.179 (p<0.001) 
(-0.267, -0.091) 
-0.257 (p=O.Ol 1) 
(-0.447, -0.067) 
-0.1 1 6 (p = 0.008) 
(-0. 196,- 0.036) 
SF- QAlYs 
1998-2001 
R2 =0.318 
(n= 157) 
Characteristics 
1998 
2.856 
-0.005 (p=0.012) 
(-0.009, -0.001) 
-0.249 (p<0.0011 
(-0.351, -0.147) 
-0.096 (p=0.052) 
(-0.192, 0) 
-0.202 (p<0.001) 
(-0.305, -0.097) 
Between parentheses the p value and the 95% confidence interval 
EQ-QAlYs 
1995-1998 
R'=0.194 
(n = 209) 
Characteristics 
1995 
2.911 
-0.228 lp<0.001) 
(-0.328,- 0. 128) 
Retinopathy: 
-0.146 (p = 0.006) 
(-0.246,- 0.046) 
-0.172 lp=O.OOl) 
(-0.272, -0.072) 
SF QAl Ys -Quality adjusted life years based on the utility of the Short Form-36 
EQ QAlYs -Quality adjusted life years based on the utility of the EuroQol 
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Discussion and conclusion 
In this study, 234 patients with DMT1 were followed for six years. This is the first 
study in which the utilities of both the SF-36 and the EuroQol have been used in a 
population of patients with DMT1. Although the SF-36 and the EuroQol are 
generic HRQOL instruments, their utilities, based on respectively only 11 and 5 
items, measured changes in HRQOL over time in patients with DMT1. Diabetes-
specific instruments are considered to be more sensitive to changes in HRQOL 
than generic instruments, since the disease-specific items of these instruments 
predominantly concern aspects of HRQOL, which are important for patients with 
that specific disease (4). Since in this study generic utilities were able to discern 
changes in HRQOL in patients with DMT1, this might undermine the presumed 
added value of diabetes-specific instruments. 
The SF (1995-1998) QALYs were significantly lower than the EQ-50 (1995-1998) 
QALYs (difference 0.14 QALYs over 3 years). This can possibly be explained by 
the fact that the SF-60 is derived from 11 items, whereas the EQ-50 is derived 
from only 5 items. Moreover the SF-60 items have more answer possibilities than 
the EQ-50. This offers the SF-60 the possibility of a more detailed assessment of 
HRQOL, and a further differentiation in various HRQOL levels. The high 
percentage of patients reporting the best EQ-50 health state, a ceiling effect, has 
been noted previously (25, 26). This ceiling effect probably makes the EQ-50 less 
suitable than the SF-60, when relatively small changes in the highest ranges are 
expected in patients with DMT1. 
This new finding, that the utility of the SF-36 is sensitive to changes in HRQOL in 
DMT1 over time, should reassure investigators that if they have employed the SF-
36, they can retrieve a utility score which is sensitive and can perform fairly well 
in patients with DMT1. It provides health planners with a useful tool to compare 
alternative treatment strategies for patients with DMT1 and supports subsequent 
decision making. 
The three most pronounced negative influences on QALYs were the presence of 
hyperglycaemic complaints, macrovascular complications and comorbidity. This 
negative influence on QALYs can be explained by the fact that these factors will 
likely cause symptoms experienced by the patients. In turn, these symptoms will 
influence a patient's physical, mental and social functioning in daily life, and will 
thereby influence a patient's HRQOL (27). The associations we found, correspond 
with prior knowledge (1 0, 11, 13, 28). This comparison supports the validity of 
these utilities in measuring HRQOL in DMT1. 
The inclusion of several socio-demographic and diabetes-specific variables in the 
regression analysis only led to a 22-30% percentage of explained variance of 
patient's HRQOL, meaning that a rather large percentage of variance in HRQOL 
remained unexplained (70-78%). A patient's personality, social environment and 
life events will to a large extent explain a person's perception of symptoms and 
functioning and in this way influence a patient's HRQOL (27). Indeed, Rose et al 
developed a model that explained 62% of variance of HRQOL, patient's 
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psychological characteristics being the most significant determinant of HRQOL 
(mostly measures of psychological condition) (27, 29, 30). 
Most of the above-mentioned characteristics were diabetes-specific factors. 
Nevertheless, the utilities of the generic SF-36 and EuroQol, which are not focused 
on aspects of special interest for patients with DMT1, apparently are sensitive 
enough to reveal associations between these diabetes-specific factors and QALYs. 
The explained percentage of variance in QALYs was higher with the SF QALY than 
the EQ QAL Y regression analysis. This might -again - be explained by the more 
detailed descriptive system of the SF-60 compared to the EQ-50. 
The EuroQol and the SF-36 both are generic and approach HRQOL as broadly as 
possible. Utilities of both instruments suggested a negative association between 
hyperglycaemic complaints and comorbidity and QALYs. This finding supports the 
validity of the two utilities and the robustness of these associations. However, this 
study showed that these two instruments can nevertheless give slightly different 
results. For example, the EQ-50 did not show an influence of macrovascular 
complications on EQ-QALYs, whereas the SF-60 did. The less detailed descriptive 
system of the EQ-50 can possibly explain this finding. However retinopathy 
showed a negative influence on EQ-QALYs, but no association with the SF-QALYs. 
We do not have an explanation for this finding. 
The negative influence of a high frequency of self-monitoring blood glucose, 
hyperglycaemia and comorbidity on HRQOL was assessed in both three-year 
periods, suggestive of a persisting influence over time. This finding can possibly 
support not only the robustness of this negative influence but also the consistency 
of the instruments used. 
This study also showed that different moments can reveal different associations 
with HRQOL. Socio-demographic and particularly diabetes-specific variables 
change over time, which can probably explain this finding. For example, in the 
second three-year period microvascular and not macrovascular complications had 
a negative influence on SF-QALYs. In this later phase of the study, the severity of 
microvascular complications might be greater and more frequently accompanied 
by symptoms, which in turn will influence patient's functioning. Coffey et al. 
showed a growing negative influence of microvascular complications with 
increased severity (11). In the case of macrovascular events, however, Clarke et al. 
showed in the UKPDS study that in patients with diabetes mellitus type 2 the 
negative influence on the EQ-50 of some complications, e.g. ischaemic heart 
disease and myocardial infarction, appeared to be less in the years subsequent to 
the year of the event (26). In our study, the macrovascular events registered in 
1995 were events that had taken place in 1995 or earlier, which thus might 
explain a diminishing influence on a patient's HRQOL. 
Conclusion 
This is the first study in which SF-36 and EuroQol utilities and QALYs were 
calculated in patients with DMT1. This study showed a statistically significant 
decline in SF-60 and EQ-50 over time in a Dutch cohort of 234 patients with 
DMT1, an indication that both generic utilities were able to reveal changes in 
HRQOL over time and offer possibilities for cost effectiveness studies in patients 
with DMT1. 
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Presence of hyperglycaemic complaints, macrovascular complications, and 
comorbidity had the most profound negative association with QALYs. Both 
instruments were able to measure these associations between diabetes-specific 
factors and QALYs, associations already known to be associated with HRQOL, and 
thus showing the robustness and the validity of these utilities in patients with 
DMT1. 
It should be emphasized, however, that the choice of the instrument and the 
moment of assessment of HRQOL can lead to partly different results. The SF-6D is 
more responsive to small changes in the highest ranges of HRQOL in patients with 
DMT1. 
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Abstract 
Background 
An ideal instrument for the assessment of Health Related Quality of Life (HRQOL) 
in patients with diabetes mellitus type I (DMT1) should incorporate the benefits of 
both generic and disease-specific instruments. The objective of this study was to 
investigate the responsiveness and the ability to provide information about 
diabetes-specific associations with HRQOL, of two generic instruments, in 
comparison with two diabetes-specific instruments, in patients with DMT1. 
Methods 
In a Dutch cohort of 234 patients with DMT1 we longitudinally assessed HRQOL 
using both generic and diabetes-specific instruments. We investigated the 
responsiveness, the associations with diabetes-specific variables and the 
identification of specific patients by the instruments used. 
Results 
The generic RAND-36 was able to detect statistically significant and clinically 
relevant changes in HRQOL over time. Moreover, the RAND-36 was associated 
with (changes in) diabetes-specific variables. The generic and diabetes-specific 
instruments partly identified different patients with lowest HRQOL. 
Conclusions 
The RAND-36 was highly responsive to changes in HRQOL in patients with DMT1 
and revealed diabetes-specific associations with HRQOL. A low correlation 
between the generic and diabetes-specific instruments and partly different 
identification of patients with lower HRQOL support the complementary use of 
these instruments in patients with DMT1. 
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Introduction 
Diabetes mellitus type I (DMT1) will permanently change a person's life. Patient's 
self care, consisting of daily insulin injections and self-monitoring of blood 
glucose, has an impact on health related quality of life (HRQOL). Moreover, the 
acute and long-term complications which might develop will also affect a person's 
HRQOL (1). 
However, only in recent years has attention been paid to HRQOL in patients with 
DMT1 (2). Many different instruments have been developed to measure the 
physical, psychological and social aspects of HRQOL (3-7). One can distinguish 
between generic and disease-specific HRQOL instruments (8, 9). Generic 
instruments are applicable to healthy people as well as to persons with diseases, 
and thereby enable comparisons to be made between various groups of patients 
and general population samples. Moreover, the general public has valued different 
health states, provided by some generic questionnaires, which makes economic 
evaluations possible (1 0-12). Disease-specific instruments focus on a population 
with a specific disease and are expected to be more sensitive to treatment effects 
and changes over time than generic instruments (8, 9). The limitation of these 
instruments, however, is that the scores such instruments generate remain specific 
for the affliction studied. 
Many cross-sectional studies, using many different instruments of both types, have 
been performed in DMT1, and have shown that older and female patients, patients 
without a partner, patient with a lower education, and patients with complications 
are at risk for a decrease in HRQOL (13-29). 
An ideal instrument for the assessment of HRQOL in DMT1 should incorporate the 
benefits of both generic and diabetes-specific instruments. This instrument should 
be sensitive for changes, should provide information about diabetes-specific 
associations with HRQOL, should enable comparisons between various groups of 
patients or general population samples and should make economic evaluations 
possible. 
The aim of this study was to investigate these properties of two generic instruments 
in the assessment of HRQOL in DMT1. Moreover, we wanted to investigate the 
feasibility of these instruments and the clinical relevance of their resu Its. 
We therefore examined whether the generic instruments used in our study are 
capable of measuring (clinically relevant) changes in HRQOL in patients with 
DMT1 (1) and whether these generic instruments can identify diabetes-specific 
associations with HRQOL (2). An additional aim was to examine whether diabetes-
specific and generic instruments identify the same patients, when low HRQOL 
scores are assessed (3). 
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Methods 
Patients 
In 1995 a series of 293 consecutive DMT1 patients seen at the outpatient clinic of 
the lsala Clinics in Zwolle, the Netherlands, was invited to participate in the study. 
A group of 281 patients agreed and was investigated from 1995 onwards on a 
yearly basis. DMT1 was defined as starting insulin therapy within six months after 
the first signs of diabetes mellitus and before the age of 30 years, or the absence of 
C-peptide secretion. Ethics committee approval was obtained from the Hospital 
Scientific and Ethics Committee. All patients gave their informed consent. 
Health Related Quality of life (HRQOL) 
We used two different, frequently applied generic instruments, the RAND-36 and 
the EuroQol, which have both been translated and validated for the Dutch 
situation. In addition we used two different diabetes-specific instruments (Problem 
Areas In Diabetes, Fear of Hypoglycamia Scale) to measure some diabetes-specific 
aspects of HRQOL and to make comparisons possible with the generic 
assessments (1 0, 30-32). 
These four instruments were sent to the patient's home address in one package. 
Patients were asked to fill in the questionnaires at home. At the next visit to the 
outpatient clinic the patients returned the completed questionnaires to the 
diabetes-specialist nurse. Patients who did not return the completed questionnaires 
when visiting the clinic were asked to send their completed questionnaires 
afterwards. 
The RAND-36 is a self-administered, generic questionnaire containing 36 items 
involving eight different subscales. For each subscale, scores are transformed to a 
scale from 0 (worst health) to 100 (best health) (31, 33). In addition, physical and 
mental component summary scores can be determined (PCS/ MCS) (34). The 
questionnaire takes about ten minutes to complete. The instrument has been 
translated into Dutch (35) and validated for the Dutch population (36). The RAND-
36 was assessed yearly. 
The Euroqo/ (EQ) 
The EuroQol was developed by a multidisciplinary group of researchers from 5 
European countries to describe and value health states (1 0). It is a generic, 
multidimensional measure, consisting of two parts, and takes about 2 minutes to 
complete by the patient. 
The first part consists of five questions covering 5 dimensions (EQ-50). Each 
dimension is divided into 3 levels: 'no problem', 'some/ moderate problems' and 
'extreme/ unable to'. A respondent's health state is defined by combining one level 
from each of the 5 dimensions. A total of 243 possible health states can be defined 
in this way. Valuations of these health states have been made, by the U.K. general 
public, using time trade-off (37). The set of possible values has a range of -0.594 to 
1, where 1 is the value of perfect health, 0 is the value of death and -0.594 
indicates the worst possible health state, which is viewed by the general public as 
considerably worse than death. 
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The second part, a single overall score, can be gained from a "thermometer": a 
self-rated health status using a graduated (0-100) visual analogue scale (EQ-VAS), 
in which 0 indicates worst HRQOL and 100 best possible HRQOL. The EuroQol 
has been validated for the Dutch situation (38). The EQ was assessed in 1995 
through 1998, and in 2001. 
The Problem Areas in Diabetes Survey (PAID) 
The PAID was developed as a new measure of psychosocial adjustment to 
diabetes. It is a diabetes-specific, unidimensional instrument. The instrument can 
be scored quickly, in 3-5 minutes, by the patient. Its primary aim is to tap the 
breadth of emotional responses to diabetes (32, 39). The PAID is a 20-item 
questionnaire in which each item represents a unique area of diabetes-related 
psychosocial distress. The items are divided over four areas. A total score, 
hypothesised to reflect the overall level of diabetes-related emotional distress, is 
computed by summing the 20 item responses. It is scored on a scale of 0 to 100, 
with higher PAID scores indicating greater emotional distress. Reliability and 
validity are good (32, 39) and the PAID has been validated for the Dutch situation 
(40). The PAID was assessed in 1998 and 2001. 
The Fear of Hypoglycaemia Scale (FHS) 
The FHS was developed as a research and clinical tool measuring the degree of 
fear experienced with respect to hypoglycaemia (30). Worries about 
hypoglycaemia as well as behaviour designed to avoid hypoglycaemia are 
examined. It is a diabetes-specific, unidimensional measure. The scale consists of 
23 items: 13 items concerning worry and fear and 10 items concerning behaviour 
or avoidance. The 13 worry items can be summed to a Worry subscale, while the 
10 behaviour items can be summed to a Behaviour subscale. Together, the two 
subscales can be summed to create the total FHS-score, a higher score indicating 
greater fear for hypoglycaemia (41). Various studies support the validity and the 
reliability of the FHS (30, 41 ). We only used the Worry subscale, since at the time 
of the study the validity of the behaviour subscale was discussed (41, 42). The 
Worry subscale was assessed in 1997 and 2001. 
Clinical data 
Socio-demographic data including sex, age, marital status and level of education 
were recorded. Therapy-specific data were recorded and included pen-/ pump use, 
frequency of insulin injections and number of blood glucose control 
measurements per week. Metabolic control was assessed by measuring 
glycosylated haemoglobin A 1 c (HbA 1 c). The acute complications of the therapy 
were also recorded; patients recorded all hypoglycaemic events during the three 
months preceding the outpatient visit. Patients were asked to report whether they 
had one or more of six different hyperglycaemic complaints during the previous 
three months (yes/ no): tiredness, weight loss, pruritus, thirst, polyuria and 
polydipsia. 
Using a list of 26 chronic diseases/ diagnoses the patients could indicate which 
other diseases they had besides diabetes (43). When they indicated one or more 
chronic diseases, apart from diabetes mellitus, they were scored as having 
comorbidity. 
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Chronic complications of the disease were recorded (micro-/ macrovascular 
complications). 
Microvascular complications 
Patients with retinopathy, neuropathy or nephropathy were categorised as having 
microvascular complications. 
Retinopathy 
The ophthalmologist examined all patients annually. The degree of diabetic 
retinopathy was assessed by fundoscopy in mydriasis. The classification of diabetic 
retinopathy used was based on de jong (44): no retinopathy ( ~ 0), background 
retinopathy ( ~ 1), preproliferative (~II) and proliferative diabetic retinopathy (~Ill). 
Retinopathy was scored positive when any type of retinopathy was present in 
either eye. When the degree of retinopathy was different in two eyes, the highest 
degree was scored. 
Neuropathy 
Sensitivity was tested by the Semmes-Weinstein pressure aesthesiometer (45). At 
five dorsal and plantar sites on the foot (left and right) sensibility was tested with 
six different monofilaments. When the monofilament 5.07 was not felt at one of 
the ten test sites, patients were considered to have neuropathy. 
Nephropathy 
The 24-hour urinary excretion of albumin (UAER) was measured annually. UAER 
was considered abnormal when it was<: 30mg/ 24 hours. Micro-albuminuria was 
defined as 30-300 mg/ 24 hours and macro-albuminuria as <:300 mg/ 24 hours. All 
patients with micro-albuminuria or macro-albuminuria were defined as having 
nephropathy (46-48). At the lsala clinics, patients with a micro-albuminuria > 100 
mg/ 24 hour received an angiotensin converting enzyme inhibitor (ACE-inhibitor) 
in 1995. We included ace-inhibitor users, even with normalbuminuria, as having 
nephropathy, when treatment was initiated for micro-albuminuria at an earlier 
stage. 
Macrovascular complications 
The clinician recorded the status of macrovascular complications. Patients were 
classified as having macrovascular complications when one or more of the 
following diagnoses was present: angina pectoris, myocardial infarction, 
intermittent claudication, transient ischaemic attack (TIA), or a cerebrovascular 
accident (CVA). 
Analysis 
We investigated the responsiveness of the RAND-36 and the EuroQol in patients 
with DMT1, in order to answer the question whether these generic instruments are 
sensitive for changes in HRQOL in patients with DMT1. Although responsiveness 
is considered to be an essential property of an evaluative instrument, the 
methodology of assessing reponsiveness tends to be less well understood (49). 
In this study we applied three methods to investigate responsiveness of the generic 
instruments used in our cohort. Firstly, we investigated the ability to detect, 
longitudinally, statistically significant changes in HRQOL over time (1998- 2001) 
using paired sample T-tests. Since the diabetes-specific instruments were assessed 
only in 1998 and 2001 we used this time interval. 
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Secondly, we investigated whether the observed changes were also clinically 
relevant. The developers of the RAND-36 and the EuroQol do not provide cut-off 
points for clinically important changes in HRQOL scores. However, changes of > 
2-5 points for the RAND-subscales and > 1 point for the RAND summary scores 
are sometimes considered as the smallest clinically significant changes (33, 50, 
51). For the EQ-5D and the EQ-VAS, 0.05 points and five points can be used as a 
rough guide although formally the EuroQol Group has not published any 
minimally significant values. 
Finally, we investigated whether the generic instruments assessed changes in 
HRQOL when changes were expected on the basis of changes in diabetes-specific 
clinical characteristics. We expected a decrease in HRQOL for the patients who 
developed microvascular complications between 1998 and 2001 and compared 
the means of the patients who did develop microvascular complications and of the 
patients who did not (using the Mann Whitney test). 
To investigate whether the generic instruments can provide information about 
diabetes-specific influences on HRQOL, we performed multivariate stepwise 
regression analyses to investigate cross-sectional associations of HRQOL scores 
with several demographic and disease-specific patient characteristics (in 2001). 
The different HRQOL scales were the dependent variables and all the personal and 
disease specific variables (see table 1) were the independent variables. We used 
the adjusted R 2 (result of the multivariate regression analysis) to describe the 
degree of variance in HRQOL explained by the model. 
To investigate whether diabetes-specific and generic instruments identify the same 
patients, we calculated correlations between the different instruments using 
Spearman rank correlation coefficients. Moreover, for each instrument the 10% 
lowest scores (in 2001) were defined and the patients, thus identified by the 
different instruments, were compared. 
Finally, we described several feasibility characteristics of the instruments, to 
provide practical information for the use of these instruments. 
Relationships were considered statistically significant when p-values :': 0.05 were 
reached. Data were analysed using SPSS for Windows, version 1 0.0. 
Results 
A total of 281 adult patients with type I diabetes mellitus entered the study in 
1995. The dropout rate over these six years was 16.7% (n ~47). Dropouts were 
more frequently women (59.6% vs. 42.7%, p~0.04), more often single (24% vs. 
9.2%, p~0.01), had a longer disease-duration (20.6 vs.16.5 years, p~0.05), and a 
higher HbA 1 c (9.0 vs. 8.1, p~0.007) and reported a lower baseline HRQOL. 
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Table 1 
Personal a
nd disease-specific characteristics of the study population (n =
 234) 
1995 
1998 
2001 
G
ender (men) 
134 
157.3%) 
134 
(57.3%) 
134 
157.3%) 
Age (years) 
38.2 
111 
.5) 
41.2 
11 1.5) 
44.2 
11 1.5) 
D
uration of diabetes (years) 
16.5 
110. 1) 
19.5 
11 0.1) 
22.5 
110.1) 
M
arried/ cohabitinh 
207 
190.8%) 
194 
189.4%) 
189 
187.9%) 
H
igh level of education 
76 
133.6%) 
72 
134.0%) 
76 
135.5%) 
Systolic blood pressure 
138.9 
11 7.8) 
131.1 
11 9.4) 
131.5 
119.2) 
D
iastolic blood pressure 
83.0 
18.4) 
79.4 
110.2) 
77.8 
110.4) 
Body m
ass index (kg/m
2) 
24.8 
13.2) 
25.6 
13.6) 
26.1 
14.0) 
H
ba1c 
1%) 
8.1 
11.9) 
7.9 
11 
.3) 
7.6 
11.1) 
Insulin pum
p 
63 
126.9%) 
76 
132.6%) 
102 
143.6%) 
Insulin pen 
171 
173.1%) 
157 
167.4%) 
132 
156.4%) 
Frequency of insulin pen injections (per day) 
1-3 
24 
114.0%) 
22 
114.0%) 
19 
114.4%) 
4 
147 
186.0%) 
128 
181.5%) 
108 
181.8%) 
>
4
 
0 
I 0.0%
) 
7 
I 4.5%) 
5 
I 3.8%) 
N
um
ber of co
ntrol m
e
a
su
re
m
e
nts (per w
e
ek) 
12.0 
111 
.3) 
18.2 
114.4) 
20.0 
11 5.2) 
Patients w
ith: 
hypoglycaem
ic ev
ents last 3 m
o
nths 
185 
180.8%) 
180 
184.9%) 
173 
187.4%) 
hyperglycaem
ic co
m
plaints last three m
o
nths 
122 
153.3%) 
105 
(50.5%) 
116 
158.3%) 
C
om
orbidity (at least o
n
e
 co
m
o
rbid co
ndition) 
133 
158.1%) 
130 
162.5%) 
107 
152.7%) 
Patients w
ith diabetic co
m
plications 
M
icrovascular 
104 
145.8%) 
111 
158.1%) 
1 1 9 
165.7%) 
R
etinopathy 
79 
134.6%) 
88 
144.9%) 
99 
148.5%) 
N
ephropathy 
43 
11 8.4%) 
33 
116.7%) 
45 
123.0%) 
N
europathy 
24 
110.4%) 
32 
115.2%) 
23 
112.2%) 
M
acrovascular 
10 
I 4.3%
) 
23 
I 9.8%) 
Values are n
u
m
ber of patients (with v
alid percentages betw
een parentheses) o
r m
e
a
n
s (with standard deviation betw
een parentheses) 
Personal and disease-specific characteristics of the patients who completed the 
study period of six years are shown in table 1 (n ~ 234). Data are shown for the 
years 1995, 1998 and 2001. Mean age at entry was 38.2 years, and 57.3% were 
men. The percentage of patients using a pump increased from 26.9% in 1995 to 
32.6 % in 1998 (p~0.002) to 43.6% in 2001 (p<0.001). The therapy was 
intensified over the six-year study period. An increased number of control 
measurements per week, a lower HbA 1c and a rise in body mass index were 
observed over this period. The percentage patients with hypoglycaemic events did 
not increase statistically significantly between 1995 and 2001 (p~0.096). The 
percentage of patients with microvascular complications increased from 45.8% in 
1995 to 58.1% in 1998 (p ~ 0.005) and later to 65.7% in 2001 (p ~0.248). In 1995 
the percentage of patients with macrovascular complications was 4.3% and in 
2001 9.8% (p<0.001). 
Ability to detect change in HRQOL over time 
Table 2 shows the HRQOL over time for the different instruments. 
RAND-36. Five subscales of the RAND-36 and the PCS showed a statistically 
significant decrease in HRQOL over time. The subscales role physical and social 
functioning and the Mental Component Summary tended to decrease, whereas the 
subscale role emotional remained stable between 1998 and 2001. Seven RAND-
subscales and the PCS showed a clinically relevant change over time within this 
study period. The subscale role emotional and the MCS did not show a clinically 
relevant change in HRQOL over time. 
EuroQoL. The EQ-50 as well as the EQ-VAS tended to decline between 1998 and 
2001. This decline was not statistically significant and/ or clinically relevant 
however. In both years the percentage of patients with the highest possible EQ-SD 
score was high (52.3% and 46.6% respectively). 
PAID. The problems related to treatment increased after 3 years follow-up 
(p~0.03). The diabetes related problems and the total score tended to increase, 
whereas the problems related to food and social support remained stable over 
time. 
Hypoglycaemia Fear. The degree of worry was not increased after the 3-year 
period. 
Ability to detect real changes in the concept being measured 
The patients, who developed microvascular complication(s) between 1998 and 
2001 reported a faster decrease in MCS and EQ-SD than the patients without new 
microvascular complication(s) [MCS -4.85 vs.+0.26, p~0.006 and EQ-50 -0.09 
vs. +0.02, p~0.013)]. 
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Table 2 
Health related quality of life in 1998 versus 2001 
1998 
RAN0-36 
Physical functioning 91.0 (15.8) 87.3 
Role physical 81.2 (33.3) 76.2 
Bodily pain 87.5 (19.9) 83.6 
General health 66.8 (18.9) 64.4 
Vitality 68.3 (19.8) 61.6 
Social functioning 86.5 (18.6) 84.2 
Role emotional 83.0 (35.5) 83.5 
Mental health 79.9 (15.9) 77.1 
Physical summary score 51.5 ( 7.6) 49.8 
Mental summary score 51.7 ( 9.5) 50.9 
EuroQol 
EQ-5D 0.87 (0.18) 0.85 
EQ-VAS 77.1 (14.4) 76.0 
PAID 
Diabetes related 13.8 (11.8) 14.9 
Treatment related 1.7 ( 2.7) 2.2 
Food related 2.5 ( 2.7) 2.4 
Social support related 1.1 ( 1.9) 1 .1 
Total Score 19.5 (17.2) 20.5 
H~~ogl~caemia Fear 
Worry subscale 10.9 ( 8.4)' 10.7 
Values are means with standard deviations between parentheses 
p-values are based on paired sample T-Tests 
2001 p value 
(19.0) 0.004 
(37.8) 0.070 
(20.2) 0.016 
(20.3) 0.015 
(20.0) <0.001 
(20.3) 0.086 
(32.6) 0.913 
(16.1 I 0.004 
I 9.1 I 0.006 
( 9.3) 0.176 
(0.19) 0.191 
(13.5) 0.054 
(12.0) 0.073 
( 2.9) 0.030 
( 2.6) 0.862 
( 1.8) 0.808 
(17.5) 0.254 
( 8.0) 1.000 
HRQOL data in this table are based on 213-220 patients, resulting in 204-213 paired 
samples 
1 Worry subscale was assessed in 1997 
EQ-5D 
EQ-VAS 
PAID 
EuroQol utility index 
EuroQol Visual Analogue Scale 
Problem Areas in Diabetes 
Ability to provide information about diabetes-specific associations with HRQOL 
Table 3 shows the results of the multivariate stepwise regression analyses. The 
explained variance in HRQOL varied from 3.8% (Worry scale) to 24.3% (PCS). 
Only four characteristics showed a statistically significant association with a 
HRQOL scale; the presence of hyperglycaemic complaints, comorbidity and 
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macrovascular complications were all negatively associated with HRQOL. A lower 
HbA1c was associated with more worries about hypoglycaemia. 
Table 3 
Results of the multivariate regression analysis of health related quality of life scores in 
2001 
R' 
Intercept 
HbAlc 
Hyper-
glycaemia 
Co morbidity 
Macrovascular 
complications 
R' 
Intercept 
PCS 
MCS 
EQ-SD 
EQ-VAS 
PAID 
PCS MCS EQ-SD 
0.243 0.075 0.180 
In~ 1801 In~ 192) ln~177) 
55.4 54.6 0.96 
-4.71 -5.03 -0.09 
lp<0.001) lp<0.001) lp<0.001) 
-2.78 -0.05 
lp~0.018) lp~0.033) 
-1 0.03 -0.135 
lp<0.001) lp~0.002) 
Adjusted R square 
Mean value of the population 
Physical component summary 
Mental component summary 
EuroQol utility index 
EuroQol Visual Analogue Scale 
Problem Areas in Diabetes 
EQ-VAS PAID- Worry 
total subscale 
0.157 0.083 0.038 
ln~177) ln~184) ln~201) 
82.9 14.4 19.77 
-1.29 
lp~0.014) 
-6.80 10.85 
lp < 0.001) lp<0.001) 
-11.6 
lp~0.001) 
The presence of macrovascular complications had the most pronounced negative 
association with HRQOL; these patients reported a lower PCS, EQ-50, EQ-VAS. 
Patients with hyperglycaemic complaints also had a lower HRQOL (PCS, MCS, 
EQ-50, EQ-VAS) and reported more diabetes related emotional distress (PAID). 
A lower HbA 1 c was associated with more worries about hypoglycaemia 
(p~0.014). 
Both generic instruments revealed a negative association between the presence of 
comorbidity and HRQOL (PCS and EQ-50). 
Identification of specific patients 
Table 4 shows the Spearman rank order correlations between the different 
instruments. 
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Table 4 
Spearman rank order correlations between the different quality of life scales 
PCS MCS EQ-5D EQ-VAS PAID-total Worry 
subscale 
PCS 
MCS 0.071 p~0.303 
EQ-SD 0.643 0.409 p<0.001 p<0.001 
EQ-VAS 0.531 0.557 0.613 p<0.001 p<0.001 p<0.001 
PAID -0.263 -0.457 -0.293 -0.432 p<0.001 p<0.001 p<0.001 p<0.001 
Worry -0.219 -0.402 -0.281 -0.296 0.627 
subscale p~0.002 p<0.001 p<0.001 p<0.001 p<0.001 
PCS Physical component summary 
MCS Mental component summary 
EQ-5D EuroQol utility index 
EQ-VAS EuroQol Visual Analogue Scale 
PAID Problem Areas in Diabetes 
Generic I generic - the PCS showed a strong correlation with the EQ-5D and a 
moderate correlation with the EQ-VAS. The MCS was moderately correlated with 
the EuroQol scales. 
The PCS and MCS were uncorrelated, inherent to the method we chose to 
calculate the summary scores (34). 
Diabetes-specific I diabetes-specific- the PAID was strongly correlated with the 
Worry subscale. 
Generic I diabetes-specific- The PCS and EQ-5D correlated only weakly with the 
more psychological health scales (i.e., the PAID and the Worry subscale), whereas 
the MCS correlated moderately with the PAID and the Worry scale. The EQ-VAS 
correlated moderately with the PAID. 
Table 5 shows the extent to which the instruments identified the same patients 
within the 10% lowest HRQOL range. The percentage of agreement was highest 
between the PCS, the EQ-5D and EQ-VAS. For example, of the patients with the 
10% lowest PCS scores, 60% reported lowest EQ-VAS scores. Of the patients with 
the highest hypoglycaemia worry scores, only a quarter was found in the lowest 
MCS-score category (26.1 %). Patients reporting most diabetes-related emotional 
distress had in 42.1% lowest MCS scores. 
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Table 5 
Percentage of patients with 10 % lowest HRQOL identified by both 
instruments 
PCS MCS EQ·5D EQ·VAS PAID· Worry total subscale 
PCS 9.5% 50.0% 60.0% 19.1% 20.0% 
MCS 9.5% 33.3% 38.9% 42.1% 30.0% 
EQ·SD 58.8% 29.4% 72.2% 23.5% 25.0% 
EQ-VAS 41.4% 24.1% 46.4% 26.7% 21.4% 
PAID 21.1% 42.1% 33.3% 47.1% 55.6% 
Worry 17.4% 26.1% 21.1% 28.6% 43.5% 
subscale 
PCS Physical component summary 
MCS Mental component summary 
EQ-50 EuroQol utility index 
EQ-VAS EuroQol Visual Analogue Scale 
PAID Problem Areas in Diabetes 
Feasibility Table 6 shows several feasibility data of the instruments used in our 
cohort. All four instruments led to very high percentages of valid scores. 
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Table 6 
Several feasibility data of the different instrum
ents u
sed in the cohort 
N
um
ber of 
N
um
ber of item
s 
Total sc
o
r
e
 
Com
pletion tim
e 
Suitable for 
V
alid sco
res 
subscales 
in m
inutes 
self a
ssessm
ent 
(1998) 
R
AN
D
-36 
8 
36 
Yes 
10 
Yes 
92.3-93.6%
 
EuroQol 
5 
6 
Yes 
2 
Yes 
93.2-93.6%
 
PAID
 
4 
20 
Yes 
3-5 
Yes 
89.7-92.7%
 
HFS 
2 
23 
Yes 
3 
Yes 
92.7%
1 
PAID
 
Problem
 A
reas in D
iabetes 
HFS 
H
ypoglycaem
ic Fear Survey 
B
ased o
n
 W
orry subscale 
Discussion and conclusion 
In our study we followed a Dutch cohort of 234 patients with DMT1 for three 
years. We used both generic and diabetes-specific HRQOL instruments to assess 
HRQOL. 
A central question was how well the generic RAND-36 and EuroQol capture 
changes in HRQOL in patients with DMT1 and whether they provide information 
about diabetes-specific associations with HRQOL. Moreover we examined the 
feasibility and the clinical relevance of their results. Could these generic 
instruments replace the diabetes-specific instruments in the assessment of HRQOL 
in DMT1? 
The responsiveness of the generic RAN D-36 was good: it was sensitive to changes 
in HRQOL over three years and the changes could also be considered clinically 
relevant. Moreover, the RAND mental summary score (MCS) was associated with a 
change in a diabetes-specific characteristic. The onset of microvascular 
complications was associated with a decrease in MCS, which we can explain by 
the fact that the knowledge of having a microvascular complication will negatively 
influence mental health. Very likely the PCS will be influenced negatively later, 
when the severity of the microvascular complications is increased, and the 
complications become symptomatic. These symptoms will influence patient's 
functioning and thereby HRQOL indirectly (52). 
The responsiveness of the EQ was limited. The mean observed changes in EQ 
between 1998 and 2001 were neither statistically significant nor clinically 
relevant. Moreover, this instrument showed a considerable ceiling effect, in that 
half of the patients reported the best possible HRQOL. This inability of the EQ to 
differentiate between small differences in the highest HRQOL ranges has 
previously been described (53, 54). Nevertheless, the EQ-5D decreased when 
microvascular complications developed. 
Patients reported more treatment related problems in 2001 than in 1998. Earlier 
studies provided support for the responsiveness for changes of the PAID (55). 
Indeed therapy was intensified during that period. Nevertheless, no associations 
were found between PAID scores and objective factors of intensified therapy (i.e. 
pump use/ more than 4 times daily pen injection, higher frequency of self 
monitoring blood glucose, lower HbA 1c) or the possible side effects of an 
intensified therapy (weight gain and more hypoglycaemic events) and PAID scores. 
The PAID scores purely reflected patient's subjective self-report and evaluation of 
problems concerning treatment. 
The Worry subscale did not show changes over time. Although the HbA 1 c 
declined significantly, the number of patients that reported hypoglycaemic events 
did not increase significantly, which might explain this result. 
We conclude that the generic RAND-36 was highly responsive to changes in 
HRQOL over time and to changes in a diabetes-specific variable. 
Both the RAND-36 and the EuroQol provided information about diabetes-specific 
influences on HRQOL. Hyperglycaemia and the presence of macrovascular 
complications were associated with a lower HRQOL. The generic instruments 
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showed a lowered HRQOL in the presence of non-diabetic morbidity 
(comorbidity), whereas the diabetes-specific instruments did not. Woodcock et al 
reported in a general practice DMT2 population the negative influence of 
comorbidity on generic measured HRQOL and used this finding to support the 
complementary use of generic and disease-specific instruments (56). 
Although the PCS is a generic measure, the model used to explain variance in PCS 
resulted in the largest percentage explained variance (i.e. 24.3%). This percentage 
was much lower for the MCS, the EuroQol, the Worry subscale of the HFS and the 
PAID. This suggests that it is easier to explain variance in the more physical aspects 
than in the more mental aspects of HRQOL. The RAND-36 is multidimensional 
and approaches HRQOL as broadly as possible, including physical, psychological 
and social aspects. In contrast, the HFS worry scale and the PAID are uni-
dimensional and focus on a small though important portion of the concept 
HRQOL of patients with DMT1 (57). 
We can state that the generic RAND-36, and the EQ in a less degree, gave 
information about diabetes-specific influences on HRQOL. This information was 
partly different from that provided by the diabetes-specific, uni-dimensional 
instruments used in our study (3, 5, 39, 57, 58). 
The low correlations between the generic and diabetes-specific instruments used 
in our study suggest that these instruments measure different aspects of health. 
Indeed, rather different aspects, ranging from problems with one's job ('did you 
have any problem with your work as result of your physical health?' RAND-36) to 
fear for hypoglycaemia ('do you worry about passing out in public?' HFS) are 
assessed (3). When instruments have a low correlation, a complementary use of 
these instruments can give additional information. 
The generic and diabetes-specific instruments in our study only partly identified 
the same patients with the lowest HRQOL. When a clinician wishes to identify and 
select patients who are at greatest risk of a worsening in HRQOL, the choice of the 
instrument will influence which patients will be identified. For example, for 
patients showing poor glycaemic control, a clinician can wonder whether these 
patients are more afraid of hypoglycaemic events than others, since this fear can 
lead to non-compliance and poor glycaemic control. This specific question should 
lead to a carefully considered choice of instrument, and in this case, the HFS 
would be the most appropriate choice. 
Although the RAND-36 questionnaire consists of more items and takes longer to 
complete than other instruments, this did not lead to a lower response rate or a 
lower percentage of valid scores. Apparently, the length of this instrument and the 
longer completion time were not a problem in this group of patients. 
Conclusion 
The generic RAN D-36 appears to be very sensitive to changes in HRQOL in a 
cohort of patients with DMT1. Although the RAND-36 is a generic instrument, it 
provides information about diabetes-specific associations with HRQOL. The 
generic and diabetes-specific instruments show low correlations and identify for 
the most part different patients with the lowest HRQOL. 
We recommend the use of the RAND-36 for assessing HRQOL in patients with 
DMT1. The complementary use of a diabetes-specific measure like the PAID and 
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the HFS will give additional information about the psychological status of patients 
with DM. 
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General discussion 

Introduction 
The main aim of this thesis was to investigate the Health Related Quality of Life 
(HRQOL) in patients with Diabetes Mellitus Type I (DMT1) and to investigate the 
possibility of providing recommendations for the assessment of the HRQOL in 
patients with DMT1. To this purpose a long-term clinical follow-up of a cohort of 
patients with DMT1 was performed. 
We were interested in the HRQOL of patients with DMT1 compared to that of 
persons of comparable age in the general population, and which factors are 
associated with their HRQOL. To explain associations between several 
demographic and diabetes-specific characteristics and HRQOL the model of 
Wilson and Cleary was followed. We hypothesized, that when disease symptoms 
are present and when the more severe complications of DMT1 will lead to 
symptoms, these symptoms will serve as important determinants of a person's 
functioning. Such impaired functioning will be associated with changes in HRQOL 
(1). 
We also investigated HRQOL during the first year after diagnosis. One year after 
diagnosis we compared HRQOL, with the HRQOL of persons from the general 
population. Furthermore, changes in HRQOL over time, in the six-year study 
period, were assessed, and compared to changes in the general population. Even 
more interesting was the question whether the changes in HRQOL are predictable 
allowing for the possibility of anticipating and preventing decreases in HRQOL. 
In our effort to provide recommendations for the assessment of HRQOL in patients 
with DMT1 several generic and disease-specific HRQOL questionnaires were used 
to assess possibilities and limitations seen with both types of questionnaires. We 
investigated whether utilities of generic instruments in patients with DMT1 can be 
used to allow cost-effectiveness studies, when taking their HRQOL into account. 
Follow-up of patients with DMT1 was possible in a cohort of patients with DMT1 
in the lsala Clinics in Zwolle, the Netherlands, from 1995 through 2001. 
In this general discussion (chapter 9) the main findings of this study will be 
presented and discussed. Recommendations for the future will be formulated. First, 
the cohort is described, followed by the main topic of the study, HRQOL in 
patients with DMT1. The chapter closes with conclusions and recommendations. 
A cohort of patients with DMT1 
Background 
DMT1 is characterized by the inability to regulate blood glucose levels due to the lack of 
insulin production, resulting in hyperglycaemia and the eventual development of micro-
and macrovascular complications. These complications associated with diabetes 
predominantly define the degree of morbidity in this group of patients. Therefore the 
primary goal in treating patients with DMT1, is to normalize blood glucose levels as much 
as possible in an effort to prevent or delay the onset and progression of complications, 
while at the same time optimizing the patient's HRQOL. 
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Major findings and discussion 
A cohort of 281 patients with DMT1 entered the study in 1995; 234 of these 
patients were followed for the entire duration of the six-year study. Therapy was 
intensified during the study period. The percentage of patients using an external or 
internal insulin pump increased significantly during these six years, from 26.9% in 
1995 up to 43.6% in 2001. Of the patients using the insulin pen, 85.6% injected 
2 4 times per day. Thus, 93.2% of the study population was treated intensively by 
the end of the study period. As a result the mean HbA 1 c dropped statistically 
significantly from 8.1% to 7.6%. There also was a significant increase in body 
mass index from 24.8 in 1995 to 26.1 kg/m 2 in 2001, which may be associated 
with the intensified insulin therapy. A consequence of the intensified insulin 
therapy was a significant increase in the number of control measurements of blood 
glucose level per week (from 12.0 in 1995 to 20.0 per week in 2001 ), (chapter 2). 
Despite this intensive therapy, the percentage of patients that reported 
hypoglycemic events during the study period, did not increase significantly. A 
possible explanation for this finding might be that severe hypoglycaemia can be 
reduced as much as 4-fold by insulin pump use, compared with multiple daily pen 
injections (2). 
The increase in the percentage of patients with micro- and macrovascular 
complications in our cohort was statistically significant, from 45.8% in 1995 to 
65.7% in 2001 for microvascular and from 4.3% in 1995 to 9.8% in 2001 for 
macrovascular complications (chapter 2). 
The Diabetes Control and Complications Trial (DCCT) showed that an intensified 
therapy delays the onset and progression of microvascular complications (3). 
Moreover, a reduction in some risk factors for cardiovascular disease suggested a 
potential beneficial effect of intensive therapy on macrovascular disease in DMT1 
(4). Despite the intensified therapy in our cohort, a significantly increased 
percentage of patients with micro- and macrovascular complications was observed 
over the six-year study period. 
Whereas in the DCCT an unusually supportive network of professionals was 
present, patients in our cohort seemed to be able to regulate and monitor their 
blood glucose levels adequately under standard diabetes care. 
limitations of our study 
-Dropouts 
The number of dropouts in this study was not high (n ~46), but unfortunately we 
were not able to follow up them adequately. At study entry these patients had a 
higher HbA 1 c (9.0 vs. 8.1 %, p ~0.007) and a longer disease duration (20.6 vs. 
16.5 years, p~0.05), factors which are known to be negatively associated with the 
development of diabetic complications. The dropouts were more often single, 
more frequently female, and reported a lower level of HRQOL at study entry. 
Dropout of these patients may have led to lower percentages of patients with 
diabetic complications in 2001, higher levels of HRQOL at baseline and less 
decrease in HRQOL over time. 
-Missing data 
During the study the percentage of missing clinical data increased. Patients were 
asked to complete a list consisting of diabetes-specific questions concerning 
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therapy, hypoglycemia, hyperglycemia and comorbidity every year. They also 
completed several HRQOL questionnaires. It is certainly possible that some of the 
patients were no longer motivated to complete the same questionnaires from 1995 
to 2001. Logistic reasons account in part for other missing data, such as the 
absence of a podiatrist in the clinic for the assessment of neuropathy at some 
follow-up visits. 
Since the number missing clinical data increased during the study period, fewer 
patients could be included for some of the multivariate regression analyses, e.g. 
when investigating associations between HRQOL and diabetes-specific factors, for 
which a complete dataset is required. Despite the sometimes limited patient 
numbers in some of the regression analyses, it was still possible to assess statistical 
significance of associations. When comparing the profiles of the patients excluded 
from the analysis with the profiles of the included patients, they did not differ 
significantly. 
- Onset of complications 
When the degree of complications becomes more severe it will lead to symptoms. 
We hypothesized that when these symptoms are present, HRQOL will be 
negatively influenced. Whereas early stages of microvascular complications will 
probably not give any symptoms, it might be the onset and just the fact of knowing 
about the presence of a microvascular complication that influences mentally 
HRQOL. However, it was impossible to assess HRQOL just at the moment of 
onset of complications. 
- Control group 
The prevalence of complications might have been even higher, when therapy 
would not have been intensified. Unfortunately we were not able to compare our 
data with data in a control group. 
Novel developments 
Recent studies emphasize the multifactorial genesis of vascular damage in diabetes 
mellitus. In the Epidemiology of Diabetes Interventions and Complications Study 
(EDIC), Nathan et al. showed that an increase in carotid intima-media thickness 
was associated with age as well as systolic blood pressure, smoking, the ratio of 
low-density lipoprotein to high-density lipoprotein and urinary albumin excretion 
(5, 6). Perkins et al showed that a glycosylated hemoglobin of less than 8 percent 
and low levels of both cholesterol and triglycerides were independently associated 
with the regression of microalbuminuria (7). In the Pittsburgh Epidemiology of 
Diabetes complications study, Orchard et al. demonstrated that insulin resistance 
related factors, and not glycemia, predicted coronary artery disease in DMT1 (8). 
Some weight gain (increased body mass index) is one of the side effects of 
intensive therapy. This often results in an increased central obesity, and may 
therefore contribute to the emergence of the insulin resistance syndrome (9). 
The EURODIAB IDDM Complications Study Group showed that cardiovascular 
disease is presaged by dyslipidemia, hypertension and increased body mass index, 
but not by elevated HbA 1 c levels (9, 1 0). 
These new insights offer possibilities for further delay and even prevention of onset 
and progression of diabetic complications. Indeed, and by analogy, the Steno-2 
Study showed that a long-term (mean 7.8 years) intensified intervention involving 
151 
multiple risk factors, including behavior modification and pharmacological therapy 
targeting hyperglycaemia, hypertension, dyslipidemia and microalbuminuria, as 
well as secondary prevention of cardiovascular disease with low dose 
acetylsalicylic acid, reduced the risk of cardiovascular and microvascular events by 
about 50 percent in patients with diabetes mellitus type 2 and microalbuminuaria 
(11). 
The UK Prospective Diabetes Study Group showed that tight blood pressure 
control in patients with hypertension and type 2 diabetes resulted in a clinically 
important reduction in the risk of mortality related to diabetes (two thirds of which 
were cardiovascular disease), complications related to diabetes, progression of 
diabetic retinopathy and deterioration in visual acuity (12). They also showed that 
quality of life in type 2 diabetic patients is affected by complications but not by 
intensive policies to improve blood glucose or blood pressure control (13). 
Health related quality of life 1n 
patients with DMT1 
Background 
HRQOL in patients with DMT1 refers to the patient's perception of the way 
diabetes mellitus affects physical, psychological and social functioning in daily life. 
It reflects the perceived burden of living with DMT1. 
Major findings and discussion 
Level of HRQOL in comparison with general population sample 
Most aspects of HRQOL in patients with DMT1 are comparable with HRQOL in 
persons of comparable age in the general population. Patients with DMT1 judge 
their physical, psychological and social functioning in daily life predominantly 
equal to persons of comparable age in the general population (chapter 3) (14). 
On the other hand, when we asked them 'How good or bad is your own health 
state today?' (EQ-VAS) or 'How is your health generally?' (Aspect of General 
Health subscale) they reported a lower HRQOL than the general population 
sample (chapter 3). 
Socio-demographic associations 
Older patients reported a lower, predominantly physical, HRQOL (PCS, EQ-50), 
patients with a higher education level reported a lower EQ-VAS. Married or 
cohabiting patients reported a higher mental HRQOL (MCS) (chapter 3). 
In this study we did not investigate the personality (patient's character) and the 
personal environment (family relationships, social support, life events) of the 
patients. It is likely that such factors will to a large extent explain a person's 
perception of symptoms and functioning, and will, in this way, be associated with 
the person's HRQOL. For example, Rose et al showed that patients with a more 
optimistic attitude reported a higher HRQOL (15, 16). 
Diabetes-related associations 
The presence of hyperglycaemic complaints and macrovascular complications 
showed the most profound negative association with HRQOL (chapter 3). 
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Hyperglycaemia and macrovascular events produce symptoms in the patients to 
such a degree as to impair daily functioning. These findings confirmed our 
hypothesis that when symptoms are present patients will experience a lower 
HRQOL. 
A higher frequency of self-monitoring blood glucose (SMBG) testing each week 
was also negatively associated with HRQOL. These tests, which are done by the 
self administration of a finger prick, are painful, and result, in accordance with our 
model, in a negative influence on HRQOL. New methods for self-administered 
glucose blood monitoring are under development, which will likely cause less 
discomfort for the patient. Courses in intensive insulin management might be 
helpful for patients learning and improving skills necessary in diabetes care and 
management. The dose adjustment for normal eating (DAFNE) study group showed 
that skills promoting dietary freedom improved quality of life and glycaemic 
control in patients with DMT1 without worsening the risk for severe 
hypoglycaemia or cardiovascular risk (17). 
No prior studies have reported either the negative association of a high frequency 
of SMBG or the presence of hyperglycaemic symptoms with HRQOL. 
Whereas others found a negative association of the presence of hypoglycaemic 
events with HRQOL, our study did not confirm this (18). De Vries et al compared 
pump use with multi-daily pen injection (MDI) and reported that, although the 
number of mild hypoglycaemic episodes was higher in the pump group, higher 
scores were measured for the general health and mental health subscales after 
starting the pump than for patients starting MDI (19). During our study period the 
percentage of patients using an insulin pump increased significantly, which might 
explain why we did not find a decreased HRQOL by hypoglycaemia. 
Newly diagnosed diabetes mellitus 
In a small group of patients with newly diagnosed DMT1 (n ~ 15) HRQOL 
improved during the first six months after diagnosis. As expected HbA 1 c 
decreased, as did the number of patients that reported hyperglycaemic complaints 
(20). One year after diagnosis HRQOL of the study group was comparable to that 
of a general population sample (chapter 4). Three months after diagnosis, HbA 1 c 
levels did not show any further significant decrease. One might expect the 
percentage of patients reporting hyperglycaemic complaints to decrease and the 
HRQOL to normalize within these first three months after diagnosis. 
Unfortunately, the time parameters for the assessment of HRQOL and the presence 
of hyperglycaemic complaints used in this study were six and twelve months after 
diagnosis and we were therefore unable to address this question. Although the 
number of patients in this part of the study was small, we nevertheless found 
statistically significant changes over time. The results are in agreement with those 
found in our cross-sectional study (chapter 3) and also confirm the hypothesis in 
our model, which states that, when symptoms are present, HRQOL will be 
impaired (chapter 1). Both findings strengthen our opinion that these study results 
are representative. 
Change in HRQOL in DMTI over time 
Patients with OMT1 have a clinically relevant loss of, predominantly physical, 
HRQOL over time. Additionally, these patients have a faster decrease in HRQOL 
over time, as measured on most subscales, when compared to age matched 
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persons from the general population (chapter 5) (21, 22). The mental subscales 
remained more or less stable over time. The subjects who dropped out of the study 
had a lower HRQOL, predominantly mental, than the patients who continued with 
the study. Loosing the dropouts may partly explain the fact that the subscales role 
emotional and mental health and the MCS did not show a significant change over 
time (chapter 2). The possibility that many patients have learned to cope with a 
demanding disease like DMT1 might also positively influence their mental health, 
and will protect them from a decrease in mental HRQOL over time. 
The faster decline of the patients with DMT1 in predominantly physical HRQOL is 
probably due to the development of chronic complications related to diabetes. 
These complications will cause symptoms, which will influence the patient's 
functioning and result in a decrease in HRQOL. 
Unfortunately, we did not have longitudinal HRQOL population data with which 
to compare our cohort; we therefore estimated the change per year in the 
population sample. Despite this limitation we consider our data are representative, 
since it confirms prior knowledge and our own cross-sectional data (chapter 1 and 
3). 
Predicting change in HRQOL over time 
It was possible to identify factors which act as predictors for change in HRQOL. 
The presence of diabetic complications in 1995 predicted a lower HRQOL in 
2001 (chapter 6). This finding can be explained by the assumption that late 
complications already present in 1995 will be more severe in 2001, will lead to 
symptoms and will in this way negatively influence HRQOL (chapter 1). 
Moreover, we found that a high diastolic blood pressure, a risk factor for the 
development and progression of complications, was predictive for a decrease in 
HRQOL (chapter 6). This is the first study, which identifies patients who are at risk 
for a faster decrease in HRQOL. 
The assessment of H RQOL m DMT1 
Background 
Generic and disease-specific HRQOL questionnaires both have their possibilities 
and limitations. Diabetes-specific instruments are said to be more sensitive to 
changes over time in patients with DMT1 and should be more suitable to assess 
diabetes-specific associations with HRQOL, whereas generic instruments allow 
comparisons with subjects in the general population and with patients with other 
diseases, looking at the relative burden of diseases (23, 24). Furthermore, 'utilities' 
derived from several of the generic instruments make cost-effectiveness studies 
possible (25-27). An ideal instrument for the assessment of HRQOL in DMT1 
would incorporate the benefits of both generic and disease-specific instruments. 
In our study, we investigated the use of two generic questionnaires, the RAND-36 
and the EuroQol (EQ), and two diabetes-specific instruments, the Problem Areas In 
Diabetes (PAID) and the Hypoglycaemia Fear Scale (HFS) for the assessment of 
HRQOL (28-30). 
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Major findings and discussion 
Responsiveness 
We showed that generic instruments can assess changes over time in DMT1. 
Several subscales and the Physical Summary Scale of the RAN D-36 showed a 
change over time which was statistically significant (chapter 5 and 8). Most 
changes were also clinically relevant as perceived by patients and clinicians. The 
RAND-36 was also able to detect changes in HRQOL when patients developed 
microvascular complications. Changes over time when using the generic EuroQol 
were not statistically significant and clinically relevant between 1998 and 2001 
(chapter 8). During the total study period (1995-2001) however, the changes were 
statistically significant (chapter 5), although they remained clinically not relevant. 
'Utilities', derived from the RAND-36 and the EuroQol, revealed changes in 
HRQOL over time in patients with DMT1 as well (chapter 7). 
Associations with diabetes-specific variables 
The RAND-36 and the EQ, and their utilities as well, assessed associations 
between diabetes-specific factors and HRQOL (chapter 3, 7 + 8). These generic 
instruments can provide information about associations of diabetes-specific 
variables and HRQOL. 
Redundancy of diabetes-specific instruments 
The question arises whether the application of diabetes-specific instruments may 
become redundant in the assessment of HRQOL in patients with DMT1. Whereas 
the RAND-36 and EQ were indeed responsive to changes over time and provided 
information about associations of diabetes-specific factors with HRQOL in patients 
with DMT1, they only partially identified the same patient group when compared 
with diabetes-specific instruments. The diabetes-specific instruments used in our 
study focus partly on different aspects of living and coping with DMT1. The 
complementary use of a diabetes-specific measure like the PAID and the HFS can 
give additional information about the (psychological) status of patients with DMT1. 
RAND-36 versus EuroQol 
The higher number of varied items of the RAND-36 will lead to a more detailed 
description of the different physical, psychological and social aspects of a patient's 
HRQOL than is assessed by the EQ. The RAND-36 is more responsive to changes 
over time than the EQ. Furthermore, the percentage patients reporting highest EQ-
5D health was almost 60%. This 'ceiling effect' probably makes the EQ less 
suitable when relatively small changes in the highest ranges of HRQOL are 
expected (chapter 8). The larger number of items of the RAND-36 did not result in 
a lower response rate or a higher percentage of missing values compared to the 
EQ. 
RAND-36 versus Short Form-36 (SF-36) 
In this study we used the RAND-36 (28-31). The RAND-36 includes the same 36 
items as those in the SF-36, but the recommended subscale scoring method is 
somewhat different from that of the SF-36 (31-34). Scoring differences exist only for 
the subscales Bodily pain and General health. RAND Bodily pain scores are 
somewhat higher and RAND General health scores are somewhat lower than the 
SF-36 scores (31). Despite these scoring differences, correlations of 0.99 were 
obtained in the Medical Outcomes Studies (MOS) panel sample when responses 
were scored using the RAND-36 versus the SF-36 scoring method (31). 
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The use of SF-36 summary scores from RAND-36 subscales 
The use of summary scores reduces the number of statistical comparisons, thereby 
reducing the role of chance, but should not lead to a substantial loss of 
information. This appeared to be the case when the SF-36 summary scores were 
used (35). The SF-36 summary scores are described and tested extensively and 
applied more frequently than the RAND-36 summary scores (31, 35, 36). We 
chose to calculate SF-36 summary scales based on RAND-36 subscales. 
Results partly depend on moment of assessment and choice of instrument 
The attentive reader of this thesis will possibly have noted that different chapters 
sometimes give varying results. These differences are not mistakes, but instead 
show the problems associated with assessing HRQOL in patients with DMT1. 
As time goes by, the sever1ty of complications will increase and will lead to 
symptoms and problems which will have an impact on the patient's functional 
capacity from day to day. However, something as a myocardial infarction or a 
Transient lschaemic Attack (TIA) a week before an assessment of HRQOL will 
certainly have a negative influence on the HRQOL scores. When no symptoms or 
problems remain after the acute phase of the incident, this does not necessarily 
lead to a decreased HRQOL several years later. Furthermore, microvascular 
complications at an early stage can be controlled of even reversed by the 
implementation of intensive treatment policies (7, 12). 
The results of each multivariate regression concern a changing number and 
different selection of patients, since inclusion in this analysis is only possible with 
a complete data set. Finally, using a different HRQOL instrument can give varying 
results through the aggregation of information pertaining to quite different 
questions. 
Conclusions 
It is feasible, under standard diabetes care, to intensify the insulin regime in a 
Dutch cohort of patients with DMT1, resulting in a mean HbA 1 c of 7.6%. Despite 
this reasonable HbA 1c, the number of patients with micro- and macrovascular 
complications still increased over the six-year period. HRQOL does not decrease 
with intensive treatment, whereas the consequences of a less strict control of blood 
glucose are associated with a decrease in HRQOL. However, higher frequencies of 
SMBG per week are associated with decreased HRQOL scores. 
HRQOL in patients with DMT1 is comparable with that of persons from the 
general population. In the first half-year after diagnosis, patients recover from a 
decreased HRQOL at diagnosis, and one year after diagnosis their HRQOL is 
comparable with that of persons from the general population. 
Patients with DMT1 have a clinically relevant loss of, predominantly physical, 
HRQOL over time. They experience a faster decrease in HRQOL over time than 
persons from the general population. This is likely due to the development of 
complications. Furthermore, high diastolic blood pressure and the presence of 
complications specific to diabetes are predictive factors for a faster decrease in 
HRQOL. 
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The generic RAND-36 appears to be very sensitive to changes in HRQOL over 
time in patients with DMT1, and can provide information about diabetes-specific 
associations with HRQOL. The complementary use of a diabetes-specific measure 
like the PAID and the HFS can give additional information about the 
(psychological) status of patients with DMT1, which can be very useful. 
Recommendations 
Studies with a multifactorial interventionist focus, promoting, for example, physical 
activity, cessation of smoking and a diet with a reduction in saturated fat, should 
be of value in achieving lower prevalences of chronic diabetic complications in 
patients with DMT1. 
In daily clinical practice a multifactorial approach, emphasizing factors like 
smoking habits, physical activity and nutrition, might lower the eventual 
prevalence of complications in patients with DMT1. Nurses and other caregivers 
specialized in diabetes could play an important role in the combined and 
sustained efforts to reach these goals. They should pay attention to these lifestyle 
factors in an effort to achieve this goal. A lower prevalence of complications will 
help keep HRQOL as normal as possible and will prevent a decrease in HRQOL in 
patients with DMT1. 
Since higher frequencies of self monitoring blood glucoses are associated with 
lower HRQOL, attention should be paid to this frequency. Clinicians should strive 
for a minimal frequency of SMBG, sufficient for reaching adequate metabolic 
control. New techniques in SMBG may also alleviate this problem. 
The RAND-36 can be recommended for the assessment of the HRQOL in patients 
with DMT1. For clinical studies and cost-effectiveness studies the RAND-36 is also 
a good choice. Clinicians who suspect a decreased HRQOL in a specific patient, 
or who wonder why a specific patient's blood glucose levels remain poorly 
controlled can, besides the RAND-36, also administer the PAID and the HFS to 
obtain additional insight into the specific problems of such a patient, in order to 
identify further possibilities to support the individual patient and thus improve 
control. 
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Summary 

Chapter 1 describes the aims of this study and the model used in this thesis. 
The main aim of this thesis was to investigate the health related quality of life 
(HRQOL) in patients with diabetes mellitus type I (DMT1). A secondary aim was to 
investigate the possibility of providing recommendations for the assessment of 
HRQOL in patients with DMT1. 
To achieve these aims a Dutch cohort of patients with DMT1 is followed for six 
years (1995-2001) and several socio-demographic and diabetes-specific 
characteristics are recorded whilst assessing HRQOL in this cohort yearly. 
In chapter 2 the longterm clinical follow-up of the cohort is described. A total of 
234 patients with DMT1 could be followed for the total study period of six years 
(1995-2001) all treated at the outpatient department of the lsala Clinics, location 
Weezenlanden, in Zwolle, The Netherlands. During the study period therapy was 
intensified. The percentage of patients using an internal or external insulin pump 
increased from 26.9% in 1995 to 43.6% in 2001. The mean HbA1c decreased 
from 8.1 to 7.6%. The body mass index increased and the percentage of patients 
reporting hypoglycaemic events tended to increase, probably both as a 
consequence of the more intensive treatment. The frequency of self-monitoring 
blood-glucose levels increased as well. Despite the intensified treatment, the 
percentage of patients with microvascular and macrovascular complications 
increased during the study period. 
Chapter 3 describes the HRQOL of patients with DMT1 in comparison with a 
sample of the general population. HRQOL was assessed using two generic 
instruments, the RAND-36, consisting of eight subscales and two summary scales 
(physical and mental), and the EuroQol, consisting of the utility (EQ-5D) and a 
Visual Analogue Scale (EQ-VAS). Most of the RAN D-36 subscales were 
comparable between the cohort of patients with DMT1 and the general population 
sample. In the cohort, the EQ-5D was comparable and the EQ-VAS was lower than 
those of subjects of comparable age from a UK general population sample. 
Multivariate regression analysis for the RAND-36 and the EQ showed that the 
presence of macrovascular complications had the most pronounced negative 
association with HRQOL in patients with DMT1. The presence of comorbidity and 
hyperglycaemic complaints and a higher frequency of self-monitoring blood-
glucose per week also had a negative association with HRQOL. Whereas HRQOL 
did not decrease with a more intensive treatment, the consequences of a less strict 
blood glucose control were associated with a decrease in HRQOL. 
In chapter 4 the follow-up of fifteen patients during the first year following their 
diagnosis of DMT1 is described. In the first six months after diagnosis mean 
HbA 1 c decreased from 14.3% to 5.9% (p <0.001). The percentage of patients with 
hyperglycaemic complaints also decreased, from 93% to 53% (p~0.014). Body 
mass index increased significantly during the first six months from 22.2 to 23.9 
kg/m 2 (p~0.001). All the subscales of the RAND-36, both the summary scores and 
the EQ-scores, showed an increase during the first six months after diagnosis. 
One year after diagnosis, HRQOL of the study population was comparable with 
that of a sample drawn from the general population. 
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Chapter 5 describes the changes in HRQOL over time in the cohort. The patients 
reported a statistically significant decrease per year, for six of the eight RAND-36 
subscales and for the PCS. The EQ-50 and the EQ-VAS showed a statistically 
significant decrease per year as well. Changes over time in the RAND subcale 
scores could be seen as clinically relevant too, after two to four years time. The 
EQ-50 did not show a clinically relevant decline in HRQOL over these six years, 
whereas the EQ-VAS showed this only after six years. The decline in HRQOL was 
steeper than in a general population sample. The steeper decline in diabetes 
patients might be due to the development of diabetic complications. 
In Chapter 6 a multilevel model, developed to identify factors predicting the 
degree of change in HRQOL over time, is described. 
Higher diastolic blood pressures in 1995 and the presence of diabetic 
complications in 1995 were predictive for a faster decline in HRQOL. 
The progression of complications already present in 1995 will give symptoms to 
the patients, will impair their functioning in daily life and will thus negatively 
influence their HRQOL. 
Chapter 7 describes the use of utilities, derived from generic instruments, in 
patients with DMT1. The SF-60, derived from 11 items of the SF-36, and the EQ-
50, based on the 5 EQ items, both measured changes over time in this group of 
patients. The SF-60 Quality Adjusted Life Years (QALYs) were significantly lower 
than the EQ-5 D QAL Ys possibly by the fact that the SF-60 is based on more items, 
allowing for a more detailed assessment of HRQOL. Furthermore, a large 
percentage of patients (51.5 up to 59.0%) reported the best possible EQ-50 health: 
a ceiling effect. 
The three most pronounced negative associations with HRQOL were the presence 
of hyperglycaemic complaints, macrovascular complications and comorbidity. 
Both utilities offer possibilities for cost-effectiveness studies in patients with DMT1. 
Chapter 8 describes the study in which we assessed HRQOL in patients with 
DMT1 using two different generic instruments and two different diabetes-specific 
instruments, to compare the two types of instruments. The RAND-36 appeared to 
be responsive to changes in HRQOL over three years. The EQ was not effective at 
measuring changes over such a time period. Both the RAN D-36 and the EQ 
assessed associations between diabetes-specific variables and HRQOL. The 
generic and diabetes-specific instruments used in this study, only partially 
identified the same patients with the lowest HRQOL scores, because the 
instruments measured different aspects of HRQOL. When a clinician wishes to 
identify and select patients with a decreased HRQOL, instrument choice will 
determine patient identification. A complementary use of both types of instruments 
seems to be warranted. 
In conclusion, we can recommend the RAND-36 for assessing HRQOL in patients 
with DMT1. The complementary use of a diabetes-specific measure will give 
additional information, particularly about the psychological status of patients with 
DMT1. 
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Chapter 9 presents the major findings of this study in the form of a general 
discussion. Conclusions and recommendadtions made on the basis of this thesis 
are: 
The cohort 
• Therapy was intensified during the six-year study period 
• Under standard diabetes care it was possible to reach a mean HbA 1 c level of 
7.6% 
• Despite the intensified therapy the percentage of patients with microvascular 
and macrovascular complications increased over time. 
Recommendation 
Studies in patients with DMT1 focusing, next to the striving for a bloodglucose 
level close to normal, on lifestyle factors such as smoking cessation, stimulation of 
physical exercise, a diet with a reduction in saturated fat, might offer possibilities 
for further delay and even prevention of onset and progression of complications in 
patients with DMT1. 
Health related quality of life 
• Most aspects of HRQOL in patients with DMTl are comparable with HRQOL 
of subjects of comparable age in the general population 
• A higher frequency of self-monitoring of blood glucose, hyperglycaemic 
complaints, and diabetic complications are associated negatively with HRQOL 
• HRQOL in newly diagnosed patients with DMT1 improves within the first six 
months after diagnosis. One year after diagnosis HRQOL is comparable with 
that of persons from the general population 
• Patients with DMT1 can experience a clinically relevant loss of predominantly 
physical HRQOL within several years 
• Patients with DMT1 have a faster decrease in HRQOL over time than 
comparably aged persons from the general population, probably due to the 
development of complications related to diabetes 
• When symptoms of the disease are present, these will negatively influence 
daily functioning, and will in this way negatively influence HRQOL 
• Higher diastolic blood pressure and the presence of diabetic complications are 
predictive for the degree of decrease in HRQOL over time. 
Recommendation: 
In consideration of the preservation of HRQOL, our results encourage intensive 
therapy to delay the onset and progression of diabetic complications. 
The assessment of HRQOL in patients with DMT1 
• The generic RAND-36 and EuroQol can assess changes in HRQOL over time in 
patients with DMT1 
• The generic RAND-36 and EuroQol can assess associations between diabetes-
specific factors and HRQOL in patients with DMT1 
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• We prefer the RAND-36 to the EuroQol in the assessment of HRQOL in 
patients with DMT1, since the more detailed description of the different 
physical, psychological and social aspects of patient's HRQOL, lead to a good 
differentiation at various HRQOL levels 
o The RAND-36 and the EuroQol only partly identify the same patients as the 
PAID and the HFS. These diabetes-specific instruments can give, in relation to 
the generic RAND-36 and EQ, additional information about patients with 
DMT1 
o The utility of the RAND-36, the SF-60, offers possibilities for cost-effectiveness 
studies in patients with DMT1. The utility of the EuroQol, the EQ-50, showed 
a large ceiling effect and makes it less suitable than the SF-60. 
Recommendation: 
The generic RAND-36 is a suitable choice for the assessment of HRQOL in 
patients with DMT1. The assessment of HRQOL (generic and diabetes-specific) 
might offer new possibilities in the support of patients with DMT1 and in 
improving glycaemic control in modern diabetes care. 
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Samenvatti ng 

Hoofdstuk 1 beschrijft de doelstellingen van dit onderzoek en het model dat is 
gebruikt. De hoofddoelstelling van dit promotieonderzoek was het onderzoeken 
van de gezondheidsgerelateerde kwaliteit van Ieven (HRQOL) van patienten met 
diabetes mellitus type I (DMT1). Daarnaast is onderzocht of het mogelijk was 
aanbevelingen te doen voor het meten van HRQOL van patienten met DMT1. Om 
deze doelstellingen te bereiken is zes jaar lang (1995-2001) een Nederlands cohort 
van patienten met DMT1 gevolgd. Naast het jaarlijks meten van de HRQOL 
werden diverse socio-demografische en diabetesspecifieke variabelen 
geregistreerd. 
In hoofdstuk 2 wordt de lange termijn follow-up van het cohort beschreven. In 
totaal konden 234 patienten met DMT1, van de polikliniek van de lsala Klinieken, 
lokatie Weezenlanden, te Zwolle (Nederland) gedurende de totale 
onderzoeksperiode van 6 jaar (1995-2001) worden vervolgd. Gedurende de 
onderzoeksperiode werd de therapie ge.,.ntensiveerd. Het percentage patienten dat 
een interne of externe insuline pomp gebruikte nam toe van 26.9% in 1995 tot 
43.6% in 2001. Het gemiddelde HbA 1 c nam af van 8.1 tot 7.6%. De bodymass 
index nam toe en het percentage patienten dat hypoglycaemieen rapporteerde liet 
een Iichte stijging zien, beide waarschijnlijk het gevolg van de meer intensieve 
behandeling. De frequentie van het aantal keren zelfcontrole van het bloedglucose 
(per week) nam ook toe. Ondanks de toegenomen intensiviteit van de behandeling 
en het verbeterde HbA 1 c, nam het percentage patienten met micro- en 
macrovasculaire complicaties toe tijdens de onderzoeksperiode. 
Hoofdstuk 3 beschrijft de HRQOL van patienten met DMT1 in vergelijking met 
een steekproef uit de algemene populatie. De HRQOL werd vastgelegd met twee 
generieke meetinstrumenten: de RAND-36, die uit acht subschalen en twee 
somscores (fysiek en mentaal) bestaat, en de EuroQol, die uit een utiliteit (EQ-SD) 
en een Visuele Analoge Schaal (EQ-VAS) bestaat. De meeste RAND-36 subschalen 
waren vergelijkbaar tussen het cohort en de steekproef uit de algemene populatie. 
In het cohort was de EQ-SD vergelijkbaar, en de EQ-VAS lager dan van rnensen 
van vergelijkbare leeftijd uit een steekproef van de Engelse bevolking. 
Multivariate regressie analyses voor de RAND-36 en de EQ lieten zien dat de 
aanwezigheid van macrovasculaire complicaties het meest uitgesproken negatieve 
verband met de HRQOL van patienten met DMT1 had. De aanwezigheid van 
comorbiditeit, hyperglycaemische klachten, en een hogere frequentie van de 
zelfcontrole van het bloedglucose (per week) had ook een negatief verband met de 
HRQOL. 
De HRQOL nam niet af bij een meer intensieve behandeling, maar juist de 
consequenties van een minder strikte bloedglucose controle lieten een verband 
zien met een afname van de HRQOL. 
In hoofdstuk 4 wordt de follow-up van 15 patienten in het eerste jaar direct na hun 
diagnose DMT1 beschreven. In de eerste zes maanden na de diagnose nam het 
gemiddelde HbA1c af van 14.3% tot 5.9% (p<0.001). Het percentage patienten 
met hyperglycemische klachten nam ook af, van 93% tot 53% (p~0.014). De 
bodymass index steeg in de eerste zes maanden, van 22.2 tot 23.9 kg/m 2 
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(p~0.001). Aile subschalen van de RAND-36, beide somscores en de EQ scores, 
lieten in de eerste zes maanden na diagnose een verbetering zien. Een jaar na 
diagnose, was de HRQOL van de studiepopulatie vergelijkbaar met die van een 
steekproef uit de algemene bevolking. 
Hoofdstuk 5 beschrijft de veranderingen in HRQOL in verloop van de tijd. De 
patienten rapporteerden een statistisch significante daling per jaar voor zes van de 
acht RAND-36 subschalen en de fysieke somscore. Ook de EQ-5D en de EQ-VAS 
lieten een statistisch significante daling per jaar zien. De veranderingen, vastgelegd 
met de RAND subschalen, konden ook, na twee tot vier jaar, als klinisch relevant 
worden beschouwd. De EQ-5D liet in deze zes jaar geen klinisch relevante 
afname zien, terwijl de EQ-VAS dit pas na zes jaar liet zien. De afname in HRQOL 
was steiler dan in een steekproef van de algemene bevolking. De steilere afname 
in patienten met DMT1 kan waarschijnlijk worden toegeschreven aan de 
ontwikkeling van complicaties ten gevolge van diabetes. 
In hoofdstuk 6 wordt een multilevel model beschreven, dat ontwikkeld werd om 
factoren te identificeren die de mate van verandering van de HRQOL in de tijd 
kunnen voorspellen. Een hogere diastolische bloeddruk in 1995 en de 
aanwezigheid van diabetische complicaties in 1995 waren voorspellend voor een 
snellere afname van HRQOL. De progressie van de complicaties, die in 1995 al 
aanwezig waren, zal symptomen veroorzaken bij de patienten. Tevens zal hun 
dagelijks functioneren belemmerd worden. Dit alles zal de HRQOL negatief 
be"invloeden. 
Hoofdstuk 7 beschrijft het gebruik van utiliteiten, afgeleid van generieke 
meetinstrumenten, bij patienten met DMT1. De SF-6D, afgeleid van 11 items van 
de SF-36, en de EQ-5D, gebaseerd op de 5 EQ items, maten allebei veranderingen 
in de tijd in deze groep patienten. De SF-6D kwaliteitsgecorrigeerde levensjaren 
(QALYs) waren significant lager dan de EQ-5D QALYs. Dit zou verklaard kunnen 
worden door het feit dat de SF-6D op meer items is gebaseerd, wat een meer 
gedetailleerde vastlegging van de HRQOL mogelijk maakt. Voorts rapporteerde 
een groot percentage van de patienten de best mogelijke EQ-5D 
gezondheidstoestand: een 'plafond effect'. De drie meest uitgesproken negatieve 
verbanden met HRQOL waren de aanwezigheid van hyperglycemische klachten, 
macrovasculaire complicaties en comorbiditeit. Beide utiliteiten bieden 
mogelijkheden voor kosteneffectiviteitonderzoek bij patienten met DMT1. 
Hoofdstuk 8 beschrijft twee verschillende generieke en twee verschillende 
diabetesspecifieke instrumenten, die werden gebruikt om de HRQOL te bepalen 
en om de instrumenten met elkaar te vergelijken. De RAND-36 was gevoelig voor 
veranderingen in HRQOL in drie jaar tijd. The EQ was niet geschikt om 
veranderingen te meten in dit tijdsbestek. Zowel de RAND-36 als de EQ legden 
verbanden vast tussen diabetesspecifieke variabelen en HRQOL. De generieke en 
diabetesspecifieke instrumenten, die in dit onderzoek werden gebruikt, 
identificeerden slechts voor een deel dezelfde patienten met de laagste HRQOL, 
omdat de instrumenten verschillende aspecten van HRQOL vastlegden. Wanneer 
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een arts patienten wil identificeren en selecteren met een afgenomen HRQOL, zal 
de keuze van het instrument bepalen welke patienten hij/ zij zal identificeren. Een 
complementair gebruik van de verschillende instrumenten lijkt aanbevolen. 
Concluderend, de RAND-36 kan worden aanbevolen voor het vaststellen van de 
HRQOL van patienten met DMTl. Het complementaire gebruik van een 
diabetesspecifiek instrument zal aanvullende informatie verschaffen, in het 
bijzonder over de psychologische status van patienten met DMTl. 
Hoofdstuk 9 presenteert de belangrijkste bevindingen uit dit onderzoek in de vorm 
van een algemene discussie. Onderstaande conclusies en aanbevelingen zijn 
gemaakt op basis van dit proefschrift: 
Het cohort: 
• Gedurende de zes jaar durende onderzoeksperiode werd de therapie 
ge"lntensiveerd 
• Het was mogelijk, met standaard diabeteszorg, een gemiddeld HbA 1 c niveau 
van 7.6% te bereiken 
• Ondanks de ge"lntensiveerde therapie steeg het percentage patienten met 
micro- en macrovasculaire complicaties in de loop van de tijd 
Aanbeveling: 
Onderzoek bij patienten met DMTl dat zich, naast het streven naar een zo 
normaal mogelijk bloedglucose, rich! op leefstijlfactoren, zoals het staken van 
roken, het stimuleren van lichamelijke inspanning, en een dieet met een beperkt 
gehalte aan verzadigde vetten, kan inzicht verschaffen in de mogelijkheden om het 
ontstaan en de progressie van complicaties bij patienten met DMTl te vertragen 
dan wei te voorkomen. 
Gezondheid gerelateerde kwaliteit van Ieven: 
• De meeste aspecten van HRQOL van patienten met DMTl zijn vergelijkbaar 
met personen, van vergelijkbare leeftijd, uit de algemene populatie 
• Een hogere frequentie van zelfcontrole van bloedglucose, hyperglycemische 
klachten, en diabetische complicaties zijn negatief geassocieerd met HRQOL 
• De HRQOL van patienten waarbij net DMTl is gediagnosticeerd verbetert in 
de eerste zes maanden na de diagnosestelling. Een jaar na de diagnosestelling 
is de HRQOL van de onderzoekspopulatie vergelijkbaar met die van een 
steekproef uit de algemene populatie 
• Patienten met DMTl kunnen, binnen enkele jaren, een klinisch relevant verlies 
van, voornamelijk fysieke, HRQOL ervaren 
• Patienten met DMTl hebben een snellere afname van HRQOL in de tijd, dan 
personen van vergelijkbare leeftijd uit de algemene populatie, waarschijnlijk 
ten gevolge van de ontwikkeling van complicaties die gerelateerd zijn aan 
DMTl 
• Wanneer symptomen van de ziekte aanwezig zijn, zullen deze het dagelijks 
functioneren negatief be"lnvloeden, en zullen zodoende de HRQOL negatief 
be"lnvloeden. 
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• Een hogere diastolische bloeddruk en de aanwezigheid van diabetische 
complicaties zijn voorspellend voor de mate van afname van HRQOL in de 
tijd. 
Aanbeveling: 
Het is aan te bevelen, met het oog op het behoud van de HRQOL, patienten met 
DMTl intensief te behandelen. 
Het meten van HRQOL van patienten met DMT1: 
• De generieke RAND-36 en EuroQol kunnen veranderingen van HRQOL in de 
tijd van patienten met DMTl vastleggen 
• De generieke RAND-36 en EuroQol kunnen verbanden tussen 
diabetesspecifieke factoren en HRQOL van patienten met DMTl vastleggen 
• Voor het meten van HRQOL van patienten met DMTl, wordt de voorkeur aan 
de RAND-36 boven de EuroQol gegeven, omdat de meer gedetailleerde 
beschrijving van de verschillende fysieke, psychologische en sociale aspecten 
van de HRQOL van deze patienten, leidt tot een goede differentiatie op 
verschillende HRQOL niveaus 
• De RAN D-36 en de EuroQol identificeren slechts ten dele dezelfde patenten 
als de PAID en de HFS. Deze diabetesspecifieke instrumenten kunnen, in 
relatie tot de generieke RAND-36 en EuroQol, aanvullende informatie geven 
over patienten met DMTl 
• De utiliteit van de RAND-36, de SF-6D, biedt mogelijkheden voor 
kosteneffectiviteitonderzoek bij patienten met DMTl. De utiliteit van de 
EuroQol, de EQ-5D, liet een groat 'plafondeffect' zien, waardoor het minder 
geschikt is dan de SF-6D 
Aanbeveling: 
Voor het bepalen van de HRQOL bij patienten met DMTl is de generieke RAND-
36 een geschikte keuze. Het vastleggen van HRQOL (generiek en 
diabetesspecifiek) kan nieuwe mogelijkheden bieden in de ondersteuning van 
patienten met DMTl en in het verbeteren van de bloedglucose controle in 
moderne diabetes zorg. 
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Het proefschrift is klaar! Begin 1999 werd ik door Els Grijseels en Marc Bruijnzeels 
gebeld dater bij het lnstituut Beleid en Management Gezondheidszorg een 
vacature was voor een promotieonderzoek onder Ieiding van Prof. Dr. A. Casparie, 
die overigens kort daarna het instituut ging verlaten. Het betrof een 'package deal' 
met een onderwijsaanstelling voor de stage 'Het Primaire Proces'. Na rijp beraad 
besloot ik de stap te wagen. 
jan Ass ink had al vee I klinische gegevens verzameld in de lsala Klinieken in 
Zwolle (lokatie Weezenlanden) bij een grote groep patienten met diabetes mellitus 
type I, mogelijk gemaakt door het Praeventiefonds. lk stort mij op een nieuw 
onderdeel van het onderzoek; de kwaliteit van Ieven van deze groep patienten. 
Allereerst wil ik de 250 patienten bedanken die zich zeven jaar lang de moeite 
hebben getroost vele lijsten in te vullen over hun kwaliteit van Ieven. Zander hun 
trouwe inzet was dit onderzoek niet mogelijk geweest. Ook dank ik de 
diabetesverpleegkundigen en het secretariaat diabeteszorg. Zander jullie waren al 
de onderzoeksgegevens nooit verzameld! 
Het klinisch chemisch onderzoek is verricht onder Ieiding van Bert Dikkeschei. 
jaarlijks werd bovendien door aile patienten de podotherapeut en de oogarts 
bezocht voor de beoordeling van een eventuele neuropathie en/ of retinopathie. 
Graag wil ik Bert Dikkeschei, de podotherapeuten en de oogartsen bedanken voor 
het registreren van deze microvasculaire complicaties, een belangrijk onderdeel 
van mijn onderzoek. Aile overige medewerkers van de polikliniek Diabeteszorg en 
lnwendige Geneeskunde ben ik dank verschuldigd voor hun inzet om a lies 
draaiende te houden. Deze 'carrousel' staat onder de bezielende Ieiding van de 
internisten Evert van Ballegooie en Henk Bilo. 
Henk, jij hebt als copromoter van het begin tot het eind een belangrijke rol 
gespeeld! Alles is mogelijk geweest, een bezoekje in de kelders om de alleroudste 
data te checken, of een duik in een diepe voorraadkast om aile statussen nog eens 
onder de loep te nemen. Greetje Kroes maakte het mogelijk om jou rustig te 
kunnen spreken, ondanks je drukke bezigheden. Aile onderzoeksgegevens en 
manuscripten werden van opbouwend commentaar voorzien. Ook is het mede 
dankzij jou mogelijk geweest dat mijn aanstelling bij het lnstituut Beleid en 
Management Gezondheidszorg tot tweemaal toe is verlengd, door gelden 
beschikbaar te stellen uit de Stichting Medisch Research Fonds Zwolle. Hierdoor 
heb ik het onderzoek af kunnen ronden in de vorm van een proefschrift. Heel vee I 
dank voor al je ondersteuning. 
Compleet en correct data verzamelen is een, het juist invoeren is een ander 
verhaal. Heidi Veltmaat heeft enorm veel data ingevoerd, in een razend tempo, en 
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met een perfecte kwaliteit. Dankzij de logistieke ondersteuning van haar zus 
Lielith is de klus in hoog tempo geklaard. Heidi, heel vee I dank! 
Zander promotor geen promotie! Begin 2001 heeft Prof.dr. B. Meyboom-de Jong 
deze taak op zich genomen. Betty, wat heb ik geboft dat jij op mijn weg kwam! 
Zander jouw geweldige inzet zou dit proefschrift er nooit gekomen zijn. lk vond 
het heel prettig om met jou samen te werken; altijd doortastend, enthousiast en 
positief. Razendsnel kwam jouw onmisbare reactie op mijn werk. Zo is de vaart er 
in gebleven. lk wens iedereen zo'n promotor toe! Heel erg vee I dank voor a lies 
wat je voor me gedaan hebt. 
Ken Redekop was mij toebedacht om me 'wat methodologisch en statistisch' te 
helpen. Voor Ken een niet geringe klus: een huisarts die komt aanwaaien en van 
toeten nag blazen weet. Ken, wat heb jij een eindeloos geduld met me gehad. lk 
waardeer het zeer dat je door bent gegaan, oak nadat er geen tijd meer is 
vrijgemaakt op mij te helpen. Terwijl het voor jou soms efficienter was geweest de 
analyses zelf te doen, liet je het altijd aan mij over. Vooral voor dit laatste ben ik 
je, achteraf dan, dankbaar. 
Kor Grit is gedurende de grootste peri ode van mijn aanstelling mijn kamergenoot 
geweest. Kor, jij hebt dan oak van dicht bij het wei en wee van mijn 
onderzoekstijd meegemaakt. Oat was waarschijnlijk niet altijd een voorrecht. 
Dank je voor de gezellige tijd. 
Het is voor mij van be lang geweest oak een Rotterdamse promotor te hebben. 
Prof. dr. M. Berg heeft deze taak op zich genomen. Beste Marc, het valt niet mee 
om ergens te starten en dan een promovendus in je schoenen geschoven te 
krijgen, waarvoor ten eerste geen gelden beschikbaar zijn gesteld, en dan oak nag 
met een onderwerp dat inhoudelijk niet in een van de onderzoekslijnen van je 
sectie past. Het is bewonderenswaardig dat ik nooit enige wanklank hierover heb 
gehoord! Je intervenieerde op de kritieke momenten, zodat het voor mij mogelijk 
is geworden het onderzoek voort te zetten en het proefschrift te voltooien. Heel 
veel dank voor je betrokkenheid. 
Anne Starreveld heeft een aantal hoofdstukken voorzien van commentaar op de 
engelse taal, een niet overbodige luxe. Dank je wei. 
Het is een voorrecht naast wetenschappelijk onderzoek in de praktijk te kunnen 
werken. Ruim twaalf jaar heb ik met veel plezier als huisarts in Schiedam gewerkt. 
In het bijzonder wil ik mijn coli ega Peter van Dijk bedanken, altijd loyaal en met 
een partie droge humor. 
Mijn 'begeleidingscommissie' in Amersfoort. Lieve papa en mama, jullie staan nu 
al 45 jaar onvoorwaardelijk achter me, een onontbeerlijke steun. Papa, jij kwam 
vanaf de eerste fase van het onderzoek met recente artikelen aan, en bleef dit 
volhouden tot de verdediging. Uiteindelijk heb je het totale manuscript gescreend 
en eigenlijk had je dolgraag her en der inhoudelijk nag wat will en toevoegen. 
AI dat werken kan natuurlijk aileen als het thuis goed loopt. Oat kon vooral 
dankzij Ali Mol, onze oppas. Ali, het is fantastisch dat we altijd op je konden 
rekenen. Nooit was iets jete vee I, altijd was jeer, een rustpunt voor de kinderen, 
en daardoor oak voor mij. Oat was wei afkicken toen we vorig jaar naar Zeist 
verhuisden. 
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Yvonne Rijnveld was vele jaren huisgenoot in Utrecht en woonde daarna nog eens 
tien jaar bij rne op de hoek. Yvon, ik bedank je voor al je gezelligheid en 
vertrouwdheid. 
Mijn paranirnfen lenske Vecht-Hart en Sibyl Ia Nooijen, trouwe vriendinnen vanaf 
1961 en 1981! lk ben blij dat jullie rnijn paranimfen willen zijn, en daarbij dat 
jullie beiden arts zijn, zodat ik tijdens de verdediging met gerust hart lastige vragen 
aan jullie kan doorspelen! 
Lieve Lodi, door jouw vertrouwen in mijn kunnen, heb je een grote bijdrage 
geleverd aan dit boek. Door het verzorgen van de lay-out, waarachtig geen geringe 
klus, is dit proefschrift ook een beetje van jou geworden! Michie! en Celine, 
volgens mij vonden jullie het allemaal wei best wat ik deed. Hoewel jij, Michie!, 
twee jaar terug verbaasd en enigszins hoopvol aan mij vroeg 'zijn er dan ook 
moeders die niet werken?' De mooie oms lag van dit boek is van jou! En Celine, jij 
vroeg mij een half jaar terug, hoeveel bladzijden m'n boek nu heeft. Toen ik daar 
antwoord op gaf, zei je opgelucht 'oh, dan zal het wei bijna klaar zijn'. Nu, ik kan 
jullie gerust stellen, het is nu echt helemaal klaar! 
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